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Abstract: Background
Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment
oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to determine if daily




AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial
conducted in 43 hospital stroke units in Australia (n=29), New Zealand (4), and
Vietnam (10).  Eligible patients were adults with a clinical diagnosis of stroke in the
previous 2-15 days and a persisting neurological deficit. Patients were randomised via
a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20mg
or matching placebo for 6 months. Patients, investigators and outcome assessors were
masked to the treatment allocation. The primary outcome was functional outcome,
measured by the modified Rankin scale (mRS), at 6 months. The primary analysis was
an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation
variables. Analyses were according to the patient’s treatment allocation. The trial is
registered with the ACTRN registry, number 12611000774921.
 
Findings
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1280 patients were recruited in Australia (n=532), New Zealand (n=42) and Vietnam
(n=706) between 11 January 2013 and 30 June 2019; 642 were allocated fluoxetine
and 638 placebo. Adherence to trial medication (mean 167 [SD 48] days) was similar
between groups. At 6 months, mRS data were available in 624 (97.2%) patients
allocated fluoxetine and 632 (99.1%) placebo. The distribution of mRS categories at 6
months was similar in the fluoxetine and placebo groups (adjusted common odds ratio
0.936, 95% CI 0.762-1.150; p=0.53), and consistent among all pre-defined subgroups.
Compared to placebo, patients allocated fluoxetine had more falls (20 [3.12%] vs 7
[1.10%]; p=0.02), bone fractures (19 [2∙96%] vs 6 [0.94%]; p=0.01) and epileptic
seizures (10 [1.56%] vs 2 [0.31%]; p=0.04) at 6 months.
Interpretation
Fluoxetine 20mg daily for 6 months after acute stroke did not improve functional
outcome and increased the risk of falls, bone fractures, and seizures. These results do
not support the use of fluoxetine to improve outcome after stroke.
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Thank you for submitting your email dated April 27, 2020 requesting a response to the reviewers' 
and editorial comments. 
 
 
Editorial points to be addressed: 
 
- Study title: To fit Lancet style, I'd suggest the following title "Safety and efficacy of fluoxetine on 
functional recovery after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled 
trial." What do you think? 
The title has been changed as proposed to “Safety and efficacy of fluoxetine on functional outcome 
after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial” 
The only change to your suggestion is that we have accepted the recommendation of the reviewer 
#3 to replace “recovery” with “outcome” as much as possible. If you disagree, and feel we should 
keep recovery in the title, that is also fine with us. 
 
- Could we cut down a couple of words here and there so have max 4600 words (our limit is 
normally 4500 words). 
 
The word count has been reduced to 4597   words 
 
- Appendix: for the Kaplan Meier survival curve- Please add 95% CI to all time-to-event data and 
other data derived from Kaplan-Meier analyses and please include number at risk (and, if 
available, number censored) in each group for each time. 
The Supplementary figure 3, Kaplan Meier curves has been modified with 95%CI of time to event 
data, and the number at risk in each group for each time. 
 
- Our journal office is currently checking if we have all forms (ie, signatures and ICMJE forms for 
the writing group members). 
 
 
Reply to Reviewers Comments
To enable readers to better appreciate research findings and to encourage full and transparent 
reporting of outcomes, The Lancet family journals offer to publish a web address in accepted 
paper that links to the study's protocol on the author's institutional website (see Lancet 2009; 373: 
992). This is particularly encouraged for randomised controlled trials, but is welcome for all types 
of research. 
Thank you  
Public access to the AFFINITY trial full protocol is available from the AFFFINITY trial website: 
https://www.affinitytrial.org/  
(accessed April 30, 2020) 
The direct web address for the protocol is: 
https://www.affinitytrial.org/download/researcher%27s_documents/Case_Report_Forms_v2/Affinit
y-Protocol-Version-5-clean-copy-18112015.pdf 
(accessed April 30, 2020) 
 
 
When you submit the revised paper, please provide one "clean" copy and one copy where your 
changes are highlighted. In addition, please provide a separate document listing the editorial and 
referee comments and your replies, point by point. These files must be submitted as MS Word 
files. 
 




Reviewer #3: Discussion: The additional information regarding the FLAME trial is useful, though 
reporting of the baseline data to demonstrate imbalance is not needed, given that the effects of 
fluoxetine remained significant when analyses were adjusted for baseline values. Instead, the 
authors could add data demonstrating the difference in baseline severity between FLAME and 
AFFINITY. This is more relevant. 
 
The unbalanced baseline data have been deleted, but the difference in baseline severity between 
FLAME and AFFINITY has been added, as stated: 
On page 16, para 1, it now reads  
“Patients enrolled in FLAME had more severe strokes (mean baseline NIHSS 13 vs median NIHSS 6 in 
AFFINITY).” 
 
Thank you for pointing out that the percentage of women in the sample is almost identical to 
FOCUS. Please add this to the manuscript. 
 
It is now stated, page 15, para 2: 
“The AFFINITY trial was smaller than the FOCUS trial9 but both trials recruited patients of similar sex 
(women 38%), stroke severity (median NIHSS=6) and at a similar time (one week, mean) after stroke 
onset.” 
 
Methods, Study design and participants, second paragraph, second sentence: "Patients were 
excluded if there was any definite indication for fluoxetine (e.g. depression)…". This creates 
uncertainly because 32 patients with depression were recruited (Table 1). It seems possible that 
fluoxetine may have been indicated but was not taken. This was raised in previous comments and 
remains unclear. 
Patients could have depression but not require treatment with an SSRI such as fluoxetine (e.g. non-
pharmacological treatment with clinical psychology, or pharmacological treatment with a non-SSRI.), 
and therefore be eligible for inclusion in the trial. 
We have removed “(e.g. depression)” to avoid confusion, and because fluoxetine could be definitely 
indicated for other conditions (e.g. anxiety). 
 
Please be more precise in your use of the term "recovery", throughout the manuscript. The mRS at 
6 months is a measure of outcome, not recovery. Recovery is improvement over time, so 
measuring recovery requires at least two measures to be made at two time points, to quantify 
change over time (as per FLAME, for example). A single measure at the end of the trial reflects the 
outcome, not recovery. Therefore, most instances of "recovery" in the manuscript need to be 
replaced with "outcome". 
 
Most instances of "recovery" in the manuscript have been replaced with "outcome". 
 
 
Reviewer #4: MINOR COMMENSTS 
 
I have only 2 minor issues to consider for revision: 
 
1. Abstract: "mood and emotional control" at 6 months are presented as a major finding in their 
first paragraph of their discussion, but no where else:  
I quote: "Other major findings were that fluoxetine improved mood and emotional control but 
increased falls, fractures, and epileptic seizures at 6 months. Could we rephrase in the discussion? 
 
“improved mood and emotional control” has been removed from the first paragraph in the 
discussion 
The opening paragraph of the discussion now just reads: 
“The main finding of the AFFINITY trial was that adding fluoxetine 20mg daily for 6 months after 
acute stroke to interdisciplinary stroke unit care did not improve functional outcome at 6 months in 
an ethnically diverse population. Other major findings were that fluoxetine increased falls, fractures, 
and epileptic seizures at 6 months.” 
 
2. Discussion, first paragraph of page 14: The lack of significant interaction effects of fluoxetine 
with motor recovery in the AFFINITY trial may also due to lower dosing of therapy in the first 
weeks post stroke when compared to the FLAME trial. However, this argument is not mentioned 
in the discussion. I suggest to consider this hypothetical factor as well in the text.   
 
The FLAME trial does not report a significant interaction between dose of fluoxetine (20 vs 40 mg 
daily) and outcome. 
The FLAME Trial manuscript states: 
1. Use of functional MRI in other studies showed that single doses of fluoxetine and paroxetine 
overactivated motor cortices compared with placebo in both healthy individuals and patients 
with stroke 
2. In Table 1, the only reported prospective randomised placebo-controlled clinical trials of 
selective serotonin-reuptake inhibitors in motor recovery after ischaemic stroke with 
fluoxetine was  Pariente et al13 Fluoxetine 20 mg (single dose). 
3. Patients were randomly allocated to fluoxetine (20 mg once per day, orally) or placebo for 90 
days. 
4. When depression occurred (according to clinical assessment) during the 3 months of 
treatment, clinicians were instructed to continue the study treatment (fluoxetine or placebo), 
to avoid use of any other antidepressant drugs and, if necessary, to give open-label 
fluoxetine (20 mg once a day) so that the patient received either 20 mg (placebo group) or 40 
mg per day (fluoxetine group). If a patient was given another antidepressant drug, the study 
treatment was stopped. 
5. The frequency of depression was significantly higher in the placebo group (17 [29%] patients) 
than in the fluoxetine group (four [7%] patients; p=0·002). 
 
 
So, only four patients assigned fluoxetine developed depression. It is not stated how many 
of them were treated with open label fluoxetine (to increase the daily dose to 40 mg) and 
when after randomisation, nor the effect of the higher dose on the primary outcome or 
mRS.  
 
6. After adjustment of our analysis for clinical depression diagnosed before day 90, we noted 
that FMMS change between day 0 and day 90 was still significantly greater in the fluoxetine 
group (adjusted mean 34·2 points [95% CI 29·7–38·6]) than in the placebo group (24·2 [19·6–
28·7]; p=0·004).  
 
a. i.e. after adjusting for those who may have had a higher dose of fluoxetine, there is 
no difference in the outcome, indeed the mean difference between groups is slightly 
higher at 10.0  (vs 9.7), suggesting that any higher dose did not have any 
incremental benefit. 
We believe it is speculative, and probably incorrect, to suggest that there is a dose-response 
association between fluoxetine dose and outcome in FLAME.  
So, we are not adding to this speculation in the discussion; we have already acknowledged that a 
higher dose of fluoxetine was not studied, in the limitations section of the discussion, page 14, as: 
 
“The dose of fluoxetine was 20 mg once daily because this was the dose reported to be effective in 
the FLAME trial5 and used in other fluoxetine trials for stroke recovery,6 and is less likely to cause 
adverse effects than higher doses. However, we did not test higher doses of fluoxetine.” 
 
Reviewer #5: Undoubtly, the paper has improved. The discussion is better and the way FLAME 
study is discussed much more appropriate. My only point is that in the abstract interpretation 
paragraph: 
 
"Fluoxetine 20mg daily for 6 months after acute stroke did not improve functional 
recovery and increased the risk of falls, bone fractures, and seizures. These results do 
not support the use, or further trials, of fluoxetine to improve recovery after stroke." 
 
the words "or further trials" should be supressed as there is no need to prevent people to do other 
clinical developments in severe stroke patients population which has not been addressed 
specifically. 
 
As recommended, we have removed “further trials”; …. However, that was only included in the first 
revision as a response to comply with the recommendation of another reviewer. 
 





Graeme Hankey, on behalf of the AFFINITY trial collaborative group. 
 
Items to include when reporting a randomized trial in a journal or conference abstract  
 
Item Description Reported on 
line number 
Title  Identification of the study as randomized Line 2, page 1 
Authors * Contact details for the corresponding author Bottom, page 1 
Trial design Description of the trial design (e.g. parallel, cluster, non-
inferiority) 
Line 6, page 2 
Methods   
  Participants Eligibility criteria for participants and the settings where 
the data were collected 
Lines 7-9 
  Interventions Interventions intended for each group 10 
  Objective Specific objective or hypothesis 3-4 
  Outcome Clearly defined primary outcome for this report 11-12 
  Randomization How participants were allocated to interventions 9 
  Blinding 
(masking) 
Whether or not participants, care givers, and those 
assessing the outcomes were blinded to group 
assignment 
10-11 
Results   
  Numbers 
randomized 
Number of participants randomized to each group 18 
  Recruitment Trial status 17-18 
  Numbers 
analysed 
Number of participants analysed in each group 19-20 
  Outcome For the primary outcome, a result for each group and the 
estimated effect size and its precision 
22 
  Harms Important adverse events or side effects 23-25 
Conclusions General interpretation of the results 26-28 
Trial registration Registration number and name of trial register 15 
Funding Source of funding 30 
 
*this item is specific to conference abstracts 
 
CONSORT abstract
CONSORT 2010 checklist  Page 1 




No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 




2a Scientific background and explanation of rationale 5 
2b Specific objectives or hypotheses 5 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 6 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 6 
4b Settings and locations where the data were collected 6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
7 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
9 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 9,10 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 6 




9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
6 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
6 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 7 
CONSORT checklist
CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 7 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 10,11 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 11 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
12 
13b For each group, losses and exclusions after randomisation, together with reasons 12 
Recruitment 14a Dates defining the periods of recruitment and follow-up 11 
14b Why the trial ended or was stopped 12 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 1,2 tables 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 




17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
12,13 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 13 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
13 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 13 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 14,15 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 14 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 15,16,17 
Other information  
Registration 23 Registration number and name of trial registry 11 
Protocol 24 Where the full trial protocol can be accessed, if available 6 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 3,11,26 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF 
FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to determine if daily fluoxetine for 6 
months after stroke improves functional outcome in Australasian and Vietnamese patients. 
  
Methods 
AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial conducted 
in 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10).  Eligible 
patients were adults with a clinical diagnosis of stroke in the previous 2-15 days and a persisting 
neurological deficit. Patients were randomised via a web-based system using a minimisation 
algorithm to once daily, oral fluoxetine 20mg or matching placebo for 6 months. Patients, 
investigators and outcome assessors were masked to the treatment allocation. The primary 
outcome was functional outcome, measured by the modified Rankin scale (mRS), at 6 months. 
The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for 
minimisation variables. Analyses were according to the patient’s treatment allocation. The trial 
is registered with the ACTRN registry, number 12611000774921. 
  
Findings 
1280 patients were recruited in Australia (n=532), New Zealand (n=42) and Vietnam (n=706) 
between 11 January 2013 and 30 June 2019; 642 were allocated fluoxetine and 638 placebo. 
Adherence to trial medication (mean 167 [SD 48] days) was similar between groups. At 6 
months, mRS data were available in 624 (97.2%) patients allocated fluoxetine and 632 (99.1%) 
placebo. The distribution of mRS categories at 6 months was similar in the fluoxetine and 
placebo groups (adjusted common odds ratio 0.936, 95% CI 0.762-1.150; p=0.53), and 
consistent among all pre-defined subgroups. Compared to placebo, patients allocated 
fluoxetine had more falls (20 [3.12%] vs 7 [1.10%]; p=0.02), bone fractures (19 [2∙96%] vs 6 
[0.94%]; p=0.01) and epileptic seizures (10 [1.56%] vs 2 [0.31%]; p=0.04) at 6 months.  
Interpretation  
Fluoxetine 20mg daily for 6 months after acute stroke did not improve functional outcome and 
increased the risk of falls, bone fractures, and seizures. These results do not support the use of 








RESEARCH IN CONTEXT 
Evidence before this trial 
We undertook a Cochrane systematic review and searched Cochrane and clinical trial registers; 
MEDLINE, Embase, PubMed, and other biomedical databases; from their inception to 16 July 
2018; for randomised controlled trials (RCTs) that recruited stroke patients who had survived 
up to one year, and randomised them to a selective serotonin reuptake inhibitor (SSRI), at any 
dose, for any period, and any indication; or to usual care or placebo. We identified 63 RCTs 
that compared any SSRI with control in 9168 stroke survivors. About half of the trials required 
patients to have depression. Potential improvements in disability with fluoxetine were only 
present in trials at high risk of bias. A meta-analysis of the three trials at low risk of bias 
(n=3356 patients) found no effect of any SSRI compared to control on functional independence 
(risk ratio [RR] 1.00, 95% CI 0.91 to 1.09; p = 0.99) or disability score (standardised mean 
difference [SMD] -0.01, 95% CI -0.09 to 0.06; p = 0.75). The evidence before this trial suggests 
that SSRIs do not improve functional outcome after stroke, but doubt remains because this 
meta-analysis was dominated by one large trial, the FOCUS (Fluoxetine Or Control under 
Supervision) trial (n=3127), in UK patients. 
Added value of this trial 
The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial externally validates the 
FOCUS trial and Cochrane systematic review of RCTs of SSRIs for stroke recovery in an 
independent population of Australasian and Vietnamese stroke patients, reinforcing the 
conclusion that fluoxetine does not improve functional outcome after stroke. The AFFINITY 
trial also adds further data regarding the potential hazards of treating acute stroke patients with 
fluoxetine 20 mg daily for 6 months, including increased risks of falls, fractures, and seizures. 
Implications of all the available evidence 
For clinicians, SSRIs should not be prescribed routinely to improve functional outcome after 
stroke because they are ineffective and increase serious adverse events. For researchers, a 
pooled analysis of individual patient data from completed RCTs of SSRIs for stroke recovery 
is needed to examine the effects of SSRIs in specific patient subgroups, such as those with 
hemiparesis, severe stroke, and cognitive impairment; and on specific outcomes, such as the 
mRS, motor domains of the Stroke Impact Scale, falls, fractures and seizures. Until these 




Stroke is the second leading cause of disability-adjusted life years globally.1,2 Fluoxetine, a 
selective serotonin re-uptake inhibitor (SSRI), may improve neurological recovery and reduce 
disability after stroke. Fluoxetine exerts neuro-protective and neuro-regenerative effects in pre-
clinical models of acute brain ischaemia.3,4 The FLuoxetine for motor recovery After acute 
ischaeMic strokE (FLAME) trial found that, in 118 patients with moderate to severe motor 
deficits, fluoxetine 20 mg once daily significantly improved motor recovery after 3 months.5 
A Cochrane systematic review of 52 randomised controlled trials (RCTs) of SSRIs for stroke 
recovery in 4059 patients concluded that SSRIs may improve disability but, given 
methodological limitations and heterogeneity of the studies, more definitive trials were 
required.6  
 
Hence, our international collaboration undertook three trials of fluoxetine for recovery after 
stroke in the United Kingdom (Fluoxetine Or Control Under Supervision [FOCUS]), Sweden 
(Efficacy of Fluoxetine–A Randomised Controlled Trial in Stroke [EFFECTS]) and Australia, 
New Zealand and Vietnam (Assessment oF FluoxetINe In sTroke recoverY [AFFINITY]).7,8 
The FOCUS trial (n=3127) reported that fluoxetine 20 mg daily for 6 months after stroke did 
not improve functional outcome as measured by the modified Rankin scale (mRS), but reduced 
depression and increased bone fractures.9 The latter results were consistent with the reported 
effectiveness of fluoxetine as an antidepressant,10 and increased risk of fractures in older people 
taking SSRIs.11,12 However, as only two thirds of FOCUS patients adhered to trial medication 
for at least 150 of the prescribed 180 days, a modest, but important, effect of fluoxetine on 
functional outcome may have been missed.9 Moreover, as 96% of patients in FOCUS were 
white, the results may not be generalisable outside the UK.9 Hence, the AFFINITY and 
EFFECTS trials continued recruitment until 30 June, 2019. 
 
Herein, we report the results of the AFFINITY trial, which aimed to evaluate whether a 6-
month course of fluoxetine is safe and effective, compared to placebo, for improving functional 
outcome after recent stroke in an ethnically diverse population. The EFFECTS trial results are 
reported in a parallel publication.13 
 
Methods 
Study design and participants 
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AFFINITY was a randomised, parallel group, double-blind, placebo-controlled clinical trial 
conducted in 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10). 
The trial protocol (appendix) was approved by the Royal Perth Hospital Ethics Committee on 
24 February, 2012 (approval number EC2011/131), and subsequent amendments to the 
protocol were also approved. All participating sites received approval from their ethics 
committee and institutional review board. The trial protocol7 and statistical analysis plan8 were 
published before recruitment stopped.  
 
Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke within 
the previous 2-15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a 
persisting neurological deficit that produced a mRS score ≥1. Patients were excluded if there 
was any definite indication for fluoxetine, or contraindication to fluoxetine (e.g. history of 
epilepsy, bipolar disorder, drug overdose, fluoxetine allergy, or recent medication that could 
interact with fluoxetine; or biochemical evidence of hepatic impairment [serum alanine 
aminotransferase  > 120 U/l], renal impairment [creatinine > 180 µmol/l or estimated 
glomerular filtration rate (eGFR) < 30ml/min/1.73m2], or hyponatremia [sodium < 
125mmol/L]); if patients were unlikely to be available for follow-up during the subsequent 12 
months; if patients had another life-threatening illness that would make 12-month survival 
unlikely [e.g. terminal malignancy]; if women were pregnant, breast-feeding or of child-
bearing age and not using contraception; or if patients were enrolled in another clinical trial of 
an investigational medicinal product (IMP) or device.  
 
Written informed consent was obtained from each patient or, if the patients were unable to 
provide consent, from their legally approved surrogate.  
 
Randomisation and masking 
The patient’s clinician entered the patient’s baseline data (table 1) into a secure, password-
protected, centralised, web-based randomisation system which checked the data for 
completeness and consistency and generated a unique study identification number and 
treatment pack number corresponding to fluoxetine or placebo in a 1:1 ratio. A minimisation 
algorithm14 was used to achieve balance between the treatment groups in four predictors of the 
primary outcome (mRS): time after stroke onset (2-8 vs 9-15 days), presence of a motor deficit 
(National Institutes of Health Stroke Scale [NIHSS] questions 5 and 6), presence of aphasia 
7 
 
(NIHSS question 9), and probability of survival free of dependency (mRS 0-2) at 6 months 
(0.00 to ≤0∙15 vs >0∙15-1.00) calculated using a validated prognostic model comprising six 
baseline variables (age, living alone before the stroke, independent in activities of daily living 
before the stroke, and able to talk, lift both arms off the bed, and walk unassisted at 
randomisation).15 
 
All patients, carers, investigators, and outcome assessors were masked to the allocated treatment 




Fluoxetine 20mg capsules or matching placebo capsules were administered orally, once daily, 
for 6 months. If patients were unable to swallow, the capsules were broken open and contents 
administered via an enteral feeding tube.  
 
Siegfried Malta Ltd, Hal Far, Malta, manufactured the capsules containing fluoxetine 20mg 
according to Good Manufacturing Practice (certificate MT/008HM/2017). Arena 
Pharmaceuticals GmbH, Zofingen, Switzerland, packed the capsules for Amneal 
Pharmaceuticals Pty Ltd, South Yarra, Australia, which was the Therapeutic Goods 
Administration (TGA) licence holder (sponsor) for the finished product in Australia. 
Pharmaceutical packaging professionals (PPP) Pty Ltd, Port Melbourne, Australia purchased 
the fluoxetine capsules and manufactured the matching placebo capsules. PPP packaged the 
trial medication in patient kits, labelled the bottles with trial-specific treatment codes 
(fluoxetine or placebo), and packaged, stored and distributed the medication. The patient kits 
in Australian and New Zealand comprised two bottles, each containing 110 capsules, which 
were dispensed at randomisation and day 90. An extra 20 capsules were a reserve in the event 
of any delay in attending the day 90 follow-up, or any loss or spillage of capsules. For patients 
in Vietnam, the kits comprised 6 bottles of trial medication, each containing 35 capsules. One 
bottle was dispensed at randomisation, two bottles at day 28, and three bottles at day 90. The 
TGA of the Australian government’s Department of Health approved the export of trial 
medication to New Zealand and Vietnam (approval Ref No: EX17/336513). 




Patients recruited in Australia and New Zealand were assessed by site investigators at 28 days 
(1 month) and 90 days (3 months) post-randomisation in the hospital ward or outpatient clinic 
or via telephone or email; or, failing that, by a study nurse at the patient’s residence. Follow-
up at 180 days (6 months) was by postal questionnaire or telephone by trained staff in the trial 
coordinating centre in Perth, Australia. Patients recruited in Vietnam were assessed by the site 
investigator at 28, 90 and 180 days post-randomisation in the hospital ward or outpatient clinic, 
or via telephone or email; or, failing that, at the patient’s residence. If the patient was unable 
to complete the assessments, assistance was sought from their proxy (next of kin, close family 
member or carer). Each assessment recorded the primary outcome (mRS), secondary outcomes 
(table 2), safety and adverse events (table 3), all current medications, and adherence to trial 
medication. Serum sodium, eGFR, and liver function were measured at the 28 day follow-up 
visit if clinically appropriate. Adherence to trial medication was assessed by asking: ‘On 
average, since the last follow-up, how many times per week was the trial medication taken? ‘0, 
1-2, 3-4, 5-6 or 7 times per week’; and by pill counts and collection of returned trial bottles. 
Bottle and pill counts were conducted by hospital trial pharmacists, and entered on a drug 
accountability form. Any interruption to trial medication was recorded as temporary or 
permanent, together with the dates and reasons for stopping and re-starting.  
 
If patients developed new depression requiring treatment during the trial treatment period, the 
protocol recommended continuation of trial medication and consideration of non-
pharmacological (e.g. psychological) interventions. If antidepressant medication was 
necessary, referral to a psychiatrist was recommended for consideration of potential 
interactions of any new medication with fluoxetine and risks of serotonin toxicity.  
 
There were 57 protocol violations in 56 patients (4.4%): 20 (1.6%) patients were prescribed 
open-label fluoxetine; 8 (0.6%) were prescribed another SSRI; 16 (1.3%) lost their trial 
medication or did not take it as prescribed; 4 (0.3%) took medications that could interact with 
fluoxetine (e.g. antipsychotic, tramadol); 7 (0.5%) patients were >14 days late for scheduled 
follow-up; one patient enrolled in another trial was ineligible, and four patients had a final 





The primary outcome was functional status, as measured by the mRS, at 6 months after 
randomization.16 The mRS is an ordinal scale which assigns patients to seven ordered, but not 
equally spaced, levels of functional ability, ranging from 0 (symptom free) to 6 (dead).  
 
Secondary outcomes at 6 months were survival, depression (PHQ-9 score > 1517), cognition 
(Telephone Interview for Cognitive Status [TICSm]18), communication, motor function, 
overall health status (Stroke Impact Scale [SIS] version 3.019), fatigue (vitality subscale of the 
SF-3620,21) and health-related quality of life (HRQoL) using the EQ-5D-5L.22 A new diagnosis 
of depression requiring treatment with antidepressants was assessed at 1, 3 and 6 months by 
asking patients if they had been diagnosed with depression since their previous assessments, 
and verifying the diagnosis and treatment with their clinician. 
 
Serious adverse events during follow-up included recurrent stroke (ischaemic or 
haemorrhagic), acute coronary syndromes, upper gastrointestinal bleeding requiring blood 
transfusion and/or endoscopy, other major bleeding (subdural, extradural, ocular, lower 
gastrointestinal) requiring blood transfusion or procedural intervention, falls with injury, new 
bone fractures, epileptic seizures, symptomatic hypoglycaemia (blood glucose < 3mmol/l), 
symptomatic hyperglycaemia (blood glucose > 22mmol/l), new hyponatraemia (blood sodium  
< 125mmol/l), attempted suicide or self-harm, and death. 
 
Statistical analysis 
A detailed statistical analysis plan was formulated and published before recruitment was 
completed and without awareness of any unblinded data.8 
 
We estimated from other concurrent studies of patients with acute stroke that 42.2% of patients 
assigned placebo would be functionally independent (mRS 0-2) at 6 months after 
randomisation.23,24 We calculated the odds ratio (OR) of functional independence (mRS 0-2) 
with fluoxetine vs placebo in the FLAME study5 to be 3.57 (95%CI: 1.2 to 10.6). We 
considered a conservative estimate of the effect of fluoxetine may be toward the lower 95% CI 
of the OR estimate reported in FLAME (e.g. OR 1.34). If fluoxetine increased the proportion 
of patients who were functionally independent at 6 months by an OR of 1.34, from 42.2% 
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(placebo) to 49.4% (fluoxetine), this would be clinically important and consistent with our 
Cochrane review.6 Assuming a common OR of 1.34 for each cut-point across the mRS (e.g. 0 
vs 1-6, 0-1 vs 2-6, etc) in the proportional odds logistic model, we estimated that the trial would 
require 1600 patients to have 90% power, if up to 10% of patients dropped out before final 
follow-up (i.e. 1440 patients with primary outcome data).8,25  
 
All analyses, including primary and secondary outcomes and adverse events, were by intention-
to-treat, according to the treatment allocation. A secondary safety analysis was undertaken 
according to the treatment patients received rather than what they were randomly allocated. 
 
The primary analysis was an ordinal analysis of the mRS scores at 6 months in each treatment 
group using ordinal logistic regression and after adjusting for the baseline factors included in 
the minimisation algorithm.8 The ordinal analysis of mRS was undertaken by treatment 
allocation, under the assumption of proportional odds in the model. The result was expressed 
as a common OR (less than 1.0 favoured placebo) and its 95% confidence interval (CI). We 
also performed 6 binary unadjusted logistic regressions, each corresponding to the 6 possible 
dichotomisations of scores on the mRS.  
 
Secondary analyses compared the following outcomes at 6 months in each treatment group: 
survival, depression (changes in PHQ-9 scores and proportion with PHQ-9 ≥ 15 ),17 cognition 
(TICSm scores),18 communication (SIS),19 motor function (SIS),19 overall health status (SIS),19 
HRQoL (EQ-5D-5L),22 new diagnosis of depression requiring treatment with antidepressants, 
fatigue (vitality domain of the SF-36)20,212, trial medication adherence and cessation, and 
serious adverse events. The frequencies of categorical outcome events in each group were 
compared using Fisher’s exact test. For continuous outcomes, the mean or median in each 
group, depending on the distribution, were calculated with measures of dispersion (standard 
deviation [SD] or inter-quartile range [IQR]). The probability that outcomes in the fluoxetine 
group were significantly different from the placebo group were calculated as p-values.   
 
Pre-specified subgroup analyses of the effect of fluoxetine vs placebo on the primary outcome 
were undertaken for country of randomisation (Australia/New Zealand vs Vietnam), age (<70 
vs >70 years), time from stroke onset to randomisation (2-8 vs 9-15 days), stroke pathology 
(ischaemic vs haemorrhagic), stroke severity (NIHSS scores < median [0-5] vs > median [>5]), 
11 
 
motor deficit (present vs absent), aphasia (present vs absent), probability of survival free of 
dependency (0.00 to <0.15 vs >0.15 to 1.00), self-reported depression at baseline, and source 
of informed consent.8  
 
We also undertook pre-specified per-protocol analyses, which sequentially excluded subgroups 
of patients who did not meet our eligibility criteria or had incomplete adherence to the trial 
medication. 
 
Post-hoc sensitivity analyses of the primary outcome were undertaken to evaluate the possible 
effect of including patients who were lost to follow-up. We tested the robustness of the results 
by assuming two extreme imputation scenarios: one favouring fluoxetine where all patients 
with missing mRS data were imputed a score of 0 in the fluoxetine arm and a score of 6 in the 
placebo arm, and another scenario favouring placebo where the imputation was reversed. 
 
Statistical analyses were undertaken with SAS, version 9.4 
 
An independent data monitoring committee (DMC) oversaw the study. The unmasked trial 
statistician (Q Yi) prepared analyses of the accumulating data, which the DMC reviewed in 
confidence at least annually. 
 
The trial is registered with the Australian New Zealand Clinical Trials Registry, number 
ACTRN12611000774921. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data 




A total of 1280 patients consented and were randomised at 43 sites in Australia, New Zealand 
and Vietnam between 11 January, 2013 and 30 June, 2019. Recruitment was terminated before 
the target of 1600 patients was reached because funding expired on 31 December 2019.  
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642 patients were randomly allocated to fluoxetine and 638 to placebo. One patient did not 
meet our eligibility criteria after discovery of participation in another trial of an IMP. In four 
patients, the diagnosis was later revised to be non-stroke (table 1).  
Baseline characteristics in the two groups were balanced (table 1)  
By 6 months, 22 (1.7%) patients had withdrawn consent for follow-up and 2 (0.2%) were lost 
to follow-up (fig 1). There was no difference in the methods of follow-up between groups 
(appendix table 1, p8). Trial medication was started in 1273 patients, and temporarily and 
permanently stopped in 158 and 208 patients respectively (appendix, table 2, p9). There was 
no significant difference between groups in temporary and permanent discontinuation of trial 
medication (appendix table 2, p9) or time to permanent discontinuation (p=0.75; appendix 
figure 1, p14). There were also no differences between groups in compliance with trial 
medication (appendix table 3, p10). The mean duration of trial treatment was 167 days (SD 
48.1) days.  
The mRS at 6 months was assessed and analysed in 624 (97.2%) patients allocated fluoxetine 
and 632 (99.1%) placebo. An ordinal comparison of the distribution of patients across mRS 
categories at 6 months, adjusted for variables in the minimisation algorithm, was similar in 
both groups (common OR 0.936, 95% CI 0.762-1.150; p=0.53; figure 2). A common OR <1.0 
favours placebo. The unadjusted analysis produced similar results (common OR 0.966, 95%CI 
0.790-1.181; p=0.74; appendix table 4, p11). The assumption of proportional odds in the model 
of mRS by treatment was upheld in the score test for proportional odds assumption (p=0.44 
unadjusted). Dichotomised mRS scores were also not significantly different between groups 
for mRS 0-2 vs 3-6 (unadjusted OR 0.855, 95%CI 0.670-1.091; p=0.21; post-hoc adjusted 
OR=0.823, 0.628-1.077; p=0.16), or other dichotomies of the mRS (appendix table 4, p11). 
Analysis of the primary outcome showed no significant interactions or modification of the 
effect of fluoxetine across several pre-specified subgroups (appendix figure 2, p15).  
Secondary efficacy outcomes at 6 months are shown in table 2. Patients allocated fluoxetine 
had higher scores in the SIS domain of mood and emotional control compared to placebo 
(p=0.003), but there were no significant differences between treatment groups in the other 10 
domains of the SIS (including measures of motor function [strength, hand ability, mobility] 
and daily activities), other assessment scales, or death. There was a reduction in new diagnoses 
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of post-stroke depression which was not statistically significant (33 [5.14%] fluoxetine vs 46 
[7.21%] placebo; absolute risk difference 2.07%; 95% CI -0.57% to 4.41%]). 
Adverse events at 6 months are shown in table 3. Compared to patients allocated placebo, those 
allocated fluoxetine had more falls causing injury (20 [3.12%] vs 7 [1.10%]; difference 2.02% 
[95CI: 0.45-3.59]; p=0.02), bone fractures (19 [2∙96%] vs 6 [0.94%]; difference 2.02% [0∙51–
3.53]; p=0∙01) and epileptic seizures (10 [1.56%] vs 2 [0.31%]; difference 1.24% [0.19-2.30]; 
p=0.04). There were no significant differences between groups in other events, including 
survival (p = 0.71, appendix, figure 3, p16). Trial medication was stopped by 68 patients (27 
allocated fluoxetine, 41 placebo) due to a suspected adverse reaction to the medication. No 
patients required a reduction in dose of trial medication (e.g. alternate daily) and there were no 
treatment-related deaths. 
The primary results were not altered by sensitivity analyses confined to patients who adhered 
to the trial protocol and allocated treatment (appendix table 5, p12).  
A post-hoc analysis, imputing missing mRS data under two extreme scenarios, also produced 
non-significant results for the most extreme scenarios in favour of fluoxetine (unadjusted OR 
1.082, 95%CI 0.887-1.320; p=0.44; adjusted OR 1.054, 0.861-1.291; p=0.61), and in favour of 
placebo (unadjusted OR 0.860, 0.705-1.050; p=0.14; adjusted OR 0.833, 0.680-1.020; p=0.09). 
Discussion 
The main finding of the AFFINITY trial was that adding fluoxetine 20mg daily for 6 months 
after acute stroke to interdisciplinary stroke unit care did not improve functional outcome at 6 
months in an ethnically diverse population. Other major findings were that fluoxetine increased 
falls, fractures, and epileptic seizures at 6 months. 
 
Key strengths of the trial are that it was undertaken in stroke units throughout Australia, New 
Zealand and Vietnam where the AFFINITY trial medication was added to best-practice, 
comprehensive interdisciplinary stroke care and rehabilitation. Several potential sources of 
systematic error (bias) in the assessment of fluoxetine vs placebo were minimised. Systematic 
pre-treatment differences in comparator groups (selection bias) were minimised by concealed, 
central, web-based randomisation. Adherence to trial medication was high and similar between 
treatment groups (performance bias). Systematic differences between groups in other care 
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provided (performance bias) and reporting and assessment of outcome events (observer 
detection bias) were minimised by masking of patients, investigators and adjudicators to the 
allocated treatment. Follow up for the primary outcome was high and there was no difference 
between groups in withdrawals from treatment (attrition bias). Random error was reduced to 
some extent by almost complete follow-up of a large number of patients (n=1256, 98%), which 
was a higher proportion than planned in our sample size calculations (90% of 1600; n=1440). 
The inclusion of an international mix of ethnic groups managed in different health care systems, 
and a comprehensive array of secondary outcome measures, including cognition, mood and 
motor scales, support the external validity (generalisability) of the trial results. 
 
Potential limitations of the trial include our failure to recruit the target sample size of 1600 
patients due to funding constraints (1280 patients recruited; 1256 with primary outcome data 
vs 1440 planned to have primary outcome data). We also failed to recruit a larger number of 
patients with severe, disabling stroke. Hence, the proportion of patients assigned placebo who 
recovered functional independence (mRS 0-2) at 6 months was higher (n=458, 72%) than 
estimated in our sample size calculations (42%). The dose of fluoxetine was 20 mg once daily 
because this was the dose reported to be effective in the FLAME trial5 and used in other 
fluoxetine trials for stroke recovery,6 and is less likely to cause adverse effects than higher 
doses. However, we did not test higher doses of fluoxetine. Our measures of adherence to trial 
medication by self-report and capsule-counting were prone to error (e.g. the absence of tablets 
in the bottles returned to investigators may not necessarily mean adherence to taking the 
tablets) and therefore, our estimates of adherence and compliance may be inflated. However, 
there was no difference between groups in reported adherence to, and discontinuation of, trial 
medication. The nature and degree of adjunctive rehabilitation was not documented because 
that would have added complexity and potential measurement error to this pragmatic trial. 
However, all patients were admitted to stroke units where organised interdisciplinary 
assessment, and rehabilitation as required, was provided as standard practice. The nature and 
intensity of all rehabilitation interventions were likely to be balanced between the treatment 
groups, in the same way that all baseline variables were balanced between groups, due to the 
randomisation process and double-blind trial treatment allocation. There was a slight difference 
in ascertainment of mRS status at 6 months between groups (fluoxetine n=624, 97.2% vs 
placebo n=632, 99.0%) but sensitivity analyses using imputations led to consistent conclusions. 
Our primary measure of efficacy was a broad measure of functional outcome which may not 
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be sensitive to changes in measures of specific neurological functions, However, we also 
measured 11 domains of the SIS, including measures of motor function (strength, hand ability, 
mobility), physical function, and daily activities, and found no effect of fluoxetine on any of 
these measures. The mRS may be less sensitive to change in patients with less severe stroke 
but there was no evidence of an effect of fluoxetine on the mRS in patients with more severe 
stroke (NIHSS > 5; appendix figure 2, p15), and no effect of fluoxetine on any secondary 
outcome except mood and emotional control. 
 
The AFFINITY trial was smaller than the FOCUS trial9 but both trials recruited patients of 
similar sex (women 38%), stroke severity (median NIHSS=6) and at a similar time (one week, 
mean) after stroke onset. The AFFINITY trial population was a unique mix of Vietnamese 
(n=727, 57%) and Australasians (n=553, 43%), whereas the FOCUS population was 
predominantly Caucasian (n=2988; 96%). Patients in AFFINITY were also younger (mean age 
64 years AFFINITY, vs 71 years in FOCUS), and more likely to be married (n=926, 72% vs 
n=1725, 55%), living with someone else (n=1120, 87% vs n=2091, 67%), employed (n=531, 
41% vs n=691, 22%), and independent before their stroke (n=1264, 99% vs n=2866, 92%) 
compared to FOCUS. Adherence to trial medication was higher in AFFINITY than FOCUS; 
34 (5.4%) patients assigned fluoxetine and 30 (4.8%) placebo stopped trial medication within 
the first 90 days, whereas in FOCUS, 143 (9%) patients assigned fluoxetine and 122 (8%) 
placebo stopped trial medication within the first 90 days. Despite these differences, the results 
of the AFFINITY trial almost replicate those of the FOCUS trial,9 supporting the internal and 
external validity of both trials. Furthermore, the EFFECTS trial of fluoxetine vs placebo in 
1500 stroke patients in Sweden also reports similar results to FOCUS and AFFINITY.13 
Moreover, the results of the FOCUS, AFFINITY and EFFECTS trials are all consistent with 
the totality of evidence from all RCTs of SSRIs for stroke recovery,26 and all RCTs specifically 
testing fluoxetine.27 Collectively, these trials provided compelling evidence that fluoxetine 
does not improve functional outcome after stroke.  
 
The outstanding inconsistency among all the RCT evidence is the FLAME trial, which did 
report a significant benefit of fluoxetine on motor recovery after stroke.5 The FLAME trial 
differed from AFFINITY, FOCUS and EFFECTS in that it was a phase II trial of fluoxetine 20 
mg daily vs placebo in a select population of 118 patients with recent (5-10 days) ischaemic 
stroke and a moderate to severe hemiparesis or hemiplegia, defined by a Fugl-Meyer motor 
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scale (FMMS) score <55.5 The FMMS ranges from 0 (hemiplegia) to 100 points (normal motor 
performance), with 66 points for the upper extremity and 34 points for the lower extremity. 
Patients enrolled in FLAME had more severe strokes (mean baseline NIHSS 13 vs median 
NIHSS 6 in AFFINITY).5 Somatosensory and other neurological deficits that may influence 
recovery were not reported. The primary outcome, the mean change in FMMS scores between 
randomisation and day 90, was greater with fluoxetine than placebo (34·0 points fluoxetine vs 
24·3 points placebo; difference 9.8 points, 95%CI: 3.4 to 16.1, p=0·003). The proportion of 
functionally independent patients (mRS scores 0-2) at day 90 was also higher with fluoxetine 
than placebo (n=15, 26% vs n=5, 9%; p=0.02), but there were no differences between 
fluoxetine and placebo for other mRS categories. The FLAME trial result may be a false-
positive due to random error (chance), as only 57 patients were treated with fluoxetine and 
followed-up to 90 days,5 and there is large variation in spontaneous motor recovery after acute 
stroke.28 Alternatively, the FLAME trial result may a true-positive, and fluoxetine may indeed 
improve motor recovery in patients with severe motor impairment. The AFFINITY trial did 
not include a large number patients with severe hemiparesis and did not measure motor 
recovery by the FMMS, but did measure motor functions as domains within the SIS and found 
no effect of fluoxetine. Our planned individual patient data meta-analysis of the FOCUS, 
AFFINITY and EFFECTS trials8 will constitute a larger number of stroke patients with severe 
motor impairments and promises to enable a more reliable analysis of the effect of fluoxetine, 
vs placebo, on the mRS and motor domains of the SIS at 6 months in this subgroup. 
 
The AFFINITY trial also confirms the FOCUS trial finding that long-term fluoxetine in stroke 
patients has hazards, increasing the risk of bone fractures.9 We also found that fluoxetine 
significantly increased the risk of falls with injury and epileptic seizures in stroke patients. The 
FOCUS trial reported similar, but not significant, increases in falls with injury and seizures in 
patients allocated fluoxetine.9 The AFFINITY and FOCUS trials collectively provide robust 
evidence about the effect of an SSRI on the incidence of falls causing injury, and fractures, 
increasing the absolute risk of each by about 2% over 6 months among patients with recent 
stroke. 
 
Although fluoxetine is more effective than placebo in treating major depressive disorders,10 
and reduced the rate of new depression in the FOCUS,9 and other trials,27,29 we observed only 
improved mood and emotional control, as measured by the SIS, at 6 months with fluoxetine; 
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the numerically lower rate of post-stroke depression with fluoxetine vs placebo was not 
statistically significant. We believe we lacked statistical power to show a significant effect of 
fluoxetine on post-stroke depression because the absolute rates of depression in both groups in 
AFFINITY were substantially lower (less than half) than in FOCUS, possibly from under-
reporting, particularly in Vietnam where the reporting of changes in mood may be affected by 
the cultural setting.30 
 
In summary, the AFFINITY trial reinforces the conclusion of a recent Cochrane review that 
SSRIs are not effective at improving functional outcome after stroke. It also confirms that 
fluoxetine may improve mood but have important adverse effects, particularly bone fractures. 
A planned individual patient data meta-analysis of the AFFINITY, FOCUS and EFFECTS 
trials will produce greater precision in the estimates of the effects of fluoxetine on functional 
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1280 consented and randomly 
assigned 
642 assigned to fluoxetine group 
 637 received fluoxetine 
 5      did not receive fluoxetine  
        (medication was lost after discharge; 
        family’s/patient’s decision to not start) 
 
638 assigned to placebo group 
 635 received placebo 
 2     did not receive placebo  
(family’s/patient’s decision to not start; 
ineligible [randomising event was a TIA]) 
 
621 submitted 180-day 
form 
 100  discontinued 
placebo 
 632  had mRS data 
available 
30 did not submit 180-day 
form 
 12   died 
 17 withdrew consent 
 1     too late (>14 days)    
17 did not submit 180-day 
form 
 11  died 
 5    withdrew consent 
 1    too late (>14 days)    
 
642 analysed 
 624 analysed for mRS  
(mRS not available for 18) 
612 submitted 180-day 
form 
 108  discontinued 
fluoxetine 
 624  had mRS data 
available  
638 analysed  
 632 analysed for mRS  












Figure 2.  
Primary outcome of the distribution of the modified Rankin Scale (mRS) scores at 6 
months by treatment group. 
The primary outcome was an assessment of scores across all seven categories of the mRS 
(ranging from 0 [no symptoms] to 6 [death]), using a shift analysis of the ordinal data. The 
odds ratio and p-values were calculated with ordinal logistic regression, adjusted for the 
baseline variables included in the minimisation algorithm (delay between stroke onset and 
randomization, probability of being alive and independent at 6 months, presence of a motor 
deficit, presence of aphasia). mRS data at 6 months were available for 624 (97.2%) patients 
allocated fluoxetine and 632 (99.1%) allocated placebo. The common odds ratio was 0.936 
(95%CI: 0.762 to 1.150), p= 0.53; adjusted for baseline minimization variables. A common 
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Sex   
Women    231 (36%) 245 (38%) 
Men 411 (64% ) 393 (62% ) 
Age   
Age < 70 years 450 (70% ) 432 (68% ) 
Age >70 years 192 (30% ) 206 (32% ) 
Mean age, years 63.5 (12.5 ) 64.6 (12.2 ) 
Ethnicity   
Asian 356 (55% ) 371 (58% ) 
White  267 (42% ) 255 (40% ) 
Other 19 (3% ) 12 (2%) 
Marital status   
Married 463 (72% ) 463 (73% ) 
Partner 29 (4% ) 19 (3% ) 
Divorced or separated 37 (6% ) 46 (7% ) 
Widowed 61 (9% ) 70 (11% ) 
Single 52 (8% ) 38 (6% ) 
Other 0 (0% ) 2 (0% ) 
Living arrangements   
Living with someone else 564 (88% ) 556 (87% ) 
Living alone 78 (12% ) 78 (12% ) 
Living in an institution 0 (0% ) 2 (0% ) 
Other 0 (0% ) 2 (0% ) 
Employment status   
Full-time employment 206 (32% ) 180 (28% ) 
Part-time employment 77 (12% ) 68 (11% ) 
Retired 315 (49% ) 363 (57% ) 
Unemployed or disabled 24 (4% ) 14 (2% ) 
Other  20 (3% ) 13 (2% ) 
Independent before stroke 634 (99% ) 630 (99% ) 
Previous medical history   
Coronary Heart Disease 58 (9% ) 57 (9% ) 
Ischaemic stroke or TIA  77 (12% ) 84 (13% ) 
Diabetes 143 (23% ) 147 (23% ) 
Hyponatraemia 1 (0% ) 3 (0% ) 
Intracranial bleed 11 (2% ) 8 (1% ) 
Upper gastrointestinal bleed 11 (2% ) 15 (2% ) 
Bone fractures 71 (11% ) 74 (12% ) 
Depression 30 (5% ) 20 (3% ) 
Stroke diagnosis   
Non-stroke (final diagnosis) 3 (0% ) 1 (0% ) 




Intracerebral haemorrhage 90 (14% ) 95 (15% ) 
OCSP classification of Ischaemic stroke   
Total anterior circulation infarct  47 (9% ) 50 (9% ) 
Partial anterior circulation infarct  271 (49% ) 283 (52%) 
Lacunar infarct 115 (21% ) 105 (19% ) 
Posterior circulation infarct 114 (21% ) 103 (19%) 
Uncertain 2 (0% ) 1 (0% ) 
Causes of ischaemic stroke (modified 
TOAST classification) 
  
Large artery disease 123 (22% ) 134 (25% ) 
Small vessel disease 261 (47%) 250 (46%) 
Embolism from the heart 95 (17%) 93 (17%) 
Another cause 9 (2%) 8 (1%) 
Unknown or uncertain cause 61 (11%) 57 (10%) 
Predictive variables    
Able to walk at time of randomisation 282 (44%) 279 (44%) 
Able to lift both arms off bed 443 (69%) 431 (68%) 
Able to talk and not confused 554 (86%) 557 (87%) 
Predicted 6-month outcome based on 
SSV 
  






0.00 to < 0.15 100 (15%) 103 (16%) 
0.15 to 1.00 542 (84%) 535 (84%) 
Neurological deficits   
NIHSS 6 (3-9)             6 (3-9) 
Presence of a motor deficit 557 (87%) 548 (86%) 
Presence of aphasia 129 (20%) 121 (19%) 
Depression at baseline   
Current diagnosis of depression (patient 
or proxy reported) 
15 (2%) 17 (3%) 
Taking a non-SSRI antidepressant 5 (1%) 5 (1%) 
Current mood   
PHQ-9, median (IQR)           4 (1-7) 4 (2-7) 
0-14 601 (98%) 596 (98%) 
>15 12 (2%) 11 (2%) 
Delay (days) since stroke onset at 
randomisation 
  
Mean delay  6.1 (3%) 6.3 (3%) 
2-8 days 486 (76%) 479 (75%) 
9-15 days 156 (24%) 159 (25%) 
Consent   
Patient consented  345 (54%) 328 (51%) 
Person responsible consented 284 (44%) 295 (46%) 
Proxy consented 3 (0%) 1 (0%) 





Data are n (%), mean (SD [standard deviation]), or median (IQR [interquartile range]) 
TIA: transient ischaemic attack 
OCSP = Oxfordshire Community Stroke Project 
TOAST = modified Trial of ORG 10172 in acute stroke treatment criteria 
SSV = Six simple variables the predict functional outcome, as measured by the mRS, after 
stroke (age, living alone before the stroke, independent in activities of daily living before the 
stroke, and able to talk, lift both arms off the bed, and walk unassisted at the time of 
randomisation).15 
NIHSS = National Institutes of Health Research Stroke Scale 
SSRI: selective serotonin reuptake inhibitor 





Table 2.  Secondary outcomes at six months by allocated treatment  
  Fluoxetine (n=642)  Placebo (n=638)  P value 
New depression  
   N / N (%) 
33 (5.1%)  46 (7.2%)  0.13 
Mood (PHQ-9) 2.0 (1.0-5.0 ) 2.0 (1.0-5.0 ) 0.42 
   PHQ-9 >15   
   N / N% 
4 (0.7%)  6 (1.0%)  0.75 
Cognition (TICSm) 24.0 (20.0 -27.0 ) 24.0 (19.0-27.0 ) 0.62 
Stroke Impact Scale 
(SIS) domains 
     
-Strength 75.0 (56.3-93.8 ) 75.0 (56.3-93.8 ) 0.26 
-Hand ability 85.0 (55.0-100.0 ) 85.0 (55.0-100.0 ) 0.39 
-Mobility 91.7 (69.4-100.0 ) 88.9 (66.7-97.2 ) 0.08 
-Motor†  83.5 (63.5-94.2 ) 82.4 (60.4-93.2 ) 0.28 
-Daily Activities 90.0 (72.5-100.0 ) 90.0 (70.0-97.5 ) 0.25 
-Physical function‡ 85.5 (66.2-94.9 ) 83.8 (63.4-93.8 ) 0.24 
-Memory 89.3 (78.6-100.0 ) 89.3 (75.0-100.0 ) 0.28 
-Communication 98.2 (89.3-100.0 ) 96.4 (85.7-100.0 ) 0.61 
-Mood/Emotions^ 80.6 (66.7 -88.9 ) 77.8 (66.7 -86.1 ) 0.003 
-Participation 81.3 (59.4 -96.9 ) 75.0 (56.3 -96.9 ) 0.48 
-Recovery (VAS) 80.0 (60.0 -90.0 ) 80.0 (60.0 -90.0 ) 0.90 
Vitality (SF-36) 70.0 (55.0 -80.0 ) 70.0 (55.0 -80.0 ) 0.36 
EQ5D-5L  0.81 0.63-1.00 0.78 0.58-0.93 0.08 
 
Data were only available for those who survived and who completed sufficient questions to derive a 
score. The number of patients with missing scores were similar in the two treatment groups. 
Data are median (IQR). 
PHQ-9: Patient Health Questionnaire 9 items (higher score indicates more depressive symptoms) 
TICSm:  Telephone Interview for Cognitive Status  
SIS: Stroke Impact Scale (where higher scores are better).      
†Mean of the Strength, Hand ability, and Mobility domains.  
‡Mean of the Strength, Hand ability, Mobility, and Daily activities domains. 
^Mood/Emotions domain of the SIS: Nine questions about “how you feel, changes in your mood, and 
your ability to control your emotions, since your stroke.” (where higher scores are better) 
VAS: visual analogue scale. 
SF-36: 36 item short form questionnaire (higher scores indicate less disability) 
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EQ5D-5L:  EuroQoL - 5 Dimensions (Mobility, Personal Care, Usual Activities, Pain/Discomfort, 
Anxiety/Depression) - 5 Levels (where 1 indicates the best health imaginable, and −0.676 indicates 






Table 3.  Adverse events at 6 months by allocated treatment group 
   




Difference (95% CI)* P-
value 
 
Death 15 (2.34%) 15 (2.35%) -0.01% (-1.64 to 1.67) 1.00 
Any stroke 18 (2.80%) 26 (4.08%) -1.27% (-3.27 to 0.72) 0.22 
All thrombotic events     
   Ischaemic stroke 11 (1.71%) 21 (3.29%) -1.58% (-3.29 to 0.13) 0.08 
   Acute coronary events 1 (0.16%) 2 (0.31%) -0.16% (-0.69 to 0.37) 0.62 
All bleeding events     
   Haemorrhagic stroke 3 (0.47%) 1 (0.16%)  0.31% (-0.30 to 0.92) 0.62 
   Upper gastrointestinal bleed 1 (0.16%) 1 (0.16%) 0.00% (-0.43 to 0.43) 1.00 
Epileptic seizures 10 (1.56%) 2 (0.31%) 1.24% (0.19 to 2.30) 0.04 
Fall with injury 20 (3.12%) 7 (1.10%) 2.02% (0.45 to 3.59) 0.02 
New bone fracture 19 (2.96%) 6 (0.94%) 2.02% (0.51 to 3.53) 0.01 
Hyponatraemia < 125mmol/l 3 (0.47%) 2 (0.31%) 0.15% (-0.53 to 0.84) 1.00 
Hyperglycaemia 0 (0%) 0 (0%) 0%  
Symptomatic hypoglycaemia 0 (0%) 0 (0%) 0%  
New depression 33 (5.14%) 46 (7.21%) -2.07% (-4.71 to 0.57) 0.13 
New antidepressant 30 (4.67%) 43 (6.74%) -2.07% (-4.61 to 0.47) 0.12 
Attempted or actual suicide 0 (0%) 2 (0.31%) -0.16% (-0.75 to 0.12) 0.25 
Other adverse event  62 (9.66%) 68 (10.66%) -1.00% (-4.31 to 2.31) 0.56 
 
Data are n (%), unless otherwise stated 
 
* Risk differences and their 95%confidence intervals were calculated in SAS  by 
means of the FREQ procedure.    
https://documentation.sas.com/?docsetId=procstat&docsetTarget=procstat_freq_detail
s54.htm&docsetVersion=9.4&locale=en (accessed March 18, 2020). The confidence 
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Essie Low, Cynthia Chen, Jennifer Bergqvist); 
Manly Hospital, NSW, [2] (Andrew Evans (PI) Queenie Leung); 
Wagga Wagga Base Hospital, NSW, [1] (Martin Jude (PI), Rachael McQueen, Katherine 
Mohr, Latitia Kernaghan); 
Flinders Medical Centre, SA, (Andrew Lee (PI), Paul Stockle, Boon Loong Tan, Sara 
Laubscher); 
Australian participating States Abbreviation Key: 
NSW = New South Wales 
QLD = Queensland 
SA = South Australia 
VIC = Victoria 
WA = Western Australia 
New Zealand [42 patients recruited] 
Hawke’s Bay Hospital [14] (John Gommans (PI), Diana Schmid, Melissa Spooner); 
Taranaki Base Hospital [14] (Bhavesh Lallu (PI), Bronwen Pepperell, John Chalissery); 
Rotorua Hospital [8] (Karim Mahawish (PI), Susan DeCaigney, Paula Broughton, Karen 
Knight, Veronica Duque); 





Supplementary table 1. 
Methods of patient follow-up  









Day 28    
Outpatient Clinic 345 356  
Telephone 195 212  
Hospital 76 57  
Other (e.g. email, home visit) 20 11  
Missing 2 1  
Total submitted  638 637 0.0928 (0.1290B) 
    
Day 90    
Outpatient Clinic 357 360  
Telephone 233 239  
Hospital 14 6  
Other (e.g. email, home visit) 21 26  
Missing 4 0  
Total submitted  629 631 0.2848 (0.1020 B) 
    
Day 180    
Outpatient Clinic 295 321  
Telephone 300 287  
Other (e.g. email, home visit) 15 12  
Missing 2 1  
Total submitted  612 621 0.4410 (0.5879 B) 
A. P-values are based on the combined methods of follow-up (in-hospital assessment, 
outpatient clinic, telephone, home visit, and email). 
B. P-values in brackets include missing data as another category. 
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Supplementary table 2. 
Adherence to trial medication in each treatment group and overall:  
















    
0-1 month 46/638 (7.2) 37/637(5.8) 83/1275(6.5) 0.3104 
1-3 month 34/629(5.4) 28/631(4.4) 62/1260(4.9) 0.4270 
3-6 month 19/612(3.1) 14/621(2.3) 33/1233(2.7) 0.3551 
Total* 87 71 158  
     
Permanent 
cessation 
    
0-1 month 47/638(7.4) 46/637  (7.2) 93/1275 (7.3) 0.9205 
1-3 month 34/629(5.4) 30/631(4.8) 64/1260 (5.2) 0.5987 
3-6 month 27/612(4.4) 24/621(3.9) 50/1233(4.1) 0.6296 
Total  108 100 208  
 




Supplementary table 3. 
Compliance with trial medication (actual dosing history compared to the prescribed 
drug regimen of once daily, 7 times per week) in each treatment group and overall.* 
Time point 
Average number of 














   
0.5703 
      0 times per week 26 /630 (4.1 ) 25 /631 (4.0 ) 51 /1261 (4.0 )  
      1-2 times per week 16 /630 (2.5 ) 9 /631 (1.4 ) 25 /1261 (2.0 )  
      3-4 times per week 8 /630 (1.3 ) 10 /631 (1.6 ) 18 /1261 (1.4 )  
      5-6 times per week 24 /630 (3.8 ) 17 /631 (2.7 ) 41 /1261 (3.3 )  
      7 times per week 556 /630 (88.3 ) 570 /631 (90.3 ) 1126 /1261 (89.3 )  
        Missing 8 6 14  
3 months 
   
0.9398 
      0 times per week 63 /622 (10.1 ) 62 /625 (9.9 ) 125 /1247 (10.0 )  
      1-2 times per week 6 /622 (1.0 ) 6 /625 (1.0 ) 12 /1247 (1.0 )  
      3-4 times per week 7 /622 (1.1 ) 6 /625 (1.0 ) 13 /1247 (1.0 )  
      5-6 times per week 15 /622 (2.4 ) 10 /625 (1.6 ) 25 /1247 (2.0 )  
      7 times per week 531 /622 (85.4 ) 541 /625 (86.6 ) 1072 /1247 (86.0 )  
      Missing 7 6 13  
6 months 
   
0.9190 
      0 times per week 72 /608 (11.8 ) 76 /616 (12.3 ) 148 /1224 (12.1 )  
      1-2 times per week 5 /608 (0.8 ) 5 /616 (0.8 ) 10 /1224 (0.8 )  
      3-4 times per week 6 /608 (1.0 ) 8 /616 (1.3 ) 14 /1224 (1.1 )  
      5-6 times per week 10 /608 (1.6 ) 15 /616 (2.4 ) 25 /1224 (2.0 )  
      7 times per week 515 /608 (84.7 ) 512 /616 (83.1 ) 1027 /1224 (83.9 )  
       Missing 4 5 9  
 
* Proportions were calculated based on non-missing observations. 
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Supplementary table 4.   
 
Results from the ordinal and binary analyses of the mRS  
 
 Estimate (95%CI) p-value 




Common odds ratio (OR)  0.97 (0.79 to 1.18) 0.7354   
 
Adjusted proportional odds model* 
 
 
Common OR   0.94 (0.76 to 1.15) 0.5296  
  
Unadjusted binary logistic regressions 
  
OR: 0     vs 1-6    0.95 (0.66 to 1.36) 0.7713 
OR: 0-1  vs 2-6    1.02 (0.82 to 1.28) 0.8531 
OR: 0-2 vs 3-6     0.86 (0.67  to 1.09) 0.2069 
OR: 0-3 vs 4-6    1.04 (0.72 to 1.50) 0.8375 
OR: 0-4 vs 5-6     0.99  (0.53 to 1.83) 0.9665 
OR: 0-5 vs 6        0.99 (0.48 to 2.04) 0.9718        
 
*The covariates used for the adjustment were the same as for the primary outcome analysis, 
that is, the analysis was adjusted for baseline minimization variables including delay since 






Supplementary table 5.   





























None –as per 
intention to treat 
analysis 
0 0 624 632 0.97 0.79-1.18 0.7354 0.5296 
1. Ineligible-
didn’t meet all 
inclusion criteria  
4  4  621  631  0.97  0.79 -1.18  0.7354  0.5296 
2. Received no 
trial medication 
7  11  616  629  0.98  0.80 -1.20  0.8510  0.6361 
3. Received <90 
days of trial 
medication due 
to failure to 
follow trial 
procedures. 
4  15  614  627  0.98  0.80 -1.20  0.8232  0.5413 
4. Received <90 




or doctor, but 
not for adverse 
reactions. 
30  45  598  613  0.97  0.79 -1.18  0.7412  0.4604 
5. Received <90 




to the trial 
medication. 
68  113  571  572  0.96  0.78 -1.17  0.6660  0.4068 
6. Allocated to 
placebo but 
received an 
SSRI for > 10 
days within the 
first 90 days 
13  126  571  559  0.89  0.72 -1.10  0.2678  0.1309 
7. Allocated to 
fluoxetine but 
received an 
SSRI for > 10 
days within the 
first 90 days. 
13  139  558  559  0.86  0.69 -1.06  0.1638  0.0783 
8. Patients who 
did not complete 
at least 150 days 
of treatment 




This per-protocol analysis sequentially excluded subgroups of patients who either did not 
meet our eligibility criteria or had incomplete adherence to the trial medication, and shows 








Supplementary figure 1.  
 








Supplementary figure 2.  
Primary outcome by pre-specified subgroups. 
The primary efficacy outcome was shift in the modified Rankin scale score distribution (range 
0 [no symptoms] to 6 [death]) at 6 months (180 days). For subcategories, black squares 
represent point estimates (with the area of the square proportional to the number of events), 
and horizontal lines represent 95% CIs. Scores on the NIHSS range from 0 to 42, with higher 
scores indicating more severe neurological deficits. Country: Country of randomization. 
AU/NZ: Australia, New Zealand. VN: Vietnam. NIHSS: National Institutes of Health Stroke 











Supplementary figure 3.  
 
Kaplan Meier survival curve to 6 months follow-up. 
 
Patients who withdrew consent to be followed-up were censored at the time of withdrawal from 
the trial. 
Estimates, their 95% confidence intervals, and the number of patients at risk for each 






























P-value=0.7061 (logrank test) 
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638 635 632 628 624 623






































1280 consented and randomly assigned 
642 assigned to fluoxetine group 
 637 received fluoxetine 
 5      did not receive fluoxetine  
        (medication was lost after discharge; 
        family’s/patient’s decision to not start) 
  
638 assigned to placebo group 
 635 received placebo 
 2     did not receive placebo  
(family’s/patient’s decision to not start; 
ineligible (randomising event was a TIA)) 
 
621 submitted 180-day form 
 100  discontinued placebo 
 632  had mRS data available 
 633  had vital status known    
30 did not submit 180-day form 
 12   died 
 17 withdrew consent 
 1     too late (>14 days)    
17 did not submit 180-day form 
 11  died 
 5    withdrew consent 
 1    too late (>14 days)    
 
642 analysed 
 624 analysed for mRS  
(mRS not available for 18) 
612 submitted 180-day form 
 108  discontinued fluoxetine 
 624  had mRS data available  
 625  had vital status known   
638 analysed  
 632 analysed for mRS  








Figure 1: AFFINITY trial profile     mRS=modified Rankin Scale 
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No symptoms Death
Figure 2. Primary outcome of the distribution of the modified Rankin Scale (mRS) scores at 6 months by treatment group  









































P-value=0.75 (logrank test) 
Supplementary figure 1. Kaplan Meier curve of time to permanent discontinuation of trial medication.
AU/NZ 284 274 0.819 [0.602,1.115]
VN 340 358 1.052 [0.797,1.39]
<=70 440 429 0.947 [0.737,1.217]
>70 184 203 0.896 [0.624,1.286]
2-8 day 475 473 0.865 [0.682,1.097]
9-15days 149 159 1.201 [0.793,1.82]
Ischaemic 534 537 0.948 [0.758,1.185]
Haemorrhagic 87 94 0.905 [0.528,1.553]
NIHSS 0-5 291 303 0.899 [0.659,1.228]
NIHSS >5 333 329 0.998 [0.756,1.317]
Yes 544 543 1.008 [0.809,1.256]
No 80 89 0.649 [0.357,1.18]
Yes 124 120 0.747 [0.467,1.196]
No 500 512 1.000 [0.796,1.258]
0-<=0.15 96 101 0.820 [0.494,1.361]
>0.15 to 1 528 531 0.948 [0.756,1.189]
Yes 14 17 0.654 [0.161,2.666]
No 610 615 0.939 [0.762,1.156]
Patient 334 324 0.857 [0.642,1.143]
Person resposible or Proxy 280 295 0.980 [0.725,1.325]
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P-value=0.7061 (logrank test) 
0 30 60 90 120 150 180
638 635 632 628 624 623




Supplementary figure 3. Kaplan Meier survival curve to 6 months follow-up.
Estimates, their 95% confidence intervals, and the number of patients at risk for each treatment group,  are indicated for each time point after randomisation
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Summary 
Background  
Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF 
FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to determine if daily fluoxetine for 6 




AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial conducted 
in 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10).  Eligible 
patients were adults with a clinical diagnosis of stroke in the previous 2-15 days and a persisting 
neurological deficit. Patients were randomised via a web-based system using a minimisation 
algorithm to once daily, oral fluoxetine 20mg or matching placebo for 6 months. Patients, 
investigators and outcome assessors were masked to the treatment allocation. The primary 
outcome was functional recoveryoutcome, measured by the modified Rankin scale (mRS), at 
6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, 
adjusted for minimisation variables. Analyses were according to the patient’s treatment 
allocation. The trial is registered with the ACTRN registry, number 12611000774921. 
  
Findings 
1280 patients were recruited in Australia (n=532), New Zealand (n=42) and Vietnam (n=706) 
between 11 January 2013 and 30 June 2019; 642 were allocated fluoxetine and 638 placebo. 
Adherence to trial medication (mean 167 [SD 48] days) was similar between groups. At 6 
months, mRS data were available in 624 (97.2%) patients allocated fluoxetine and 632 (99.1%) 
placebo. The distribution of mRS categories at 6 months was similar in the fluoxetine and 
placebo groups (adjusted common odds ratio 0.936, 95% CI 0.762-1.150; p=0.53), and 
consistent among all pre-defined subgroups. Compared to placebo, patients allocated 
fluoxetine had more falls (20 [3.12%] vs 7 [1.10%]; p=0.02), bone fractures (19 [2∙96%] vs 6 




Fluoxetine 20mg daily for 6 months after acute stroke did not improve functional 
recoveryoutcome and increased the risk of falls, bone fractures, and seizures. These results do 
not support the use , or further trials, of fluoxetine to improve recoveryoutcome after stroke. 
Funding 




RESEARCH IN CONTEXT 
Evidence before this trial 
We undertook a Cochrane systematic review and searched Cochrane and clinical trial registers; 
MEDLINE, Embase, PubMed, and other biomedical databases; from their inception to 16 July 
2018; for randomised controlled trials (RCTs) that recruited stroke patients who had survived 
up to one year, and randomised them to a selective serotonin reuptake inhibitor (SSRI), at any 
dose, for any period, and any indication; or to usual care or placebo. We identified 63 RCTs 
that compared any SSRI with control in 9168 stroke survivors. About half of the trials required 
patients to have depression. Potential improvements in disability with fluoxetine were only 
present in trials at high risk of bias. A meta-analysis of the three trials at low risk of bias 
(n=3356 patients) found no effect of any SSRI compared to control on functional independence 
(risk ratio [RR] 1.00, 95% CI 0.91 to 1.09; p = 0.99) or disability score (standardised mean 
difference [SMD] -0.01, 95% CI -0.09 to 0.06; p = 0.75). The evidence before this trial suggests 
that SSRIs do not improve functional recoveryoutcome after stroke, but doubt remains because 
this meta-analysis was dominated by one large trial, the FOCUS (Fluoxetine Or Control under 
Supervision) trial (n=3127), in UK patients. 
Added value of this trial 
The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial externally validates the 
the FOCUS trial and Cochrane systematic review of RCTs of SSRIs for stroke recovery in an 
independent population of Australasian and Vietnamese stroke patients, reinforcing the 
conclusion that fluoxetine does not improve functional recoveryoutcome after stroke. The 
AFFINITY trial also adds further data regarding the potential hazards of treating acute stroke 
patients with fluoxetine 20 mg daily for 6 months, including increased risks of falls, fractures, 
and seizures. 
Implications of all the available evidence 
For clinicians, SSRIs should not be prescribed routinely to improve functional 
recoveryoutcome after stroke because they are ineffective and increase serious adverse events. 
For researchers, a pooled analysis of individual patient data from completed RCTs of SSRIs 
for stroke recovery is needed to examine the effects of SSRIs in specific patient subgroups, 
such as those with hemiparesis, severe stroke, and cognitive impairment; and on specific 
outcomes, such as the mRS, motor domains of the Stroke Impact Scale, falls, fractures and 
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seizures. Until these results are available, further trials of fluoxetine for stroke recovery are not 
recommended.  
Introduction 
Stroke is the second leading cause of disability-adjusted life years globally.1,2 Fluoxetine, a 
selective serotonin re-uptake inhibitor (SSRI), may improve neurological functional recovery 
and reduce disability after acute stroke. Fluoxetine exerts neuro-protective and neuro-
regenerative effects in pre-clinical models of acute brain ischaemia.3,4 TIn the FLuoxetine for 
motor recovery After acute ischaeMic strokE (FLAME) trial found that,, a double-blind, 
randomised controlled trial (RCT) in in 118 patients with acute ischaemic stroke and moderate 
to severe motor deficits, fluoxetine 20 mg once daily significantly improved motor and 
functional recovery afterover 3 months.5 A subsequent Cochrane systematic review of 52 
randomised controlled trials (RCTs) of SSRIs for stroke recovery in 4059 patients concluded 
that SSRIs may improve disability but, given methodological limitations and heterogeneity of 
the available studies, more definitive, larger trials were required.6  
 
Hence, our international collaboration ve group designed and undertook three clinical trials of 
fluoxetine for recovery after stroke in the United Kingdom (Fluoxetine Or Control Under 
Supervision [FOCUS]), Sweden (Efficacy of Fluoxetine–A Randomised Controlled Trial in 
Stroke [EFFECTS]) and Australia, New Zealand and Vietnam (Assessment oF FluoxetINe In 
sTroke recoverY [AFFINITY]).7,8 The FOCUS trial (n=3127) reported that fluoxetine 20 mg 
given daily for 6 months after stroke did not improve functional outcome as measured by the 
modified Rankin scale (mRS),s but reduced  the occurrence of depression and increased the 
frequency of bone fractures.9 The latter results were consistent with the reported s of the 
effectiveness of fluoxetine as an antidepressant,10 and of an increased risk of fractures in older 
people taking SSRIs.11,12 However, as only two thirds of FOCUS trial patients adhered totook 
the trial medication for at least 150 of the prescribed 180 days, a modest, but important, effect 
of fluoxetine trial medication on functional outcome may have been missed.9 Moreover, as 
96% of patients in FOCUS were white, the results may not be generalisable outside of the UK.9 
Hence, the AFFINITY and EFFECTS trials continued to recruitment  patients in parallel until 
30 June, 2019. 
 
Herein, we report the results of the AFFINITY trial, which aimed to evaluate whether a 6-
month course of fluoxetine is safe and effective, compared to placebo, for improving functional 
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recoveryoutcome after recent stroke in an ethnically diverse population. The results of the 
EFFECTS trial results are reported in a parallel publication.13 
 
Methods 
Study design and participants 
AFFINITY was a randomised, parallel group, double-blind, placebo-controlled clinical trial 
conducted in 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10). 
The trial protocol (appendix) was approved by the Royal Perth Hospital Ethics Committee on 
24 February, 2012 (approval number EC2011/131), and subsequent amendments to the 
protocol to facilitate trial recruitment were also approved. All participating sites received 
approval from their ethics committee and institutional review board. The trial protocol7 and 
statistical analysis plan8 were published before recruitment stopped was completed.  
 
Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke within 
the previous 2-15 days, brain imaging consistent with ischaemic or haemorrhagic stroke 
(including a normal CT brain scan), and a persisting neurological deficit that produced a 
modified Rankin scale (mRS) score ≥1. Patients were excluded if there was any definite 
indication for fluoxetine (e.g. depression), or contraindication to fluoxetine (e.g. history of 
epilepsy, bipolar disorder, drug overdose, allergy to fluoxetine allergy, or any recent 
medication that could interact with fluoxetine; or biochemical evidence of hepatic impairment 
[serum alanine aminotransferase (ALT)  > 120 U/l], renal impairment [creatinine > 180 µmol/l 
or estimated glomerular filtration rate (eGFR) < 30ml/min/1.73m2], or hyponatremia [sodium 
< 125mmol/L]); if patients were unlikely to be available for follow-up during the subsequent 
12 months; if patients had another life-threatening illness that would make 12-month survival 
unlikely [e.g. terminal malignancy]; if patients were women wereand pregnant, breast-feeding 
or of child-bearing age and not without the usinge of contraception; or if patients were enrolled 
in another clinical trial of an investigational medicinal product (IMP) or device.  
 
Written informed consent was obtained from each patient or, if the patients were unable to 
provide consent, from their legally approved surrogate.  
 
Randomisation and masking 
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The patient’s clinician entered the patient’s baseline data (table 1) into a secure, password-
protected, centralised, web-based randomisation system which checked the data for 
completeness and consistency and then generated a unique study identification number and 
treatment pack number which correspondinged to fluoxetine or placebo in a 1:1 ratio. A 
minimisation algorithm14 was used to achieve balance between the treatment groups in four 
predictors of the primary outcome (mRS): time after stroke onset (2-8 vs 9-15 days), presence 
of a motor deficit (National Institutes of Health Stroke Scale [NIHSS] questions 5 and 6), 
presence of aphasia (NIHSS question 9), and probability of survival free of dependency (mRS 
0-2) at 6 months (0.00 to ≤0∙15 vs >0∙15-1.00) as calculated using a previously validated 
prognostic model comprising six baseline prognostic variables (age, living alone before the 
stroke, independent in activities of daily living before the stroke, and able to talk, lift both arms 
off the bed, and walk unassisted at the time of randomisation).15 
 
All patients, carers, investigators, and outcome assessors were masked to the allocated treatment 




Fluoxetine 20mg capsules or matching placebo capsules were administered to patients orally, 
once daily, for 6 months. If the patients wereas unable to swallow, the capsules werecould be  
broken open and the contents administered via an enteral feeding tube.  
 
Siegfried Malta Ltd, Hal Far, Malta, manufactured the capsules containing fluoxetine 20mg 
according to Good Manufacturing Practice (certificate MT/008HM/2017). Arena 
Pharmaceuticals GmbH, Zofingen, Switzerland, packed the capsules for Amneal 
Pharmaceuticals Pty Ltd, South Yarra, Australia, which was the Therapeutic Goods 
Administration (TGA) licence holder (sponsor) for the finished product in Australia. 
Pharmaceutical packaging professionals (PPP) Pty Ltd, Port Melbourne, Australia purchased 
the fluoxetine capsules and manufactured the matching placebo capsules. PPP packaged the 
trial medication in patient kits, labelled the bottles with trial-specific treatment codes 
(fluoxetine or placebo), and packaged, stored and distributed the medication. The patient kits 
in Australian and New Zealand comprised two bottles, each containing 110 capsules, which 
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were dispensed at randomisation and day 90. An extra 20 capsules were a reserve in the event 
of any delay in attending the day 90 follow-up, or any loss or spillage of capsules. For patients 
in Vietnam, the kits comprised 6 bottles of trial medication, each containing 35 capsules. One 
bottle was dispensed at randomisation, two bottles at day 28, and three bottles at day 90. The 
TGA of the Australian government’s Department of Health approved the export of trial 
medication to New Zealand and Vietnam (approval Ref No: EX17/336513). 
All patients received organised, interdisciplinary care and rehabilitation in stroke units. 
 
Patients recruited in Australia and New Zealand were assessed by site investigators at 28 days 
(1 month) and 90 days (3 months) post-randomisation in the hospital ward or outpatient clinic 
or via telephone or email; or, failing that, by a study nurse at the patient’s residence. Follow-
up at 180 days (6 months) was by postal questionnaire or telephone by trained staff in the trial 
coordinating centre in Perth, Australia. Patients recruited in Vietnam were assessed by the site 
investigator at 28, 90 and 180 days post-randomisation in the hospital ward or outpatient clinic, 
or via telephone or email; or, failing that, at the patient’s residence. If the patient was unable 
to complete the assessments, assistance was sought from their proxy (next of kin, close family 
member or carer). Each assessment recorded the primary outcome (mRS), secondary outcomes 
(table 2), safety and adverse events (table 3), all current medications, and adherence to trial 
medication. Serum sodium, eGFR, and liver function were measured at the first (28 day) 
follow-up visit if clinically appropriate. Adherence to trial medication was assessed by asking: 
‘On average, since the last follow-up, how many times per week was the trial medication taken? 
‘0, 1-2, 3-4, 5-6 or 7 times per week’; and by pill counts and collection of returned trial bottles. 
Bottle and pill counts were conducted by hospital trial pharmacists, and entered on a drug 
accountability form. Any interruption to trial medication was recorded as temporary or 
permanent, together with the dates and reasons for stopping and re-starting.  
 
If patients developed new depression requiring treatment during the trial treatment period, the 
protocol recommended continuation of trial medication and consideration of non-
pharmacological (e.g. psychological) interventions. If antidepressant medication was 
considered necessary, referral to a psychiatrist was recommended for consideration of potential 




There were 57 protocol violations in 56 patients (4.4%): 20 (1.6%) patients were prescribed 
open-label fluoxetine; 8 (0.6%) were prescribed another SSRI; 16 (1.3%) lost their trial 
medication or did not take it the trial medication as prescribed; 4 (0.3%) took medications that 
could interact with fluoxetine (e.g. antipsychotic, tramadol); 7 (0.5%) patients were >more than 
14 days late for a scheduled follow-up; one patient enrolled in another trial was deemed 
ineligible, and four patients had a final diagnosis other than stroke  (table 1). Emergency 
unblinding was not necessary for any patient.  
 
Outcomes 
The primary outcome was functional status, as measured by the mRS, at 6 months after 
randomization.16 The mRS is an ordinal scale which assigns patients to seven ordered, but not 
equally spaced, levels of functional ability, ranging from 0 (symptom free) to 6 (dead).  
 
Secondary outcomes at 6 months were survival, depression (PHQ-9 score > 1517), cognition 
(Telephone Interview for Cognitive Status [TICSm]18), communication, motor function, 
overall health status (Stroke Impact Scale [SIS] version 3.019), fatigue (vitality subscale of the 
SF-3620,21) and health-related quality of life (HRQoL) using the EQ-5D-5L.22 A new diagnosis 
of depression requiring treatment with antidepressants was assessed at 1, 3 and 6 months by 
asking patients if they had been diagnosed with depression since each of their previous 
assessments, and verifying the diagnosis and treatment plan with their clinician. 
 
Serious adverse events at any time during follow-up included recurrent stroke (ischaemic or 
haemorrhagic), acute coronary syndromes, upper gastrointestinal bleeding requiring blood 
transfusion and/or endoscopy, other major bleeding (subdural, extradural, ocular, lower 
gastrointestinal) requiring blood transfusion or procedural intervention, falls with injury, new 
bone fractures, epileptic seizures, symptomatic hypoglycaemia (blood glucose < 3mmol/l), 
symptomatic hyperglycaemia (blood glucose > 22mmol/l), new hyponatraemia (blood sodium  





A detailed statistical analysis plan was formulated and published before recruitment was 
completed and without awareness of any unblinded data.8 
 
We estimated from other concurrent studies of patients with acute stroke that 42.2% of patients 
assigned placebo would be functionally independent (mRS 0-2) at 6 months after 
randomisation.23,24 We calculated the odds ratio (OR) of functional independence (mRS 0-2) 
with fluoxetine vs placebo in the FLAME study5 to be 3.57 (95%CI: 1.2 to 10.6). We 
considered a conservative estimate of the effect of fluoxetine may be toward the lower 95% CI 
of the OR estimate reported in FLAME (e.g. OR 1.34). If fluoxetine increased the proportion 
of patients who were functionally independent at 6 months by an OR of 1.34, from 42.2% 
(placebo) to 49.4% (fluoxetine), this would be clinically important and consistent with our 
Cochrane review.6 – that is, a 7.2% absolute increase in functional independence in patients 
allocated fluoxetine compared with placebo. Assuming a common OR of 1.34 for each cut-
point across the mRS (e.g. 0 vs 1-6, 0-1 vs 2-6, etc) in the proportional odds logistic model, we 
estimated that the trial would require 1600 patients to have 90% power, if up to 10% of patients 
dropped out before final follow-up (i.e. 1440 patients with primary outcome data).8,25  
 
All analyses, including primary and secondary outcomes and adverse events, were by intention-
to-treat, according to the treatment allocation. A secondary safety analysis was undertaken 
according to the treatment patients received rather than what they were randomly allocated. 
 
The primary analysis was an ordinal analysis of the mRS scores at 6 months in each treatment 
group using ordinal logistic regression and after adjusting for the baseline factors included in 
the minimisation algorithm.8 The ordinal analysis of mRS was undertaken by treatment 
allocation, under the assumption of proportional odds in the model. The result was expressed 
as a common OR (less than 1.0 favoured placebo) and its 95% confidence interval (CI). We 
also performed 6 binary unadjusted logistic regressions, each corresponding to the 6 possible 
dichotomisations of scores on the mRS.  
 
Secondary analyses compared the following outcomes at 6 months follow-up in each treatment 
group: survival, depression (changes in PHQ-9 scores and proportion with PHQ-9 ≥ 15 ),17 
cognition (TICSm scores),18 communication (SIS),19 motor function (SIS),19 overall health 
status (SIS),19 HRQoL (EQ-5D-5L),22 new diagnosis of depression requiring treatment with 
11 
 
antidepressants, fatigue (vitality domain of the SF-36)20,212, trial medication adherence and 
cessation, and serious adverse events. The frequencies of categorical outcome events , 
including adverse events, in each treatment group were compared using Fisher’s exact test. For 
continuous outcomes, the mean or median in each group, depending on the distribution, were 
calculated with measures of dispersion (standard deviation [SD] or inter-quartile range [IQR]). 
The probability that outcome measures in the fluoxetine treatment group were significantly 
different from those observed in the placebo group were calculated and expressed as p-values.   
 
Pre-specified subgroup analyses of the effect of fluoxetine vs placebo on the primary outcome 
were undertaken for key baseline variables, including country of randomisation (Australia/New 
Zealand vs Vietnam), age (<70 vs >70 years), time from stroke onset to randomisation (2-8 vs 
9-15 days), stroke pathology (ischaemic vs haemorrhagic), stroke severity (NIHSS scores < 
median [0-5] vs > median [>5]), motor deficit (present vs absent), aphasia (present vs absent), 
probability of survival free of dependency (0.00 to <0.15 vs >0.15 to 1.00), self-reported 
depression at baseline, and source of informed consent.8  
 
We also undertook pre-specified per-protocol analyses, which sequentially excluded subgroups 
of patients who did not meet our eligibility criteria or had incomplete adherence to the trial 
medication. 
 
Post-hoc sensitivity analyses of the primary outcome were undertaken to evaluate the possible 
effect of including those patients who were lost to follow-up. We tested the robustness of the 
results by assuming two extreme imputation scenarios: one favouring fluoxetine where all 
patients with a missing mRS data were imputed a score of 0 in the fluoxetine arm and a score 
of 6 in the placebo arm, and another scenario favouring placebo where the imputation was 
reversed. 
 
Statistical analyses were undertaken with SAS, version 9.4 
 
An independent data monitoring committee (DMC) oversaw the study. The unmasked trial 
statistician (Q Yi) prepared analyses of the accumulating data, which the DMC reviewed in 




The trial is registered with the Australian New Zealand Clinical Trials Registry, number 
ACTRN12611000774921. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data 




A total of 1280 patients consented and were randomised at 43 sites in Australia, New Zealand 
and Vietnam between 11 January, 2013 and 30 June, 2019. Recruitment was terminated before 
the target sample size of 1600 patients was reached becauseas grant  funding expired on 31 
December 2019.  
642 patients were randomly allocated to fluoxetine and 638 to placebo. One patient did not 
meet our eligibility criteria after randomisation because of later discovery of participation in 
another clinical trial of an  IMPinvestigational medicinal product. In four patients, the initial 
diagnosis was later revised to be non-stroke  after review of investigations at the one month 
follow up (table 1).  
Baseline characteristics in the two treatment groups were balanced (table 1)  
By 6 months, 22 (1.7%) patients had withdrawn consent for follow-up and a further 2 (0.2%) 
patients were lost to follow-up (fig 1). There was no difference in the methods of follow-up 
between treatment groups (appendix table 1, p8). Trial medication was started in 1273 patients, 
and it was temporarily and permanently stopped in 158 and 208 patients respectively , before 
the 6-month follow-up (appendix, table 2, p9). There was no significant difference between 
treatment groups in temporary and permanent discontinuation of trial medication (appendix 
table 2, p9) or time to permanent discontinuation (p=0.75; appendix figure 1, p14). There were 
also no significant differences between groups in compliance with trial medication at one 
(p=0.57), three (p=0.94) or six (p=0.92) months (appendix table 3, p10). The mean duration of 
trial treatment during the 6 months follow-up was 167 days (SD 48.1) days.  
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The primary outcome, the mRS at 6 months, was assessed and analysed in 624 (97.2%) patients 
allocated fluoxetine and 632 (99.1%) placebo. An ordinal comparison of the distribution of 
patients across the mRS categories at 6 months, adjusted for variables included in the 
minimisation algorithm, was similar in both the two groups (common OR 0.936, 95% CI 0.762-
1.150; p=0.53; figure 2). A common OR <1.0 favours placebo. The unadjusted analysis 
produced similar results (common OR 0.966, 95%CI 0.790-1.181; p=0.74; appendix table 4, 
p11). The assumption of proportional odds in the model of mRS by treatment was upheld in 
the score test for proportional odds assumption (p=0.44 unadjusted). Comparison of 
Ddichotomised mRS scores (0–2 vs 3–6) were also showed not significantly differentce 
between treatment groups for mRS 0-2 vs 3-6 (unadjusted OR 0.855, 95%CI 0.670-1.091; 
p=0.21; post-hoc adjusted OR=0.823, 0.628-1.077; p=0.16; appendix table 4, p11), or. There 
was also no difference between groups in other dichotomies of the mRS (appendix table 4, 
p11). 
Analysis of the primary outcome showed no significant interactions or modification of the 
effect of fluoxetine across several pre-specified subgroups (appendix figure 2, p15).  
Secondary efficacy outcome measures at 6 months are shown in table 2. Patients allocated 
fluoxetine had better mood and emotional control, as measured by higher scores in the SIS 
domain of mood and /emotional control s compared to placebo (p=0.003), but there were no 
significant differences between treatment groups in the other 10 domains of the SIS (including 
measures of motor function [strength, hand ability, mobility] and daily activities), other 
assessment scales, or death. There was a reduction in new diagnoses of post-stroke depression 
which was not statistically significant (33 [5.14%] fluoxetine vs 46 [7.21%] placebo; absolute 
risk difference 2.07%; 95% CI -0.57% to 4.41%]). 
Adverse events at 6 months are shown in table 3. Compared to patients allocated placebo, those 
allocated fluoxetine had more falls causing injury (20 [3.12%] vs 7 [1.10%]; difference 2.02% 
[95CI: 0.45-3.59]; p=0.02), bone fractures (19 [2∙96%] vs 6 [0.94%]; difference 2.02% [0∙51–
3.53]; p=0∙01) and epileptic seizures (10 [1.56%] vs 2 [0.31%]; difference 1.24% [0.19-2.30]; 
p=0.04). There were no significant differences between treatment groups in other events,  at, 
or during, the 6 months follow-up, including survival (p = 0.71, appendix, figure 3, p16). Trial 
medication was stopped by 68 patients (27 allocated fluoxetine, 41 placebo) due to a suspected 
14 
 
adverse reaction to the medication. No patients required a reduction in dose of trial medication 
(e.g. alternate daily) and there were no treatment-related deaths. 
The primary results were not altered by sensitivity analyses confined to patients who adhered 
to the trial protocol and allocated treatment (appendix table 5, p12).  
A post-hoc analysis, which consisted of imputing missing mRS data under two extreme 
scenarios, also produced consistent, non-significant results for the most extreme scenarios in 
favour of fluoxetine (unadjusted OR 1.082, 95%CI 0.887-1.320; p=0.44; adjusted OR 1.054, 
0.861-1.291; p=0.61), and for the most extreme scenario in favour of placebo (unadjusted OR 
0.860, 0.705-1.050; p=0.14; adjusted OR 0.833, 0.680-1.020; p=0.09). 
Discussion 
The main finding of the AFFINITY trial was that adding fluoxetine 20mg daily for 6 months 
after acute stroke to interdisciplinary stroke unit care did not improve functional outcome at 6 
months in an ethnically diverse population. Other major findings were that fluoxetine improved 
mood and emotional control but increased falls, fractures, and epileptic seizures at 6 months. 
 
Key strengths of the trial are that it was undertaken in stroke units throughout Australia, New 
Zealand and Vietnam where the AFFINITY trial medication was added to best-practice, 
comprehensive interdisciplinary stroke care and rehabilitation. Several potential sources of 
systematic error (bias) in the assessment of fluoxetine vs placebo were minimised. Systematic 
pre-treatment differences in comparator groups (selection bias) were minimised by concealed, 
central, web-based randomisation. Adherence to trial medication was high and similar between 
treatment groups (performance bias). Systematic differences between groups in other care 
provided (performance bias) and reporting and assessment of outcome events (observer 
detection bias) were minimised by masking of patients, investigators and adjudicators to the 
allocated treatment. Follow up for the primary outcome was high and there was no difference 
between groups in withdrawals from treatment (attrition bias). Random error was reduced to 
some extent by almost complete follow-up of a large number of patients (n=1256, 98%), which 
was a higher proportion than planned in our sample size calculations (90% of 1600; n=1440). 
The inclusion of an international mix of ethnic groups managed in different health care systems, 
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and a comprehensive array of secondary outcome measures, including cognition, mood and 
motor scales, support the external validity (generalisability) of the trial results. 
 
Potential limitations of the trial include our failure to recruit the target sample size of 1600 
patients due to funding constraints (1280 patients recruited; 1256 with primary outcome data 
vs 1440 planned to have primary outcome data). We also failed to recruit a larger number of 
patients with severe, disabling stroke. Hence, the proportion of patients assigned placebo who 
recovered functional independence (mRS 0-2) at 6 months was higher (n=458, 72%) than 
estimated in our sample size calculations (42%). The dose of fluoxetine was 20 mg once daily 
because this was the dose reported to be effective in the FLAME trial5 and used in other 
fluoxetine trials for stroke recovery,6 and is less likely to cause adverse effects than higher 
doses. However, we did not test higher doses of fluoxetine. Our measures of adherence to trial 
medication by self-report and capsule-counting were prone to error (e.g. the absence of tablets 
in the bottles returned to investigators may not necessarily mean adherence to taking the 
tablets) and therefore, our estimates of adherence and compliance may be inflated. However, 
there was no difference between groups in reported adherence to, and discontinuation of, trial 
medication. The nature and degree of adjunctive rehabilitation was not documented because 
that would have added complexity and potential measurement error to this pragmatic trial. 
However, all patients were admitted to stroke units where organised interdisciplinary 
assessment, and rehabilitation as required, was provided as standard practice. The nature and 
intensity of all rehabilitation interventions were likely to be balanced between the treatment 
groups, in the same way that all baseline variables were balanced between groups, due to the 
randomisation process and double-blind trial treatment allocation. There was a slight difference 
in ascertainment of mRS status at 6 months between groups (fluoxetine n=624, 97.2% vs 
placebo n=632, 99.0%) but sensitivity analyses using imputations led to consistent conclusions. 
Our primary measure of efficacy was a broad measure of functional outcome which may not 
be sensitive to changes in measures of specific neurological functions, However, we also 
measured 11 domains of the SIS, including measures of motor function (strength, hand ability, 
mobility), physical function, and daily activities, and found no effect of fluoxetine on any of 
these measures. The mRS may be less sensitive to change in patients with less severe stroke 
but there was no evidence of an effect of fluoxetine on the mRS in patients with more severe 
16 
 
stroke (NIHSS > 5; appendix figure 2, p15), and no effect of fluoxetine on any secondary 
outcome except mood and emotional control. 
 
The AFFINITY trial was smaller than the FOCUS trial9 but both trials recruited patients of 
similar sex (women 38%), stroke severity (median NIHSS=6) and at a similar time (one week, 
mean) after stroke onset. The AFFINITY trial population was a unique mix of Vietnamese 
(n=727, 57%) and Australasians (n=553, 43%), whereas the FOCUS population was 
predominantly Caucasian (n=2988; 96%). Patients in AFFINITY were also younger (mean age 
64 years AFFINITY, vs 71 years in FOCUS), and more likely to be married (n=926, 72% vs 
n=1725, 55%), living with someone else (n=1120, 87% vs n=2091, 67%), employed (n=531, 
41% vs n=691, 22%), and independent before their stroke (n=1264, 99% vs n=2866, 92%) 
compared to FOCUS. Adherence to trial medication was higher in AFFINITY than FOCUS; 
34 (5.4%) patients assigned fluoxetine and 30 (4.8%) placebo stopped trial medication within 
the first 90 days, whereas in FOCUS, 143 (9%) patients assigned fluoxetine and 122 (8%) 
placebo stopped trial medication within the first 90 days. Despite these differences, the results 
of the AFFINITY trial almost replicate those of the larger FOCUS trial,9 supporting the internal 
and external validity of both trials. Furthermore, the EFFECTS trial of fluoxetine vs placebo 
in 1500 stroke patients in Sweden also reports very similar results to FOCUS and AFFINITY.13 
Moreover, the results of the FOCUS, AFFINITY and EFFECTS trials are all consistent with 
the totality of evidence from all RCTs of SSRIs for stroke recovery,26 and all RCTs specifically 
testing fluoxetine.27 Collectively, these trials provided compelling evidence that fluoxetine 
does not improve functional recoveryoutcome after stroke.  
 
The outstanding inconsistency among all the RCT evidence is the FLAME trial, which did 
report a significant benefit of fluoxetine vs placebo on motor recovery after strokefunctional 
recovery measured by the mRS.5 The FLAME trial differed from AFFINITY, FOCUS and 
EFFECTS in that in that it was a phase II trial of fluoxetine 20 mg daily vs placebo in a highly 
select population of 1183 patients with recent (5-10 days) ischaemic stroke and a moderate to 
severe hemiparesis or hemiplegia, defined by a Fugl-Meyer motor scale (FMMS) score <55.5 
The FMMS motor score ranges from 0 (hemiplegia) to a maximum of 100 points (normal motor 
performance), with divided into 66 points for the upper extremity and 34 points for the lower 
extremity. Patients enrolled in FLAME had more severe strokes (mean baseline NIHSS 13 vs 
median NIHSS 6 in AFFINITY).At baseline, there was some imbalance between the treatment 
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groups; the mean total FMMS score was higher (better motor performance) in the fluoxetine 
group (17·1; SD 11·7) than placebo group (13·4; SD 8·8), and the mean total NIHSS was 
marginally lower (less severe stroke) in the fluoxetine group (12·8; SD 3·9) than placebo group 
(13·1; SD 4·3).5 Somatosensory and other neurological deficits that may influence recovery 
were not reported. The primary outcome measure, the mean change in FMMS scores between 
randomisation and day 90, was greater with fluoxetine than placebo (34·0 points fluoxetine vs 
24·3 points placebo; difference 9.8 points, 95%CI: 3.4 to 16.1, p=0·003). The proportion of 
functionally independent patients (mRS scores 0-2) at day 90 was also higher with fluoxetine 
than placebo (n=15, 26% vs n=5, 9%; p=0.02), but there were no differences between 
fluoxetine and placebo for other mRS categories. The FLAME trial result may be a false-
positive due to random error (chance), as only 57 patients were treated with fluoxetine and 
followed-up to 90 days,5 and there is large variation in spontaneous motor recovery after acute 
stroke.28 Alternatively, the FLAME trial result may a true-positive, and fluoxetine may indeed 
improve motor recovery of motor function in patients with severe motor impairment. The 
AFFINITY trial did not include a large number patients with severe hemiparesis and did not 
measure motor recovery by the FMMS, but did measure motor functions as domains within the 
SIS and found no effect of fluoxetine. Our planned individual patient data meta-analysis of the 
FOCUS, AFFINITY and EFFECTS trials8 will constitute a larger number of stroke patients 
with severe motor impairments and promises to enable a more reliable analysis of the effect of 
fluoxetine, vs placebo, on the mRS and motor domains of the SIS at 6 months in this subgroup. 
 
The AFFINITY trial also confirms the FOCUS trial finding that long-term fluoxetine in stroke 
patients has hazards, increasing the risk of bone fractures.9 We also found that fluoxetine 
significantly increased the risk of falls with injury and epileptic seizures in stroke patients. 
These hazards of fluoxetine were sought apriori during patient follow-up.7,8 The FOCUS trial 
reported similar, but not significant, increases in falls with injury and seizures in patients 
allocated fluoxetine.9 The AFFINITY and FOCUS trials collectively provide robust evidence 
about the effect of an SSRI on the incidence of falls causing injury, and fractures, increasing 
the absolute risk of each by about 2% over 6 months among patients with recent stroke. 
 
Although fluoxetine is more effective than placebo in treating major depressive disorders,10 
and reduced the rate of new depression in the FOCUS,9 and other trials,27,29 we observed only 
improved mood and emotional control, as measured by the SIS, at 6 months with fluoxetine; 
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the numerically lower rate of post-stroke depression with fluoxetine vs placebo was not 
statistically significant. We believe we lacked statistical power to show a significant effect of 
fluoxetine on post-stroke depression because the absolute rates of depression in both groups in 
AFFINITY were substantially lower (less than half) than in FOCUS, possibly from under-
reporting, particularly in Vietnam where the reporting of changes in mood may be affected by 
the cultural setting.30 
 
In summary, the AFFINITY trial reinforces the conclusion of a recent Cochrane review that 
SSRIs are not effective at improving functional recoveryoutcome after stroke. It also confirms 
that fluoxetine may improve mood but have important adverse effects, particularly bone 
fractures. A planned individual patient data meta-analysis of the AFFINITY, FOCUS and 
EFFECTS trials will produce greater precision in the estimates of the effects of fluoxetine on 
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1280 consented and randomly 
assigned 
642 assigned to fluoxetine group 
 637 received fluoxetine 
 5      did not receive fluoxetine  
        (medication was lost after discharge; 
        family’s/patient’s decision to not start) 
 
638 assigned to placebo group 
 635 received placebo 
 2     did not receive placebo  
(family’s/patient’s decision to not start; 
ineligible [randomising event was a TIA]) 
 
621 submitted 180-day 
form 
 100  discontinued 
placebo 
 632  had mRS data 
available 
30 did not submit 180-day 
form 
 12   died 
 17 withdrew consent 
 1     too late (>14 days)    
17 did not submit 180-day 
form 
 11  died 
 5    withdrew consent 
 1    too late (>14 days)    
 
642 analysed 
 624 analysed for mRS  
(mRS not available for 18) 
612 submitted 180-day 
form 
 108  discontinued 
fluoxetine 
 624  had mRS data 
available  
638 analysed  
 632 analysed for mRS  












Figure 2.  
Primary outcome of the distribution of the modified Rankin Scale (mRS) scores at 6 
months by treatment group. 
The primary outcome was an assessment of scores across all seven categories of the mRS 
(ranging from 0 [no symptoms] to 6 [death]), using a shift analysis of the ordinal data. The 
odds ratio and p-values were calculated with ordinal logistic regression, adjusted for the 
baseline variables included in the minimisation algorithm (delay between stroke onset and 
randomization, probability of being alive and independent at 6 months, presence of a motor 
deficit, presence of aphasia). mRS data at 6 months were available for 624 (97.2%) patients 
allocated fluoxetine and 632 (99.1%) allocated placebo. The common odds ratio was 0.936 
(95%CI: 0.762 to 1.150), p= 0.53; adjusted for baseline minimization variables. A common 
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Sex   
Women    231 (36%) 245 (38%) 
Men 411 (64% ) 393 (62% ) 
Age   
Age < 70 years 450 (70% ) 432 (68% ) 
Age >70 years 192 (30% ) 206 (32% ) 
Mean age, years 63.5 (12.5 ) 64.6 (12.2 ) 
Ethnicity   
Asian 356 (55% ) 371 (58% ) 
White  267 (42% ) 255 (40% ) 
Other 19 (3% ) 12 (2%) 
Marital status   
Married 463 (72% ) 463 (73% ) 
Partner 29 (4% ) 19 (3% ) 
Divorced or separated 37 (6% ) 46 (7% ) 
Widowed 61 (9% ) 70 (11% ) 
Single 52 (8% ) 38 (6% ) 
Other 0 (0% ) 2 (0% ) 
Living arrangements   
Living with someone else 564 (88% ) 556 (87% ) 
Living alone 78 (12% ) 78 (12% ) 
Living in an institution 0 (0% ) 2 (0% ) 
Other 0 (0% ) 2 (0% ) 
Employment status   
Full-time employment 206 (32% ) 180 (28% ) 
Part-time employment 77 (12% ) 68 (11% ) 
Retired 315 (49% ) 363 (57% ) 
Unemployed or disabled 24 (4% ) 14 (2% ) 
Other  20 (3% ) 13 (2% ) 
Independent before stroke 634 (99% ) 630 (99% ) 
Previous medical history   
Coronary Heart Disease 58 (9% ) 57 (9% ) 
Ischaemic stroke or TIA  77 (12% ) 84 (13% ) 
Diabetes 143 (23% ) 147 (23% ) 
Hyponatraemia 1 (0% ) 3 (0% ) 
Intracranial bleed 11 (2% ) 8 (1% ) 
Upper gastrointestinal bleed 11 (2% ) 15 (2% ) 
Bone fractures 71 (11% ) 74 (12% ) 
Depression 30 (5% ) 20 (3% ) 
Stroke diagnosis   
Non-stroke (final diagnosis) 3 (0% ) 1 (0% ) 




Intracerebral haemorrhage 90 (14% ) 95 (15% ) 
OCSP classification of Ischaemic stroke   
Total anterior circulation infarct  47 (9% ) 50 (9% ) 
Partial anterior circulation infarct  271 (49% ) 283 (52%) 
Lacunar infarct 115 (21% ) 105 (19% ) 
Posterior circulation infarct 114 (21% ) 103 (19%) 
Uncertain 2 (0% ) 1 (0% ) 
Causes of ischaemic stroke (modified 
TOAST classification) 
  
Large artery disease 123 (22% ) 134 (25% ) 
Small vessel disease 261 (47%) 250 (46%) 
Embolism from the heart 95 (17%) 93 (17%) 
Another cause 9 (2%) 8 (1%) 
Unknown or uncertain cause 61 (11%) 57 (10%) 
Predictive variables    
Able to walk at time of randomisation 282 (44%) 279 (44%) 
Able to lift both arms off bed 443 (69%) 431 (68%) 
Able to talk and not confused 554 (86%) 557 (87%) 
Predicted 6-month outcome based on 
SSV 
  






0.00 to < 0.15 100 (15%) 103 (16%) 
0.15 to 1.00 542 (84%) 535 (84%) 
Neurological deficits   
NIHSS 6 (3-9)             6. (3-9) 
Presence of a motor deficit 557 (87%) 548 (86%) 
Presence of aphasia 129 (20%) 121 (19%) 
Depression at baseline   
Current diagnosis of depression (patient 
or proxy reported) 
15 (2%) 17 (3%) 
Taking a non-SSRI antidepressant 5 (1%) 5 (1%) 
Current mood   
PHQ-9, median (IQR)           4 (1-7) 4 (2-7) 
0-14 601 (98%) 596 (98%) 
>15 12 (2%) 11 (2%) 
Delay (days) since stroke onset at 
randomisation 
  
Mean delay  6.1 (3%) 6.3 (3%) 
2-8 days 486 (76%) 479 (75%) 
9-15 days 156 (24%) 159 (25%) 
Consent   
Patient consented  345 (54%) 328 (51%) 
Person responsible consented 284 (44%) 295 (46%) 
Proxy consented 3 (0%) 1 (0%) 





Data are n (%), mean (SD [standard deviation]), or median (IQR [interquartile range]) 
TIA: transient ischaemic attack 
OCSP = Oxfordshire Community Stroke Project 
TOAST = modified Trial of ORG 10172 in acute stroke treatment criteria 
SSV = Six simple variables the predict functional outcome, as measured by the mRS, after 
stroke (age, living alone before the stroke, independent in activities of daily living before the 
stroke, and able to talk, lift both arms off the bed, and walk unassisted at the time of 
randomisation).15 
NIHSS = National Institutes of Health Research Stroke Scale 
SSRI: selective serotonin reuptake inhibitor 





Table 2.  Secondary outcomes at six months by allocated treatment  
  Fluoxetine (n=642)  Placebo (n=638)  P value 
New depression  
   N / N (%) 
33 (5.1%)  46 (7.2%)  0.13 
Mood (PHQ-9) 2.0 (1.0-5.0 ) 2.0 (1.0-5.0 ) 0.42 
   PHQ-9 >15   
   N / N% 
4 (0.7%)  6 (1.0%)  0.75 
Cognition (TICSm) 24.0 (20.0 -27.0 ) 24.0 (19.0-27.0 ) 0.62 
Stroke Impact Scale 
(SIS) domains 
     
-Strength 75.0 (56.3-93.8 ) 75.0 (56.3-93.8 ) 0.26 
-Hand ability 85.0 (55.0-100.0 ) 85.0 (55.0-100.0 ) 0.39 
-Mobility 91.7 (69.4-100.0 ) 88.9 (66.7-97.2 ) 0.08 
-Motor†  83.5 (63.5-94.2 ) 82.4 (60.4-93.2 ) 0.28 
-Daily Activities 90.0 (72.5-100.0 ) 90.0 (70.0-97.5 ) 0.25 
-Physical function‡ 85.5 (66.2-94.9 ) 83.8 (63.4-93.8 ) 0.24 
-Memory 89.3 (78.6-100.0 ) 89.3 (75.0-100.0 ) 0.28 
-Communication 98.2 (89.3-100.0 ) 96.4 (85.7-100.0 ) 0.61 
-Mood/Emotions^ 80.6 (66.7 -88.9 ) 77.8 (66.7 -86.1 ) 0.003 
-Participation 81.3 (59.4 -96.9 ) 75.0 (56.3 -96.9 ) 0.48 
-Recovery (VAS) 80.0 (60.0 -90.0 ) 80.0 (60.0 -90.0 ) 0.90 
Vitality (SF-36) 70.0 (55.0 -80.0 ) 70.0 (55.0 -80.0 ) 0.36 
EQ5D-5L  0.81 0.63-1.00 0.78 0.58-0.93 0.08 
 
Data were only available for those who survived and who completed sufficient questions to derive a 
score. The number of patients with missing scores were similar in the two treatment groups. 
Data are median (IQR). 
PHQ-9: Patient Health Questionnaire 9 items (higher score indicates more depressive symptoms) 
TICSm:  Telephone Interview for Cognitive Status  
SIS: Stroke Impact Scale (where higher scores are better).      
†Mean of the Strength, Hand ability, and Mobility domains.  
‡Mean of the Strength, Hand ability, Mobility, and Daily activities domains. 
^Mood/Emotions domain of the SIS: Nine questions about “how you feel, changes in your mood, and 
your ability to control your emotions, since your stroke.” (where higher scores are better) 
VAS: visual analogue scale. 
SF-36: 36 item short form questionnaire (higher scores indicate less disability) 
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EQ5D-5L:  EuroQoL - 5 Dimensions (Mobility, Personal Care, Usual Activities, Pain/Discomfort, 
Anxiety/Depression) - 5 Levels (where 1 indicates the best health imaginable, and −0.676 indicates 






Table 3.  Adverse events at 6 months by allocated treatment group 
   




Difference (95% CI)* P-
value 
 
Death 15 (2.34%) 15 (2.35%) -0.01% (-1.64 to 1.67) 1.00 
Any stroke 18 (2.80%) 26 (4.08%) -1.27% (-3.27 to 0.72) 0.22 
All thrombotic events     
   Ischaemic stroke 11 (1.71%) 21 (3.29%) -1.58% (-3.29 to 0.13) 0.08 
   Acute coronary events 1 (0.16%) 2 (0.31%) -0.16% (-0.69 to 0.37) 0.62 
All bleeding events     
   Haemorrhagic stroke 3 (0.47%) 1 (0.16%)  0.31% (-0.30 to 0.92) 0.62 
   Upper gastrointestinal bleed 1 (0.16%) 1 (0.16%) 0.00% (-0.43 to 0.43) 1.00 
Epileptic seizures 10 (1.56%) 2 (0.31%) 1.24% (0.19 to 2.30) 0.04 
Fall with injury 20 (3.12%) 7 (1.10%) 2.02% (0.45 to 3.59) 0.02 
New bone fracture 19 (2.96%) 6 (0.94%) 2.02% (0.51 to 3.53) 0.01 
Hyponatraemia < 125mmol/l 3 (0.47%) 2 (0.31%) 0.15% (-0.53 to 0.84) 1.00 
Hyperglycaemia 0 (0%) 0 (0%) 0%  
Symptomatic hypoglycaemia 0 (0%) 0 (0%) 0%  
New depression 33 (5.14%) 46 (7.21%) -2.07% (-4.71 to 0.57) 0.13 
New antidepressant 30 (4.67%) 43 (6.74%) -2.07% (-4.61 to 0.47) 0.12 
Attempted or actual suicide 0 (0%) 2 (0.31%) -0.16% (-0.75 to 0.12) 0.25 
Other adverse event  62 (9.66%) 68 (10.66%) -1.00% (-4.31 to 2.31) 0.56 
 
Data are n (%), unless otherwise stated 
 
* Risk differences and their 95%confidence intervals were calculated in SAS  by 
means of the FREQ procedure.    
https://documentation.sas.com/?docsetId=procstat&docsetTarget=procstat_freq_detail
s54.htm&docsetVersion=9.4&locale=en (accessed March 18, 2020). The confidence 
intervals around the risk differences are Wald intervals based on the normal 
approximation. 
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1. SUMMARY 
Title An Australasian, investigator-driven, NHMRC funded, multi-centre, 
prospective, randomised, parallel group, double-blind, placebo-controlled 
trial to establish the effect(s) of routine administration of fluoxetine (20 mg 
once daily) in patients with recent stroke 
Short title Assessment of fluoxetine in stroke recovery (AFFINITY) trial 
Acronym AFFINITY 
Clinical phase IIIb (i.e. fluoxetine is an established drug for depression, but not for stroke 




Associate Professor Maree Hackett, The George Institute for Global Health & 
The University of Sydney 





Does treatment with fluoxetine, 20 mg once daily, started 2-15 days after 
stroke onset and continued for 180 days, improve functional outcome at  180 
days after randomisation?  
Trial design Parallel group, randomised, placebo-controlled clinical trial.  
Setting Australian and New Zealand hospital stroke units and rehabilitation centres 
Eligibility 
criteria 
Inclusion Criteria  
Men or women aged ≥ 18 years with all of the following: 
 Clinical diagnosis of stroke 2-15 days previously (Day of stroke onset=Day 
0, randomise on Day 2-15) 
 Brain imaging consistent with ischaemic or haemorrhagic (intracerebral 
and/or subarachnoid) stroke (including normal CT brain scan) 
 Persisting measurable focal neurological deficits (e.g. motor, 
somatosensory, visual, language, cognitive) present at randomisation and 
severe enough to produce a modified Rankin Scale (mRS) score of >1 and 
to warrant treatment from the perspective of patient or carer(s). 
Exclusion Criteria 
Any of the following:  
 History of epileptic seizures  
 History of bipolar disorder 
 History of drug overdose or attempted suicide 
 Ongoing treatment with any selective serotonin reuptake inhibitor (SSRI) 
 Allergy or contra indication to fluoxetine including  
 Hepatic impairment (serum alanine aminotransferase [ALT] >120 U/l), 
 Renal impairment (creatinine >180micromol/l or eGFR < 
30ml/min/1.73m2),  
 Hyponatremia (sodium <125mmol/L) despite treatment of the cause 
and confirmed on repeat testing, 
 Use of medications that may interact seriously with fluoxetine 
 Proposed use of a monoamine oxidase inhibitor (MAOI), or use of a 
MAOI within 14 days prior to randomisation 
 Current treatment with an antipsychotic drug (neuroleptic), pimozide, 
tamoxifen, or tramadol, unless the patient, doctor and if possible 
prescribing doctor, believe it is appropriate to discontinue use.  
 Not available for follow up over the next 365 days e.g. no fixed home 
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address 
 Life-threatening illness (e.g. advanced cancer) that is  likely to reduce 365 
day survival 
 Pregnant, breast-feeding or of child-bearing potential and not using 
contraception  
 Enrolled in another interventional clinical research trial involving an 
investigational product (medicine) or device 
Randomisation Randomisation is by means of a password protected, computerised central 
randomisation service available 24 hours-a-day, using a minimisation 
algorithm to achieve balance between the two treatment groups for the 
following four prognostic factors: 
 Time from stroke onset (2-8 vs 9-15 days) 
 Presence of a motor deficit  
 Presence of aphasia 
 Predicted probability of survival free of dependency at 6 months (0-15% 
vs 16-100%).  
Interventions Participants are randomly assigned to 180 days of treatment with either:  
 Fluoxetine, 20mg capsules, to be taken once daily, or  
 Placebo capsules that match the fluoxetine capsules, once daily.  
For participants unable to swallow, the contents of an opened capsule can be 
given via enteral tube. 
Outcome 
measures 
Primary outcome  
 Functional outcome as measured by the mRS using the simplified 
modified Rankin Scale questionnaire (smRSq) at 180 days after 
randomisation 
 
Secondary outcomes at  180 and 365 days after randomisation  
 Survival, 
 Mood (Patient Health Questionnaire-9 item [PHQ-9] [46]), 
 Cognitive function (Telephone Interview of Cognitive Status [TICSm] [47]), 
 Communication (Stroke Impact Scale [SIS] [48]); 
 Motor function (SIS [48]); 
 Overall health status (SIS [48]); 
 Health-Related Quality of Life (HRQoL) (EuroQoL [EQ-5D-5L] [49]); and 
 Functional ability (smRSq [44, 45]) at the 365 day assessment. 
 New diagnosis of depression requiring treatment with antidepressants; 
 Fatigue (vitality domain of the Short Form 36 item, SF-36 [50, 51]); 
 
Serious adverse events at any time during follow-up and which are also 
recorded as other  secondary outcomes   
 New Stroke, ischaemic or haemorrhagic [not  the qualifying event leading 
to enrolment] 
 Acute coronary syndrome [Myocardial infarction confirmed by ECG and/ 
or raised serum Troponin] 
 Upper gastrointestinal bleed requiring blood transfusion and/or 
endoscopy 
 Other major bleed (i.e. not upper GI or intracerebral) requiring blood 
transfusion or procedural intervention  
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 Fall 
 New fracture [confirmed on X ray] 
 Epileptic seizure [focal or generalised] 
 Symptomatic hypoglycaemia [blood sugar < 3mmol/l] 
 Symptomatic hyperglycaemia [blood sugar > 22mmol/l] 
 New hyponatraemia [Na < 125mmol/l] 
 Attempted suicide/self-harm 
 Death 
 
Cost of health care over the first year 
 
Cost-effectiveness 
Follow up   At 28, 90, 180 and 365 days after randomisation. 
Participants are assessed by the site investigator at 28 and 90 days after 
randomisation, in the hospital ward, outpatient clinic or via telephone.  
Participants are followed-up at 180 and 365 days after randomisation by the 
trial coordinating centre, by telephone or postal questionnaire. 
Sample size 
estimate 
90% power to detect an absolute increase in the proportion of participants 
with an mRS of 0-2 at 6 months from 50% to 57.5%  
Number of 
participants 
1,600 (800 in each group)  
Statistical 
methods 
An ordinal logistic regression analysis of the mRS adjusted for baseline 
variables included in minimisation algorithm 
Trial duration 2013-2018 
 
 
Figure 1. Flow summary of trial participants and assessments 
 
1,600 patients 
Central randomisation 2 to 15 days post-stroke 
Intervention group (n=800) Control group (n=800) 
Informed consent, trial specific screen and baseline assessment 
 180 day end of intervention assessment, central 
28 and 90 day assessment, site 
 
365 day 6-month off-intervention assessment, central 
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2. LIST OF ABBREVIATIONS 
ADL/IADL activities of daily living/instrumental activities of daily living  
ALT Alanine Aminotransferase 
BDNF brain derived neurotrophic factor  
cAMP cyclic adenosine monophosphate    
cGMP current Good Manufacturing Processes 
CI confidence interval 
CLOTS Clots in Legs Or sTockings after Stroke  
CNS Central nervous system 
CRF Case Report Form 
CT Computerised Tomography  
CV Curriculum Vitae   
DALYs Disability adjusted life years 
DMC Data monitoring committee 
DSM-IV Diagnostic and Statistical manual of mental disorders-fourth edition 
EFFECTS Swedish multicentre randomised placebo-controlled trial to 
establish the efficacy of fluoxetine in patients with a recent stroke 
eGFR Glomerular Filtration Rate  
EQ-5D-5L EuroQol 5 dimensions 5 levels  
FLAME FLuoxetine for motor recovery after Acute ischaeMic strokE 
FMMS Fugl-Meyer Motor Scale Score  
fMRI functional Magnetic resonance Imaging  
FOCUS Fluoxetine Or Control Under Supervision 
GCP Good clinical practice 
GCS Glasgow Coma Scale 
GP General Practitioner  
GSK GlaxoSmithKline 
HR hazard ratio 
HREC Health review ethics committee 
HRQoL Health Related Quality of Life 
ICH International conference on harmonisation 
IMP Investigational medicinal product 
IQR Interquartile Range  
ISF Investigator site file 
MAOI Monoamine oxidase inhibitors 
mRS modified Rankin Scale 
NHMRC National Health and Medical Research Council 
NIHSS National Institutes of Health Stroke Scale 
OCSP Oxfordshire Community Stroke Project 
OD once daily 
OR odds ratio 
pCREB Phosphorylated cAMP response element binding  
PHQ-9 Patient Health Questionnaire-9 item 
POISE Psychosocial Outcome In Stroke 
PISC Participant Information and Consent Form  
PPP Pharmaceutical packaging professionals 
QALY Quality adjusted life year 
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RCTs Randomised Controlled Trials  
RR risk ratio 
SAE Serious Adverse Event 
SAR Serious Adverse Reaction 
SCAST Scandinavian Candesartan Acute Stroke Trial 
SD Standard deviation  
SF-36 Vitality Subscale of the Short Form-36 
SIADH Syndrome of inappropriate anti-diuretic hormone   
SIS Stroke Impact Scale 
smRSq Simplified modified Rankin Scale questionnaire 
SSRI selective serotonin reuptake inhibitor 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TGA Therapeutic Goods Administration 
TICSm Telephone Interview for Cognitive Status- m 
TOAST Trial of org 10172 in acute stroke treatment  
UK United Kingdom 
USA United States of America 
VITATOPS VITAmins TO Prevent Stroke 
 
AFFINITY Protocol Version 5, 18
th
 November 2015  Page 11 of 112 
3. BACKGROUND 
Long-term disability after stroke is common, and is the third most common cause of 
disability adjusted life years (DALYs) 
About 60,000 Australians experience a stroke each year [1,2]. Thrombolysis, endovascular 
thrombectomy, antiplatelet therapy and stroke unit care facilitate the one-year survival of 
about 48,000 (80%) but 15,000-24,000 (30-50% of survivors) remain disabled [3-5]. In 2010, 
stroke was the third leading cause of disability-adjusted life years (DALYs) worldwide among 
291 diseases and injuries [6]. 
Treatments that improve recovery and reduce disability after stroke are lacking 
One reason for the substantial disability after stroke is a shortage of effective, safe, 
affordable and accessible interventions that facilitate functional recovery [7]. Numerous 
clinical trials have failed to translate promising experimental data into clinically effective 
therapies [8]. However, hope has been re-ignited by the publication of the results of the 
fluoxetine for motor recovery after acute ischaemic stroke (FLAME) trial in 2011 (see page 
12) [9]. 
Fluoxetine is a promising neuroprotective and neuroregenerative agent 
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that is commonly used to treat 
depression. It is also a promising neuroprotective and neuroregenerative / neurorestorative 
agent. 
Animal studies indicate that SSRIs may be of benefit to stroke survivors 
Animal models have produced results consistent with the hypothesis that fluoxetine, and 
possibly other SSRIs, might improve the clinical outcome of stroke survivors in a number of 
ways. First, brain stem and spinal cord -motor neurons receive dense serotonergic inputs, 
and serotonergic fibres innervate secondary motor structures such as the basal ganglia 
[10,11]. Second, SSRIs have a neurotrophic effect and stimulate neurogenesis in the adult 
brain [12-17]. They stimulate the secretion of growth factors, and other proteins associated 
with increased plasticity such as brain-derived neurotrophic factor (BDNF) [8,9] and 
phosphorylated cAMP response element binding (pCREB) protein [12-16], cell proliferation 
and the number of newborn neurons derived from the adult subgranular zone of the 
dentate gyrus in the hippocampus increases after prolonged treatment with fluoxetine [17]. 
Third, fluoxetine may have a neuroprotective role associated with its anti-inflammatory 
effect [18], thereby leading to a reduction of infarct size and enhancement of the expression 
of proteins (e.g. hypoxia-inducible factor 1 alpha) that facilitate recovery from ischaemic 
injury [19].  
Human studies indicate that fluoxetine use may improve stroke recovery 
Functional magnetic resonance imaging (fMRI) studies have found that fluoxetine can 
modulate motor activity in healthy subjects [20]. A subsequent double-blind placebo-
controlled crossover trial reported that a single dose of fluoxetine improved motor 
performance and increased fMRI activation in 8 patients who had a lacunar stroke resulting 
in a pure motor hemiparesis [21]. These findings were replicated in a trial of 10 stroke 
patients [22]; participants who took a single dose of fluoxetine 20 mg showed increased 
muscle activation in the paretic arm. Among 52 post-stroke hemiplegic participants who 
were receiving physiotherapy and were randomly assigned to fluoxetine 20 mg daily, 
maprotiline 150 mg daily or placebo for 3 months, those assigned fluoxetine showed the 
greatest functional improvement as judged by a graded neurological scale and a measure of 
activities of daily living (Barthel Index) [23,24]. In another randomised trial, daily 
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administration of 10 mg of the SSRI citalopram to stroke patients for 4 months was 
associated with a reduction in neurological impairment National Institute of Health Stroke 
Scale (NIHSS) score (appendix 1) of 2.3 versus 3.5 control, p=0.03) at trial completion [25]. In 
another randomised trial of fluoxetine (n=32), nortriptyline (n=22) and placebo (n=29), three 
months of treatment with either nortriptyline or fluoxetine produced greater improvements 
in the modified Rankin Scale (mRS) measured at 1 year (i.e., 9 months after the start of 
treatment) compared with placebo, after adjusting for age depression, stroke severity, and 
rehabilitation intensity [26]. The significant benefits of treatment, as measured by the mRS 
compared with placebo, continued for at least 1 year. 
The fluoxetine for motor recovery after acute ischemic stroke (FLAME) trial in humans. 
Among 118 patients with ischaemic stroke 5-10 days earlier, hemiparesis and a Fugl-Meyer 
Motor Scale Score (FMMS) < 55, random allocation to double-blind treatment with 
fluoxetine 20 mg daily (n=57) for 3 months, compared with placebo (n=56), improved motor 
function (adjusted mean FMMS 34.0 vs 24.3 points; p=0.003), functional independence mRS 
score of 0-2: 26.3% vs 8.9%; odds ratio [OR]: 3.8, 95% confidence interval [CI]: 1.2 to 10.7), 
and maintained participants free of depression (96% vs 71%; p=0.002) [9]. Adverse effects 
included transient nausea, diarrhoea, and abdominal pain (14 [25%] fluoxetine vs 6 [11%] 
placebo). Despite its encouraging results, the FLAME trial has raised several questions [27]: 
1. Are the results of the FLAME trial valid? 
Although systematic error was minimised by double-blinding and randomisation, random 
error might have occurred because of the small sample size (n=118) and limited statistical 
power. 
Other studies in humans: a systematic review of all randomised controlled trials of fluoxetine 
In order to minimise random error and explore external validity (generalisability), we 
completed a Cochrane systematic review and meta-analysis of 52 randomised controlled 
trials (RCTs) of SSRIs on recovery after stroke in a total of 4,059 patients [26]. Overall, use of 
SSRIs was associated with less dependency (risk ratio [RR] 0.81, 95% CI: 0.68 to 0.97) (two 
trials, n=223) at the end of treatment compared with control (placebo or usual care) [28] 
(see Figure 2), 
 
 
Figure 2. Risk ratio of dependence, defined by modified Rankin Scale score (mRS score 3-5) 
[28]. 
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and less disability (standard mean difference 0.91, 95% CI: 0.60 to 1.22) (22 trials, n=1343) at 
the end of treatment compared with control (placebo or usual care) (see Figure 3) [28]. 
 
 
Figure 3. Standard mean difference in disability between SSRI and control groups at the end 
of treatment.  
However, the validity of these results is compromised by substantial heterogeneity among 
the trials (I2=86; p<0.0001), methodological limitations (e.g. lack of blinding, incomplete 
outcome data), and clinical heterogeneity (e.g. many trials excluded aphasic and cognitively 
impaired patients). Further, adverse event data were inadequate to determine risks, only 7 
trials (n=495) followed patients after treatment ended, and trials at low risk of bias reported 
smaller treatment effects.  
Moreover, only 12 trials of fluoxetine were placebo-controlled in a total of only 682 patients, 
and an average treatment duration of only 7 weeks. Of these 12 trials, the primary outcome 
was disability (binary) in only one trial and functional recovery (continuous) in two trials; 5 
trials assessed functional recovery as one of many secondary endpoints, and no trial 
followed-up patients beyond the treatment period. 
A meta-analysis of the 6 placebo-controlled trials of fluoxetine which measured degree of 
functional recovery showed that in a total of 277 patients fluoxetine was associated with less 
disability compared with placebo (standardized mean difference: 0.35, 95% CI 0.03 to 0.61) 
[28]. 
These data are not sufficiently robust to be conclusive or to change clinical practice. 
However, they are sufficiently promising to warrant further evaluation of the effects of 
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fluoxetine on recovery after stroke. One or more large RCTs, conducted according to the 
world’s best standards, would reliably answer the question [29,30]. 
2. Are the results of FLAME & other trials generalisable to patients without severe 
hemiparesis? 
The effect of fluoxetine in patients with mild to moderate hemiparesis, disabling non-motor 
neurological deficits and severe disability (NIHSS score >20) is uncertain. 
3. Are the results of FLAME & other trials generalisable to non-motor outcomes? 
The effects of fluoxetine on cognition, communication, quality of life, and fatigue are 
uncertain. 
4. Do any beneficial effects of fluoxetine on recovery persist after it is stopped? 
The effects of fluoxetine on recovery after fluoxetine is stopped have not been investigated 
yet. 
5. Is the effect of fluoxetine on recovery due to antidepressant or neuroregenerative 
effects? 
It is uncertain if there is an interaction between mood and recovery. The FLAME trial results 
remained significant after adjusting for depression [9], but in our systematic review the 
effect of SSRIs on recovery was greater in people with depression at randomisation [28]. 
Even if fluoxetine does improve recovery only because of its favourable effects on mood 
(e.g. less depression may facilitate participation in rehabilitation and increased physical and 
cognitive activity), that would still be an important finding that would change clinical 
practice. 
6. Does the risk of serious adverse events offset or exceed any benefits of fluoxetine? 
Our systematic review indicated that SSRIs, compared with placebo or usual care, were 
associated with a non-significant excess of seizures (RR 2.7; 95% CI 0.6-11.6) (7 trials, 444 
participants), gastrointestinal adverse effects (RR 1.9; 0.9-3.8) (14 trials, 902 participants) 
and bleeding (RR 1.6; 0.2-13) (2 trials, 249 participants) [28]. Cohort studies, whilst prone to 
confounding and indication bias, have also reported that SSRI use is associated with 
increased risk of seizures, bleeding and hyponatraemia, particularly during the first 4 weeks 
of treatment [31-35]. 
Summary of fluoxetine as a promising neuroprotective and neuroregenerative agent 
Our Cochrane review suggests that fluoxetine has promising effects on stroke recovery, 
perhaps via neuroregeneration [28]. Further, fluoxetine is widely known, available and 
affordable (Aus$4.50 per month; no longer patented). However, the data from our review 
are not sufficiently compelling to prove that fluoxetine improves functional recovery after 
stroke, that any effects are independent of its effects on mood, and that any possible 
favourable effects are not offset by serious adverse effects, particularly among older stroke 
patients taking antithrombotic agents [28]. As in several areas of medicine, clinical practice 
in stroke recovery has been influenced by premature reports of beneficial effects from small 
trials that have not been replicated by more methodologically robust studies [36-39]. It is 
not only ethical but also essential that sound large clinical trials are undertaken to provide 
valid and more precise estimates of the efficacy and safety of fluoxetine for post-stroke 
recovery and function [27,29,40-42]. Other leading investigators in the United Kingdom (UK) 
(GE Mead and MS Dennis), Sweden (E Lundström and the late V Murray) and United States 
of America (USA) also see the need for large RCTs [30,43]. The AFFINITY trial, whilst unique 
in many aspects, has been designed to allow future pooling of data with the concurrently 
ongoing UK Fluoxetine Or Control Under Supervision (FOCUS) trial (see section 15) and the 
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Swedish multicentre randomised placebo-controlled trial to establish the efficacy of 
fluoxetine in patients with a recent stroke (EFFECTS) trial (see section 15). 
4. OBJECTIVES 
Hypothesis 
Administration of fluoxetine (20mg once daily; (od) for the first 180 days after stroke 
improves functional ability at the 180 day assessment, and the effect persists for 180 days 
after fluoxetine is stopped. 
Primary Objective 
To determine if treatment with fluoxetine, 20mg once daily, started 2-15 days after stroke 
onset and continued for 180 days, improves functional ability at the 180 day assessment as 
measured by the mRS using the simplified modified Rankin Scale questionnaire (smRSq) 
[44,45] (appendix 2). 
Secondary Objectives 
Secondary outcomes at 180 and 365 days after randomisation  
 Survival; 
 Mood (Patient Health Questionnaire-9 item [PHQ-9] [46]) (appendix 4); 
 Cognitive function (Telephone Interview of Cognitive Status [TICSm] [47]) (appendix 
5); 
 Communication (Stroke Impact Scale [SIS] [48]) (appendix 7); 
 Motor function (SIS [48]); 
 Overall health status (SIS [48]); 
 Health-Related Quality of Life (HRQoL) (EQ-5D-5L [49]) (appendix 8); and 
 Functional ability (smRSq [44, 45]) at the 365 day assessment. 
 New diagnosis of depression requiring treatment with antidepressants; 
 Fatigue (vitality domain of the short form- 36 [SF-36] [50, 51]) (appendix 6). 
Serious adverse events which occur at any time during follow-up and which are also 
recorded as secondary outcome measures include:  
 New Stroke, ischaemic or haemorrhagic [not the qualifying event leading to 
enrolment] 
 Acute coronary syndrome [myocardial infarction confirmed by ECG and/or raised 
serum Troponin] 
 Upper gastrointestinal bleed [requiring blood transfusion and/or endoscopy 
 Other major bleed (i.e. not upper GI or intracerebral) requiring blood transfusion or 
procedural intervention  
 Fall  
 New fracture [confirmed on X ray] 
 Epileptic seizure [focal or generalised] 
 Symptomatic hypoglycaemia [blood sugar < 3mmol/l] 
 Symptomatic hyperglycaemia [blood sugar > 22mmol/l] 
 New hyponatremia [Na < 125mmol/l] 
 Attempted suicide/self-harm  
 Death 
Cost of health care over the first year 
Cost-effectiveness. 
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5. TRIAL PLAN AND PROCEDURES 
Trial design 
Parallel group, randomised, placebo-controlled clinical trial in which the participants, site 
investigators, and assessors will all remain unaware (i.e. blinded) of the intervention 
assignments throughout the trial (i.e. “double-blind” for centres where the site investigator 
and assessor are the same individual; “triple-blind” for centres where the site investigator 
and assessor are distinct individuals). 
Setting and recruitment 
Participants are being recruited in Australian and New Zealand hospital stroke units and 
rehabilitation centres by site investigators trained in relevant aspects of the trial by 
members of the trial coordinating centre. Screening, assessments and consent are 
conducted by the site investigator and data on randomised patients will be entered into a 




Men or women aged ≥ 18 years with all of the following: 
 Clinical diagnosis of stroke 2-15 days previously (Day of stroke onset = Day 0, 
randomise on Day 2-15)  
 Brain imaging consistent with ischaemic or haemorrhagic (intracerebral and/or 
subarachnoid) stroke (including normal computerised tomography (CT) brain scan) 
 Persisting measurable focal neurological deficits (e.g. motor, somatosensory, visual, 
language, cognitive) present at randomisation and severe enough to produce a 
modified Rankin Scale (mRS) score of ≥1 and to warrant treatment from the 
perspective of patient or carer(s). 
Exclusion criteria 
Any of the following: 
 History of epileptic seizures  
 History of bipolar disorder 
 History of drug overdose or attempted suicide 
 Ongoing treatment with any selective serotonin reuptake inhibitor (SSRI) 
 Allergy or contra indication to fluoxetine including  
 Hepatic impairment (serum alanine aminotransferase [ALT] >120 U/l), 
 Renal impairment (creatinine > 180 micromol/l or estimated Glomerular 
Filtration Rate [eGFR] < 30ml/min/1.73m2), 
 Hyponatremia (sodium < 125 mmol/L) despite treatment of the cause and 
confirmed on repeat testing,   
 Use of medications that may interact seriously with fluoxetine 
 Proposed use of a monoamine oxidase inhibitor (MAOI), or use of a MAOI 
within 14 days prior to randomisation  
 Current treatment with an antipsychotic drug (neuroleptic), pimozide, 
tamoxifen, or tramadol, unless the patient, doctor and if possible prescribing 
doctor, believe it is appropriate to discontinue use.  
 Not available for follow-up over the next 365 days; e.g. no fixed home address 
 Life-threatening illness (e.g. advanced cancer) that is likely to reduce 365 day survival 
 Pregnant, breast-feeding or of child-bearing potential and not using contraception  
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 Enrolled in another interventional clinical research trial involving an investigational 
product (medicine) or device. 
Co-enrolment 
Co-enrolment in another clinical trial of a medicinal or surgical intervention is not permitted 
because the other intervention could affect the primary outcome measure in AFFINITY and, 
because it is not assigned at random to the AFFINITY trial patients, it may confound the 
AFFINITY trial results. Co-enrolment in observational studies is acceptable.   
Consent 
It is the primary responsibility of the investigator at each participating site to obtain 
informed consent from participants to participate in the AFFINITY trial for 365 days using 
one of the approved methods outlined in section 9 of this protocol.  
Randomisation 
Consenting participants who meet the inclusion and exclusion criteria are randomised 2 to 
15 days after stroke onset by means of a computerised central randomisation service 
(www.affinitytrial.org) that is available 24 hours a day.  
Minimisation 
At the time of randomisation, the following six prognostic variables are collected: age, living 
alone, independence in activities of daily living before the stroke, the verbal component of 
the Glasgow Coma Scale (GCS) (as derived from the NIHSS), arm power, and ability to walk 
[52]. The trial website has  a computer program installed that automatically calculates the 
probability of survival free of dependency at the 180 day assessment, based on the 
prediction model developed and validated by Counsell et al [52]. It is anticipated that about 
half of randomised patients will have a predicted probability of 0-15%, and the other half 16 
to 100% of being independent at the 180 day assessment. 
After entering the baseline demographic and clinical data of the participant randomisation 
occurs using a minimisation algorithm to achieve balance between the two treatment 
groups for the following four prognostic factors: 
1. Delay between stroke onset and randomisation (2-8 vs 9-15 days). As spontaneous 
recovery may be quicker in the first week, we want to ensure that there is no 
substantial difference between treatment groups in the number of patients 
randomised in the first week, and also no difference between treatment groups in 
the number of patients randomised in the second week.  
2. Presence of a motor deficit. To ensure the prevalence of patients with and without a 
motor deficit is equal in both treatment groups.   
3. Presence of aphasia. To ensure the prevalence of patients with and without aphasia 
is equal in both treatment groups.   
4. Probability of survival free of dependency at 6 months (0.15 vs 0.16-1.0) [52]. To 
ensure that at baseline, patients in each treatment group have equal probability of 
being alive and independent (mRS: 0-2) at the 180 day assessment.  
The purpose of the minimisation process is to ensure an equitable prevalence or balance of 
major prognostic factors for survival free of dependency between the two treatment arms.  
At randomisation, participants are assigned to the group which minimises the 
difference across all four variables but only with a probability of 0.8 (rather than 1.0). This 
adds a random element to the treatment assignment which means that the likely treatment 
allocation cannot be guessed in advance.  
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At randomisation, the system automatically generates a treatment allocation in a ratio of 1:1 
active drug (fluoxetine) or placebo. Participants are allocated an AFFINITY number and a 
treatment number, that corresponds to a treatment pack located at the local hospital 
pharmacy. An email notification is sent to the trial coordinating centre and the site investigator 
with the randomisation details (AFFINITY number and treatment number). The site 
investigator is then responsible for ensuring the randomisation notification and medication 
prescription are delivered to the local hospital pharmacy so the participant may commence 




Participants are randomly assigned to six months treatment with either: 
 Fluoxetine, 20mg capsules, to be taken once daily, or 
 Placebo capsules that match the fluoxetine capsules (in appearance (same colour and 
shape), weight and texture), to be taken once daily.  
For participants unable to swallow, the contents of an opened capsule can be given via 
enteral tube. 
The fluoxetine capsules are a Generic brand of capsule supplied by Pharmaceutical 
Packaging Professionals (PPP) PTY LTD in South Australia.  
 
The placebo capsules are manufactured and bottled at PPP. 
The bottles of active drug [fluoxetine] and placebo are labelled by PPP in accordance with 
the randomisation schedule, according to regulatory requirements, and stored at PPP in 
accordance with standards of the South Australian Department of Human Services in a cGMP 
(current good manufacturing processes) dedicated warehouse at below 25 degrees celsius.   
The trial coordinating centre is responsible for ordering the trial medication for the 
individual sites from PPP. 
PPP distributes the AFFINITY trial medication usually in blocks of 10 treatment packs (5 
active and 5 placebo) directly to the local pharmacy departments of the participating sites at 
the request of the trial coordinating centre.  Each treatment pack consists of two bottles per 
participant (i.e. each bottle will contain a 90 day supply of 110 capsules of either fluoxetine 
or matching placebo). This includes an extra 20 capsules in each bottle to allow for delays in 
follow-up appointments or lost trial medication. Participating sites will instruct their hospital 
pharmacies to store the product under appropriate conditions (below 25 degrees celsius).    
Site investigators will prescribe 180 days [6 months] supply of the trial medication by means 
of a local hospital prescription to be dispensed to the participant at baseline. The treatment 
packs are dispensed by the local hospital pharmacy. All treatment packs will be returned to 
the trial coordinating centre at the 180 day follow up where they will be counted and 
forwarded to PPP for destruction. 
Participants are encouraged to minimise any unintentional non-adherence by using simple 
strategies, such as linking tablet-taking to the same time as other medication or having 
breakfast.  It is the responsibility of each site investigator to ensure that accurate records of 
trial medication prescriptions are maintained. 
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Drug interactions 
 
Metabolism of fluoxetine 
Following oral administration, fluoxetine is well absorbed from the GI tract. Oral 
bioavailability is estimated to be at least 60-80%. Peak plasma concentrations occur within 6-
8 hours following a single oral dose. Food does not affect the systemic bioavailability of 
fluoxetine but it delays the absorption by 1-2 hours (not clinically significant). 95% is bound 
to human serum proteins 
 
Fluoxetine appears to be extensively metabolized, likely in the liver, to norfluoxetine and 
other metabolites via isoenzymes of the cytochrome P450 system, including 2D6, 3A4, 2C9, 
3A5, and 2C19.  
 
Norfluoxetine, the principal active metabolite, is formed via N-demethylation of fluoxetine.  
 
Fluoxetine has a slow elimination half-life of 1 to 3 days after acute administration and 4 to 6 
days after chronic administration. Its active metabolite, norfluoxetine has an elimination 
half-life of 4 to 16 days after acute and chronic administration. The long elimination half-
lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug 
substance will persist in the body for weeks (primarily depending on individual patient 
characteristics, previous dosing regimen, and length of previous therapy at discontinuation). 
 
Genetic polymorphisms that may reduce the metabolism of serotonin (and thereby increase 
blood and brain concentrations of serotonin) 
A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme 
cytochrome P450 2D6 (CYP2D6) - they are referred to as poor metabolizers. When a poor 
metabolizer takes several doses of fluoxetine the fluoxetine may accumulate to higher than 
usual concentrations in the blood, resulting in a greater exposure to fluoxetine than occurs 
in patients who have normal activity of enzyme. This could lead to adverse drug reactions of 
fluoxetine including anorexia, nervousness, tremor, tachycardia, and seizures. 
 
Drugs that may reduce the metabolism of serotonin (and thereby increase blood and brain 
concentrations of serotonin) 
Medications that inhibit the enzyme CYP2D6, and thereby increase blood and brain 
concentrations of fluoxetine, include: 
 Antiarrhythmic drugs: Amiodarone, Quinidine (a medicine for heart arrhythmias.  
 Antipsychotic drugs: Haloperidol, Pimozide. Some evidence suggests a possible 
pharmacodynamic and/or pharmacokinetic interaction between some SSRIs and 
some antipsychotics, including possible elevation of blood levels of haloperidol and 
clozapine. Concurrent use of fluoxetine with pimozide increases the risk of QTc 
prolongation.  
 
Drugs that may interact with fluoxetine to increase blood and brain concentrations of 
serotonin 
Fluoxetine, which increases the amount of serotonin that can act on receptors in the blood 
and brain, may interact with other medications that also increase blood and brain 
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concentrations of serotonin [53]. These medications, which should be avoided with 
fluoxetine, include: 
 Other SSRIs 
 Tramadol and other synthetic opiates 
 Triptans, such as sumatriptan (Imitrex®, GlaxoSmithKline (GSK)  
 Tryptophan,  
 Lithium 
 MAOIs, such as phenelzine (Nardil®, Parke-Davis), tranylcypromine (Parnate®, GSK), 
and selegiline (Eldepryl®, Somerset; and others). 
1. The concurrent use of fluoxetine with MAOIs is contraindicated.  
2. After stopping MAOIs, fluoxetine should not be started until at least 14 days have 
elapsed (after stopping the MOAI).  
3. After stopping fluoxetine, MAOIs should not be started until at least 5 weeks have 
elapsed (after stopping the fluoxetine), since fluoxetine is slowly eliminated from 
the body; and 
 The herbal remedy St John's Wort (Hypericum perforatum) can potentially also 
increase the levels of serotonin. 
Consequences of an increase in blood and brain concentrations of serotonin (see also 
“Overdose” below) 
Serotonin syndrome 
The potential consequence of co-administration of fluoxetine with serotonergic drugs (see 
above) is an increase in blood and brain concentrations of serotonin and a cluster of 
symptoms called the serotonin syndrome. 
The symptoms and signs of serotonin syndrome include: restlessness, irritability, altered 
behaviour, confusion, shivering, fever/hyperthermia, diarrhoea, tremor, hyperreflexia, 
rigidity, clonus, myoclonus, autonomic instability with rapid fluctuations of vital signs, 
seizures, and mental status changes that include extreme agitation progressing to delirium 
and coma. 
Effect of fluoxetine on the blood concentrations of other drugs 
Inhibition of CYP2D6.  
Fluoxetine is also a potent inhibitor of the liver enzyme, CYP2D6.  
Hence, fluoxetine can alter the blood concentrations of other medications that are 
metabolized by CYP2D6, such as: 
 Tricyclic antidpressants: amitriptyline, imipramine, and desipramine 
 Antiepileptic drugs: carbamazepine, phenytoin and  
 Antipsychotic drugs: thioridazine.  
 Codeine 
These drugs should be started at low dose in patients taking fluoxetine, otherwise toxicity 
with these drugs may arise. 
In contrast, fluoxetine inhibits the conversion of codeine to its active form morphine and 
thereby diminishes the analgesic effect of codeine.  
Similarly, fluoxetine, by inhibiting CYP2D6, also inhibits the conversion of tamoxifen to its 
active metabolite, thus reducing the amount of active drug to protect against breast cancer 
recurrence.  
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Inhibition of CYP2C9 and CYP2C19 
Fluoxetine also inhibits the CYP2C9 and CYP2C19 enzymes and thereby may interfere with 
the elimination of many medications including warfarin (an anticoagulant) and phenytoin (an 
antiepileptic medication). The effects of these medications therefore require careful 
monitoring. 
Potential Effects of Co-administration of Drugs Highly Bound to Plasma Proteins 
Because fluoxetine is tightly bound to plasma proteins, the administration of fluoxetine to a 
participant taking another drug which is tightly bound to protein (e.g. warfarin) may cause a 
shift in plasma concentrations potentially resulting in an adverse effect. Conversely, adverse 
effects may result from displacement of protein bound fluoxetine by other tightly bound 
drugs. 
Participant adherence and compliance 
Participants are asked to keep a record of their use of the trial and other medication (e.g. 
concurrent/additional medications). 
Participants are encouraged to adhere to (i.e. continue) the allocated treatment and are 
asked to record the dates and reasons of any temporary or permanent discontinuation.  
Participants will also be encouraged to comply with (i.e. consistently take) the allocated trial 
medication. They are asked to keep their capsule bottles and any remaining capsules for 
return to the trial coordinating centre in Perth at the 180 day assessment so that the 
compliance rate (the ratio of taken doses to total possible doses) can be calculated. 
Premature discontinuation of trial medication  
Participants who choose to stop taking the allocated treatment are still followed up for study 
outcome measures as per the study protocol and included in the primary intention-to-treat 
analysis.  
The reason(s) for stopping the trial treatment prematurely is/are recorded in the participants 
case report form (CRF).  
If withdrawal results from a Serious Adverse Event (SAE), Serious Adverse Reactions (SAR) or 
Suspected Unexpected Serious Adverse Reaction (SUSAR) the event is reported as per protocol 
(Please see section 7 of this protocol for more information regarding SAEs, SARs and SUSARs). 
Participants may also choose to withdraw completely from the trial, so that no further data 
are collected on the participant. If the participant is willing, we will record the reason for any 
such withdrawal on the “withdrawal of consent” form. 
Emergency Un-blinding  
Un-blinding is strongly discouraged. 
In the event of an emergency, such as a suspected serotonin syndrome, discontinue the trial 
medication and treat the participant in the usual manner.  
If an emergency occurs and un-blinding is required please contact your local hospital 
pharmacy who will contact the 24 hour un-blinding hotline on 1800 175 982, in Australia and 
[+61 438 356 411] in New Zealand, this service is provided by PPP. Your local hospital 
pharmacy is required to provide the participants AFFINITY treatment number to break the 
code and receive the treatment allocation i.e. active (fluoxetine) or placebo.  
The trial medication must be discontinued after emergency un-blinding. 
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Overdose 
Symptoms of overdose of fluoxetine include nausea, vomiting, and seizures. Cardiovascular 
dysfunction, ranging from asymptomatic arrhythmias to cardiac arrest, can occur, as may 
pulmonary dysfunction, and central nervous system (CNS) dysfunction, ranging from 
excitation to coma.  
Cardiac and vital sign monitoring is recommended, along with general symptomatic and 
supportive measures.  
No specific antidote is known. Activated charcoal, which may be used with sorbitol, may be 
as or more effective than emesis or lavage. Forced diuresis, dialysis, haemoperfusion, and 
exchange transfusion are unlikely to be of benefit because fluoxetine is highly protein-
bound. 
In managing over dosage, consider the possibility of multiple drug involvement. An extended 
time for close medical observation may be needed in participants who have taken excessive 
quantities of a tricyclic antidepressant if they are also taking, or have recently taken, 
fluoxetine. 
Fatalities attributed to overdose of fluoxetine alone are extremely rare; the severity is 
usually mild and the course benign.  
Stopping the trial medication at the 180 day assessment (or earlier) 
Sudden cessation of an SSRI may lead to a withdrawal syndrome characterised by symptoms 
including anxiety, restlessness, insomnia, headache and tremor. However, of all the SSRIs, 
fluoxetine has the longest half-life (4-6 days) and therefore a withdrawal syndrome is very 
uncommon and tapering of the dose (especially from only 20mg od) is not regarded as 
necessary. 
Possible Side Effects of Fluoxetine 
Adverse effects and suggested management (Adapted from reference [54])  
 




Occurs in about one in 10 people who take second 
generation antidepressants but is less common with 
fluoxetine 
 
Check blood pressure standing and lying; symptoms 
usually improve over time;  Ensure adequate fluid 
intake 
Sedation Not common but can occur  Sedation may be desirable; it may improve over time. 
Change time of dosing and treatment 
Dry mouth Probably dose related Tolerance may develop; suggest sugarless gum or 
saliva substitutes 
Sexual dysfunction 
[Male and female] 
Common but often not asked about Discuss participant’s willingness to continue trial 
medication in view of stroke diagnosis, possible 
positive effects of the medication and 6 month 
treatment regime. Short term use of sildenafil [males] 
could also be considered if clinically appropriate.  
Insomnia Common problem but hard to distinguish from 
insomnia caused by depression 
Change time of dosing (earlier or later may help), pay 
attention to sleep hygiene. Monitor participant’s 
mood [Possible new diagnosis of depression.]  
Suicidal thoughts Antidepressants may paradoxically increase suicidal 
thoughts in those aged under 30 
Protocol specific assessment of the participant:  
includes the PHQ-9 assessment which asks about 
suicidal thoughts. No evidence exists that asking 
about suicide makes people more likely to harm 
themselves. Urgent clinical management of the 
participant with suicidal ideation is required.  .  
Anxiety Often occurs when starting SSRIs Monitor participant and reassure that symptoms 
usually subside.   
Hyponatraemia Particularly a problem in the elderly and more 
common with SSRIs 
Check sodium levels if the patient is symptomatic and 
treat clinically. Stopping the trial medication should 
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Adverse effect Comment Management 
not be necessary unless symptoms persist.  
Serotonin 
syndrome 
Characterised by changes in mental state (eg 
confusion or agitation), autonomic instability (eg 
high temperature, shivering, sweating, changes in 
blood pressure), and neuromuscular hyperactivity 
(eg clonus or hyper-reflexia). Seen particularly with 
SSRIs and other drugs that effect serotonin 
Stop the trial medication Use supportive measures 
such as hydration, management of hyperthermia, and 
benzodiazepines. Consider cyproheptadine or 
chlorpromazine in severe cases 
Discontinuation 
syndrome  
More common with SSRIs that have a short half-life 
(eg paroxetine or venlafaxine) 
Advise the participant that fluoxetine has a long half-
life and, as such, reducing dosage prior to 
discontinuation is not considered necessary.  
SSRIs=selective serotonin reuptake inhibitors. 
Return and disposal of unused medication at the end of the treatment phase (180 day 
follow up) 
All unused medication is returned to the trial coordinating centre in Perth for medication 
accountability and from there returned to PPP for disposal. 
Returns will be coordinated by the trial office in Perth by secure express post.    
Lost trial medication / Replacement stock 
The trial coordinating centre will liaise with Pharmaceutical Packaging Professionals [PPP], 
supplying them with the participants AFFINITY and treatment allocation numbers and the 
details of the participating site’s pharmacy for shipment of the replacement trial medication.  
The trial coordinating centre will liaise with the site Principal Investigator or their delegated 
staff so that the replacement medication can be prescribed and dispensed to the participant. 
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6. TRIAL ASSESSMENTS, MEASUREMENTS, ENDPOINTS  
Figure 4: Flow diagram summarising the process of the AFFINITY trial 
 
Baseline assessment (2-15 days after stroke onset) (appendix 9) 
Prior to randomisation, the following are recorded: gender, date of birth, ethnicity, marital 
status, living arrangements, employment status,  independence in activities of daily living 
before stroke, date of stroke, previous history of  depression*, co morbidities, medications, 
classification of clinical stroke type (Oxfordshire Community Stroke Project, OCSP [55]) 
(appendix 3) ischaemic stroke subtype (Trial of Org 10172 in Acute Stroke Treatment [TOAST] 
criteria [56]), neurological impairments (NIHSS [57]) ; arm strength; ability to walk; 
functional ability (smRSq [44,45]), mood (PHQ-9 [46]), and the results of laboratory tests 
(serum creatinine, eGFR, sodium, ALT; pregnancy test if premenopausal woman; see below).  
28 +/- 7 days: Site Telephone/Face to Face assessment on treatment  
Survival, living arrangements, clarification of the final diagnosis and cause of qualifying stroke, current medications, 
medication compliance, serious adverse events, pregnancy (female participants of child bearing age), primary outcome 
(smRSq), current depression, mood (PHQ-9), 





Letter informing GP 
Collect baseline data 
Randomise 
20mg  for 6/12 
Placebo 
180 +/- 14 days: Central Telephone/Postal assessment at end of treatment 
Survival, living arrangements, current medications, medication compliance, serious adverse events, pregnancy (female 
participants of child bearing age), health care utilisation, primary outcome (smRSq), current depression, mood (PHQ-9), 
cognition (TICSm), Fatigue (vitality subscale of SF36), health-related quality of life (EQ-5D-5L), overall health status 
(SIS). 
365 +/-14 days: Central Telephone/Postal assessment at end of follow-up off 
treatment 
Survival, living arrangements, current medications, serious adverse events, pregnancy (female participants of child bearing 
age), health care utilisation,  primary outcome (smRSq), current depression, mood (PHQ-9), cognition (TICSm), Fatigue (vitality 
subscale of SF36), health-related quality of life (EQ-5D-5L), overall health status (SIS). 
 
90 +/- 14 days: Site Telephone/Face to Face assessment on treatment 
Survival, living arrangements, current medications, medication compliance, serious adverse events, pregnancy (female 
participants of child bearing age), primary outcome (smRSq), current depression, mood (PHQ-9) 
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*A history of “previous depression requiring previous treatment” is recorded at baseline. 
This should refer to a clinical diagnosis made by a GP, psychologist or hospital clinician prior 
to enrolment in AFFINITY. The responses to these questions should be completed before, 
and are independent of, the subsequent completion of the PHQ-9 and the associated score.  
Baseline Laboratory Tests  
A pregnancy test is performed on pre-menopausal women to confirm eligibility for the trial. 
Pregnant participants are excluded.  
The following blood tests are performed at baseline and determine the eligibility of the 
participant for the trial. 
Participants are excluded if: 
• The ALT enzyme is 3 or more times above the upper limit of normal (> 120U/l) 
• The serum creatinine is > 180micromol/l  
• eGFR is < 30ml/min/1.73m2 
• Blood sodium concentration is low (< 125mmol/L)  
If the participant has an abnormal blood result at this baseline test please treat the cause, 
repeat the test and reassess before randomising.  
Laboratory tests completed within 15 days post stroke onset are accepted as baseline 
measures. 
Randomisation 
The trial medication is dispensed and administered.  
The contact sheet containing participant and GP contact details for central follow up is 
completed and filed in the participant AFFINITY folder. 
The site will then be required to send a letter to the participant’s GP, including details of the 
trial, management guidelines and the trial coordinating centre contact details. 
Participants will also be asked to keep a record of any hospitalisations over the duration of 
the trial. 
28 and 90 day follow-up (appendix 9) 
At 28 days +/- 7 days and the 90 day +/- 14 days after randomisation, the participant will 
undergo a telephone or face to face interview with the randomising site staff to assess 
survival, living arrangements, clarification of the final diagnosis and cause of stroke (28 day 
follow-up only), current medications, medication compliance and tolerance, SAEs, pregnancy 
(female participants of child bearing age), primary outcome (mRS [44,45]), recent 
depression, and current mood (PHQ-9 [46]).  
 Routine blood tests are not required  
 Repeat blood tests (ALT, creatinine, eGFR and Blood sodium) may be necessary if the 
investigator deems it to be clinically indicated (ie the participant is clinically unwell 
and is displaying possible side effects of the trial medication [fluoxetine]).  
If the blood sodium concentration during follow-up is low (<125mmol/L, the cause of the 
hyponatraemia may be syndrome of inappropriate anti-diuretic hormone (SIADH) secretion. 
If SIADH is confirmed, by low plasma sodium concentration and osmolality and an 
inappropriately high urinary osmolality, the recommended treatment is to treat or remove 
the cause (if it is known) and restrict fluid intake to 800ml-1 Litre per day until the blood 
sodium concentration returns to normal. 
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As Fluoxetine may cause SIADH, and the AFFINITY trial medication may contain fluoxetine (or 
placebo), it is recommended that the AFFINITY Trial medication should be withheld until the 
blood sodium concentration has returned to normal (e.g. within 3-7 days of fluid restriction).  
Once the sodium concentration has returned to normal, the AFFINITY trial medication can be 
re-started if the patient is willing to take it again.  
If the SIADH reoccurs, then the trial medication should be ceased permanently and this 
should be reported to the AFFINITY trial office.  
Completion of the 90 day follow up:  
When the 90 day follow up assessment has been completed and the participant contact 
details have been received by the trial coordinating centre, a letter of introduction will be 
sent to the participant from the trial coordinating centre, with the contact details of the trial 
coordinating centre.  
The letter will also advise participants to notify their GP or specialist of their participation in 
the AFFINITY trial, and to raise any concerns they may have regarding their participation in 
the trial with their GP, specialist and/or the trial coordinating centre. Participants will also be 
advised to report any temporary or permanent discontinuations of the trial medication to 
the trial coordinating centre and will be advised regarding forthcoming central follow up at 
the 180 and 365 day assessments including the procedure for the return of trial medication 
on completion of their allocated treatment.  
180 and 365 day follow-ups (appendix 9) 
At 180 days +/- 14 days and at 365 days +/- 14 days the participant will be followed up 
centrally by means of a telephone  interview with trial coordinating centre  staff to assess 
survival, living arrangements, current medications, medication compliance (180 day follow-
up only), SAEs, pregnancy (female participants of child bearing age), health care utilisation, 
primary outcome (mRS [44,45]), recent depression, current mood (PHQ-9 [46]), cognition 
(TICSm [47]), fatigue (vitality subscale of SF36 [50,51]), health-related quality of life (EQ-5D-
5L [49]) and overall health status (SIS [48]). The (SIS) can be delivered as a postal 
questionnaire.  
Table 1. Trial assessment schedule 
 Baseline 28 Day 90 Day 180 Day 365 Day 
Informed Consent X     
In/exclusion criteria X     
Demographics X X X X X 
Details of Stroke X     
Neurological Impairments (NIHSS [35]) X     
Functional Ability - smRSq [24, 25] X X X X X 
Classification of stroke - OCSP [30] X X    
Ischaemic Stroke sub-type TOAST [34]  X X    
Clinical Depression X X X X X 
PHQ-9 [26] X X X X X 
Medical co-morbidities X     
Hospital admissions   X X X X 
Medications in use X X X X X 
Compliance monitoring  X X X  
SUSARS/SAEs  X X X X 
Cognition - TICSm [27]    X X 
Overall Health Status - SIS [28]    X X 
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Health-related Quality of Life - EQ-5D-5L [29]    X X 
Fatigue (Vitality subscale of SF36 [30,31]    X X 
Health care utilization    X X 
Pregnancy Test (for premenopausal women) X     
ALT X     
Serum creatinine and eGFR X     
Blood Sodium X     
Contact sheet   X     
GP Letter  X     




The primary outcome is functional ability 180 days after randomisation, as measured by the 
modified Rankin Scale [mRS], using the simplified modified Rankin Scale questionnaire 
[smRSq 44, 45]. The mRS is a simple, reliable and valid 6-point measure of functional 
outcome commonly used as the primary outcome in most stroke treatment trials [44, 45]. 
The mRS is measured at baseline [pre and post stroke scores are recorded], 28, 90, 180 and 
365 day assessments. 
The mRS is derived from the smRSq assessment which consists of the following five 
questions: 
1. Could you live alone without any help from another person? This means being able to 
bathe, use the toilet, shop, prepare or get meals, and manage finances 
2. Are you able to do everything you were doing right before your stroke, even if slower 
and not as much?  
3. Are you able to walk (from one room to another) without help from another person? 
4. Are you completely back to the way you were right before your stroke?  
5. Are you bedridden or needing constant supervision? 
The mRS is scored as follows:  
0 no symptoms;  
1 no significant disability despite symptoms, able to carry out all usual duties and 
activities;  
2 slight disability, unable to carry out all previous activities but able to look after own 
affairs without assistance;  
3 moderate disability requiring some help, but able to walk without assistance;  
4 moderate-severe disability, unable to walk without assistance and unable to attend to 
own bodily needs without assistance;  
5 severe disability, bedridden, incontinent and requiring constant nursing care and 
attention;  
6  dead.  
Secondary Outcomes  
Secondary outcome measures, recorded at follow-up assessments 28, 90, 180 and 365 days 
after randomisation are: 
 Survival 
Survival is recorded at the 28, 90, 180 and 365 day assessments.  
If the participant has died, details of the event including the date and cause of death are  
recorded as an outcome event on the SAE form. 
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 Mood  
Mood is assessed at baseline, and at 28, 90, 180 and 365 days after randomisation, by 
completing the PHQ-9 [46], which scores each of the 9 Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition (DSM-IV) criteria [58] as ‘0’ (not at all) to ‘3’ (nearly 
every day), generating a total score from 0-27. Scores ≥ 15 indicate significant depressive 
symptoms requiring treatment. The PHQ-9 has been validated for use in stroke patients 
and can generate a DSM-IV equivalent diagnosis [58].    
 New diagnosis of depression requiring treatment; 
A new clinical diagnosis of depression refers to, treatment for depression and 
prescription of an antidepressant since the previous assessment, therefore   recorded at 
the 28, 90, 180 and 365 day assessments. This should refer to a clinical diagnosis made 
by a GP, psychologist, psychiatrist or hospital clinician since enrolment in the AFFINITY 
trial.  
The responses to the following questions (which form part of the assessment of a new 
clinical diagnosis of depression at all follow up visits) should be completed before, and 
are independent of, the subsequent completion of the PHQ-9 and the associated score. 
a. Has the patient been diagnosed with depression since the last assessment? 
b. Has the patient been treated for depression since the last assessment? (non-
pharmacological) 
c. Has the patient been prescribed an antidepressant drug for treatment of 
depression since the last assessment? 
Note: (b) Treatment non pharmacological can include psychotherapy, herbal remedies 
and other non-pharmacological therapies and electroconvulsive therapy. 
 Fatigue  
Fatigue is assessed at 180 and 365 day assessments by completing the vitality subscale 
of the full SF-36 [50,51]. 
 Cognitive function  
Cognition is assessed at 180 and 365 day assessments using the TICSm, which scores 13 
items (including orientation, recent and delayed memory, attention and comprehension) 
to a maximum possible score of 39 [47]. The TICSm has been validated in stroke patients 
and can be administered face-to-face or via telephone. 
 Communication, motor function and overall Health Status  
Communication, motor function, and overall health status is assessed at the 180 and 365 
day assessments by the SIS [48], which measures 8 health domains (strength, hand 
function, activities of daily living/instrumental activities of daily living (ADL/IADL), 
mobility, communication, emotion, memory and thinking, participation). It has been 
evaluated successfully for use by proxy respondents [59]. 
 Health-Related Quality of Life (HRQoL)  
Health related quality of life is assessed at the 180 and 365 day assessments by 
completing the EQ-5D-5L [49], a   standardised instrument that provides a simple 
descriptive profile and a single index value for health status.  
 Functional ability 
The simplified modified Rankin Score (smRSq [44,45] is assessed at the 365 day 
assessment to ascertain if any beneficial effects of fluoxetine on recovery persist after it 
is stopped 
Serious adverse events and secondary outcome events 
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Assessed and recorded at the 28, 90, 180 and 365 day assessments. 
 New Stroke, ischaemic or haemorrhagic [not the qualifying event leading to 
enrolment] 
 Acute coronary syndrome [MI confirmed by ECG and/or raised serum Troponin] 
 Upper gastrointestinal bleed requiring blood transfusion and/or endoscopy 
 Other major bleed (i.e. not upper GI or intracerebral) requiring blood transfusion or 
procedural intervention 
 Fall  
 New fracture [confirmed on X ray] 
 Epileptic seizure [focal or generalised] 
 Symptomatic hypoglycaemia [blood sugar < 3mmol/l] 
 Symptomatic hyperglycaemia [blood sugar > 22mmol/l] 
 New hyponatremia [Na < 125mmol/l] 
 Attempted suicide/self-harm 
 Death 
 Health care utilisation 
Assessed at the 180 and 365 day follow-ups by asking participants and using data linkage 
to provide information on hospital admissions, outpatient visits, days spent in care 
homes, health care visits and services utilised. 
Other Measures  
Trial Medication Adherence 
Adherence is measured: 
a) Subjectively, by response to the question ‘On average, since the last follow up how many 
times per week was the trial medication taken? ‘0’, ‘1-2’, 3-4’, ‘5-6’ or ‘7’ times per week 
(acknowledging that unintentional non-adherence is likely to be underestimated because 
some participants are unaware of their forgetfulness); and 
b) Objectively, by pill counts and collection of returned trial bottles (acknowledging that 
absence of tablets in the bottle does not necessarily mean adherence to taking the 
tablets). Information on participants who temporarily or permanently stop the trial 
medication, and dates of and reasons for stopping are recorded. Analysis of medication 
adherence will compare groups based on the reported non-adherence and number of 
residual tablets. 
Trial Medication Cessation  
Medication cessation is recorded as temporary or permanent, together with dates and 
reasons for stopping.  
Concurrent antidepressant medication 
Participants are asked if they have been started on any antidepressant medication since 
enrolment (if yes, which drug(s) and indication).   
7. SERIOUS ADVERSE EVENTS/REACTIONS  
AFFINITY is evaluating fluoxetine, a very widely used SSRI that has been licensed for the 
treatment of depression since 1988 and used in thousands of patients with stroke to treat 
depression and emotionalism. Even though there is the potential for interactions of fluoxetine 
with medications frequently prescribed for stroke patients, such as aspirin and warfarin, these 
rarely cause significant problems. The trial materials given to the participant, and/or their 
carer will contain details of the known adverse reactions to fluoxetine [60, 61].  
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A population-based cohort study of more than 60 000 patients aged 65 years or more who 
were diagnosed with depression and followed up found that 764,650 prescriptions for SSRI 
antidepressants were issued and that, compared with when these drugs were not being used, 
SSRIs were associated with significantly higher rates of:  
 all cause mortality (11.42% per year if taking fluoxteine vs 7.04% per year if not 
taking antidepressant; adjusted hazard ratio [HR]: 1.54, 95% [CI]: 1.48 to 1.59),  
 stroke/transient ischaemic attack (2.57% per year fluoxetine vs 2.23% per year no 
antidepressant; HR: 1.17, 1.10 to 1.26),  
 myocardial infarction (1.31% vs 1.0% per year; HR: 1.15, 1.04 to 1.27),  
 upper gastrointestinal bleeding (0.48% vs 0.42% per year; HR: 1.22, 1.07 to 1.40), 
 falls (5.6% vs 3.5% per year; HR: 1.66, 1.58 to 1.73),  
 fracture (2.76% vs 1.76% per year; HR: 1.58, 1.48 to 1.68),  
 epilepsy/seizures (0.31% vs 0.21% per year; HR: 1.83, 1.49 to 2.26),  
 attempted suicide/self-harm (0.53% vs 0.25% per year; 2.16, 1.71 to 2.71), and 
 hyponatraemia (0.49% vs 0.29% per year; HR: 1.52, 1.33 to 1.75) [61]. 
Rates of most outcomes were highest in the first 28 days after starting an antidepressant, 
and also in the first 28 days after stopping.  
The main concern with the above results is that they are based on observational studies and 
are therefore prone to residual confounding and indication bias [61]. Indication bias occurs 
when patients are prescribed drugs for a condition that is itself associated with the outcome 
of interest. This means that apparent associations with fluoxetine may be due to the 
condition for which it was prescribed (i.e. depression) rather than to the drug itself. 
Nevertheless, the above data are presented to indicate what could be causal adverse effects 
[61]. 
Irrespective of whether fluoxetine treatment is administered or not, about 20% of hospitalised 
patients with stroke would be expected to die in the first month after a stroke and another 
10% by the end of the first year as part of the natural history of stroke. Up to a third will 
develop a chest or urinary infection whilst in hospital up to 5% may develop venous 
thromboembolism, epileptic seizures or gastrointestinal bleeding.  
Definitions 
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant which 
does not necessarily have a causal relationship with an investigational medicinal product 
(IMP). 
An AE can therefore be any unfavourable or unintended sign (including an abnormal 
laboratory finding, for example), symptom or disease temporally associated with the use of a 
medicinal product, whether or not it is considered related to the medicinal product.  
An adverse reaction (AR) is any untoward or unintended response to an IMP which is related 
to any dose administered to that participant. 
An unexpected adverse drug reaction (UAR) is an adverse reaction, the nature or severity of 
which is not consistent with the applicable product information (e.g. investigator brochure 
for an unapproved investigational product or package insert/summary of product 
characteristic for an approved product).   
The product information is provided and can be used as a guide to determine whether the 
event is expected or unexpected. 
A serious adverse event (SAE), serious adverse reaction (SAR) or suspected unexpected 
serious adverse reaction (SUSAR) is any AE, AR or UAR that, at any dose: 
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 results in death; 
 is life threatening (i.e. the participant was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it were 
more severe); 
 requires hospitalisation or prolongation of existing hospitalisation; 
 results in persistent or significant disability or incapacity; 
 results in a congenital anomaly or birth defect; 
 results in a secondary outcome event for the AFFINITY Trial (New stroke, ischaemic or 
haemorrhagic [not the qualifying stroke leading to enrolment], Acute coronary 
syndrome [MI confirmed on ECG and/or raised serum Troponin], Upper 
gastrointestinal bleed requiring blood transfusion and/or endoscopy, Other major 
bleed (i.e. not upper GI or intracerebral) requiring blood transfusion or procedural 
intervention, New fracture [confirmed on X Ray], Epileptic seizure [focal or 
generalised], New hyponatraemia [Na<125mmol/l], Attempted suicide/self-harm). 
To ensure no confusion or misunderstanding of the difference between the terms "serious" 
and "severe", which are not synonymous, the following note of clarification is provided: 
The term "severe" is often used to describe the intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); the event itself, however, may be of 
relatively minor medical significance (such as severe headache).  This is not the same as 
"serious," which is based on patient/event outcome or action criteria usually associated with 
events that pose a threat to a participant's life or functioning as defined in the bullet points 
above.  Seriousness (not severity) serves as a guide for defining regulatory reporting 
obligations. 
A hospitalisation is to be considered an SAE only if it is an official admission. In addition, a 
hospitalisation planned before the start of the study for a pre-existing condition that has not 
worsened does not constitute an SAE. 
Recording and Reporting 
All SAEs, SARs and SUSARs are recorded from the time of consent until the end of follow-up. 
SAEs, SARs and SUSARs will also be assessed at the 28, 90, 180 and 365 day assessments. 
If the event is serious and/or related to the trial medication it must be reported to the trial 
coordinating centre immediately (within 24 hours) of the site investigator becoming aware of 
the event. This is done by completing the serious adverse event form [Hard Copy] and then 
entering the information on the web-based CRF. If for any reason the web –based system 
cannot be accessed, the site investigator will need to fax the completed hard copy to the trial 
coordinating centre.   
The site investigator is also responsible for reporting any SAEs, SARs and SUSARs that their 
participants may experience to the Lead Human Research Ethics Committee (HREC) 
responsible for their site immediately (within 24hrs) of becoming aware of the event and 
according to their local guidelines. 
SUSARs are reported according to regulatory requirements to the Therapeutic Goods 
Administration (TGA) in an expedited manner by the trial coordinating centre when a report is 
received from a site, the initial report is due within 7 calendar days of receipt of the event if 
the event is fatal or life threatening, with a follow up report within a further 8 days or within 
15 calendar days of receipt of the event for non-fatal, non-life threatening events.  
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The Data Monitoring Committee (DMC) will closely monitor the relative frequency of SAEs in 
the treatment and control groups and, in turn, will advise the steering committee of any 
concerns.  
The trial coordinating centre will collate all SAEs, SARs and SUSARs that occur in the trial and 
submit 6 monthly reports to the lead HRECs as applicable. Site investigators will also receive 
copies of these reports and are responsible for submitting them to their local research 
governance office as per local guidelines.  
Monitoring Side Effects and Interactions of fluoxetine 
Participants are assessed 28 days after baseline to monitor for drug safety and SAEs and are 
clinically managed as appropriate. Any reported unexpected serious adverse events are 
discussed with one of the trial clinicians and the participant’s GP. This information is used to 
guide a decision regarding their continuation on the trial medication. In addition, we will 
provide all participants and their GPs with a list of common serious adverse effects and drug 
interactions.  
GPs are able to contact a trial clinician if any medication concerns arise during the trial. 
Depression 
Pre-existing (prevalent) depression is common amongst stroke patients. 
Subsequent (incident) depression is also common after stroke, occurring in around a third of 
stroke survivors.  
Depression may be detected during the AFFINITY trial: 
1. At the baseline assessment, before randomisation by a score of 15 or greater on the 
PHQ-9 test.  
2. During one of the AFFINITY trial follow-up assessments by a score of 15 or greater on 
the PHQ-9 
3. During a visit to the participant’s  general practitioner (GP) or another clinician e.g. 
physician 
After randomisation in the AFFINITY trial, participants are advised to inform their GP and any 
treating clinician that they are participating in a clinical trial and taking either fluoxetine 
20mg or a placebo daily.  
After randomisation, the site will send a letter to the GP of each participant. If there is no 
regular GP, participants are encouraged to nominate one. The letter provides information 
about the duration of the trial, medications to avoid due to potential interactions with 
fluoxetine, and suggestions on the management of a major depressive episode during the 
trial follow up period.   
During the course of the trial, the AFFINITY trial coordinating centre will alert GPs if their 
patient displays moderate/severe depressive symptoms (PHQ-9 score ≥ 15) during any 
follow-up assessments. 
Some suggestions for managing depression in the AFFINITY trial are: 
A. Prevalent (existing) depression: patients who are depressed before/at the time of 
randomisation. 
1. If the patient is already taking an antidepressant medication and wishes to 
participate in the AFFINITY trial, the treating clinician should discuss with the patient 
and if possible the prescribing clinician whether or not it is possible and appropriate 
to discontinue the antidepressant (and perhaps start non-pharmacological treatment 
[e.g. clinical psychologist; see below] for the depression) before randomisation (to 
fluoxetine 20 mg, or placebo, daily) in the AFFINITY trial. 
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Most antidepressants can be titrated down to zero over 5-7 days, but the treating 
clinician should check with their local pharmacy regarding specific guidelines for 
individual antidepressants. When the patient has been titrated off the current 
antidepressant they should then have a further 2-3 days free of medication before 
starting the AFFINITY trial medication.  
2. If the patient is not being treated for depression but warrants it, and wants to 
participate in the AFFINITY trial, consider non-pharmacological treatment for the 
depression (i.e. referral to a clinical psychologist; see below) before randomisation in 
the AFFINITY trial. 
Clinical psychology can be accessed through the Medicare Better Access initiative and is 
available  to Australian residents and citizens. There is provision for up to 10 rebated 
sessions per year as part of a GP mental health treatment plan 
(http://www.health.gov.au/mentalhealth-betteraccess) . 
B. Incident (new) depression: patients who develop depression after randomisation 
0-6 months after randomisation 
If the patient develops depression after randomisation in the AFFINITY trial and during 
the first 6 months of follow-up, whilst taking the AFFINITY trial medication (fluoxetine 20 
mg, or placebo, daily) 
1. Consider non-pharmacological treatment for the depression if appropriate. such as 
advising an increase in social outlets, regular exercise or referral to a clinical 
psychologist.  
1a. Clinical psychology can be accessed through the Medicare Better Access initiative 
and is available  to Australian residents and citizens.  
1b. There is provision for up to 10 rebated sessions per year as part of a GP mental 
health treatment plan (http://www.health.gov.au/mentalhealth-betteraccess).  
2. If the treating clinician feels that antidepressant medication is necessary, consider 
the following:  
2a. Commence treatment with an antidepressant that is NOT an SSRI, in addition to 
the AFFINITY trial medication.  
   The patient should be informed about the possibility of an interaction between the 
prescribed antidepressant and the AFFINITY trial drug (if fluoxetine), and the nature 
of symptoms of serotonin toxicity (which include confusion, sweating, unsteadiness, 
shaking, and diarrhoea) and hyponatraemia (confusion, seizures). The patient 
should be monitored regularly for the above symptoms and, if hyponatraemia is 
suspected, undergo a blood test for plasma sodium concentration.  
  2b. Consider referral to (or consultation with) a specialist psychiatrist. 
6-12 months after randomisation 
If the patient develops depression 6-12 months after randomisation in the AFFINITY trial, 
after having ceased the AFFINITY trial medication, 
1. Consider non-pharmacological treatment for the depression if appropriate, such as 
advising an    increase in social outlets, regular exercise or referral to a clinical 
psychologist.  
1a. Clinical psychology can be accessed through the Medicare Better Access initiative 
and is available  to Australian residents and citizens.  
1b. There is provision for up to 10 rebated sessions per year as part of a GP mental 
health treatment plan (http://www.health.gov.au/mentalhealth-betteraccess).  
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2. If the treating clinician feels that antidepressant medication is necessary,  
Consider the following:  
2a. Commence treatment with an antidepressant that is NOT an SSRI 
2b. Consider referral to (or consultation with) a specialist psychiatrist. 
8. STATISTICAL METHODS 
Primary analysis 
The primary analysis will compare the mRS scores at the 180 day assessment for each 
treatment group by an ordinal logistic regression analysis, after adjusting for any baseline 
imbalance between the treatment groups in factors included in the minimisation algorithm 
[62, 63]. The analysis will retain participants in the treatment groups they were originally 
allocated to [64, 65]. 
Secondary analyses 
The main secondary analysis will compare, in each treatment group, at the 365 day 
assessment the mRS scores by means of an ordinal logistic regression analysis. Other 
secondary analyses will compare, in each treatment group, at 180 and 365 day assessments: 
the proportion of participants who are functionally independent according to the mRS score 
(0-2) by means of dichotomized outcome analysis, functional independence after controlling 
for survival (Cox proportional hazards model), mood (changes in PHQ-9 scores and 
proportion with PHQ-9 ≥ 15 [46], cognition (TICSm scores [47]), communication (SIS [48]), 
motor function (SIS [48]), overall health status (SIS [48], HRQoL (EQ-5D-5L [49], new 
diagnosis of depression requiring treatment with antidepressants, fatigue (vitality domain of 
the SF-36 [50, 51]), medication adherence and cessation, and SAEs/SARs.  
Economic analyses 
An economic evaluation is conducted from the perspective of the health sector and will 
assess the incremental cost per Quality Adjusted Life Year (QALY) of the intervention 
strategy over placebo. Inpatient and outpatient costs, including the study drug, are 
estimated from each assessment and are costed using standard published rates (e.g. from 
Medical Benefits Schedule for non-hospital medical services, Pharmaceutical Benefits 
Schedule for prescribed medications and Australian Refined-Diagnostic Related Groups cost 
weights for hospital services). The average costs incurred by participants in both treatment 
groups are calculated. 
Average HRQoL scores at the 365 day assessment for each participant are estimated and 
weighted by survival up to 365 days to determine a measure of QALY post-stroke. The 
average of this measure for participants in each treatment group is estimated to determine 
the incremental QALY gain/loss from the intervention and, when set alongside data on costs, 
will enable estimation of an incremental cost-effectiveness ratio. Sensitivity analysis will test 
uncertainty in key parameters (e.g. selection of cost weights and statistical variation in 
HRQoL scores). 
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Descriptive statistics 
For descriptive purposes baseline characteristics are presented by treatment groups. 
Discrete variables are summarised by frequencies and percentages, continuous variables by 
use of standard measures of central tendency and dispersion, mean and standard deviation 
(SD) or median and interquartile range (IQR). All variables are graphically analysed (i.e. box 
plots) to determine if variances between groups are equal and variables with unequal 
variances are transformed (e.g. log transformation) where necessary to ensure that any 
difference in coefficients are true differences. 
Sample size 
The AFFINITY trial will recruit 1600 participants over 4 years. Based on data from the Clots in 
Legs Or sTockings after Stroke (CLOTS) trial [66] and the Scandinavian Candesartan Acute 
Stroke Trial (SCAST) [67], we expect the proportion of participants not dependent on others 
(as indicated by a score of 0-2 on the mRS [44]) to be 50% in the AFFINITY control group 180 
days after randomisation (see Table 2).  
Table 2. Expected distributions of smRSq scores at the 180 day assessment 
smRSq score 0 1 2 3 4 5 6 
Control group 0.10 0.20 0.20 0.15 0.10 0.10 0.15 
Intervention group 0.13 0.24 0.21 0.14 0.09 0.08 0.12 
We expect that random assignment to fluoxetine will increase the odds of being functionally 
independent (mRS 0-2) at the 180 day assessment by 1.35 compared with control, which is a 
conservative estimate based on the effect of fluoxetine detected in the FLAME trial (OR = 
3.8, 95% CI 1.2 to 10.7) [9].  An odds ratio of 1.35 is equivalent to an increase in the 
proportion of participants being functionally independent at the 180 day assessment by 7.5 
percentage points (absolute increase; i.e. from 50% to 57.5%) providing a clinically 
significant relative improvement of 15% (relative increase).  
Assuming a common odds ratio of 1.35 in the ordinal logistic regression [68] and 90% power, 
the trial will require 1600 participants taking into account the fact that up to 10% of living 
participants may be lost to follow-up.  
With an effective sample size of at least 1440 participants completing follow-up, we will also 
be able to detect a mean difference in the PHQ-9 score of 1 with more than 90 percent 
power. This is based on a standard deviation of 5 as reported in other trials [69, 70].  
The target of 1600 are reviewed by the blinded steering committee taking account accruing 
data on the distribution of participants (across both treatment groups) between different 
mRS categories and losses to follow up since these may influence the power of the trial. The 
steering committee would have the option of increasing the target for randomisation to 
maintain the trial power. 
9. ETHICS 
Declaration of Helsinki, National Statement, International Conference on Harmonisation 
Good Clinical Practice (ICH-GCP) Guidelines  
The trial is performed in agreement with the Declaration of Helsinki and in accordance with 
relevant national and international regulatory and ethical frameworks. 
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Ethics review and approval 
It is the responsibility of the investigator at each participating site to obtain written approval 
from their relevant ethics committee and regulatory bodies before starting the trial. This 
documentation must be filed in the investigator site file (ISF) provided by the trial 
coordinating centre.  
Informed consent 
The informed consent procedures for this trial are listed below and should be followed 
according to local HREC guidelines which may differ between States and Territories in 
Australia and New Zealand.  
The site investigator is responsible for ensuring informed consent is obtained from the 
participant before any protocol specific procedures are carried out.   
Participants will receive oral and written information about the trial. The current ethics 
approved version of the participant information and consent form is provided for review to 
all potential participants. The oral explanation to the participant is performed by the site 
investigator or designated person, and covers all the elements specified in the participant 
information sheet and consent (PISC) form.  
The participant is given every opportunity to clarify any points they do not understand and, 
if necessary, ask for more information. Sufficient time is given to the participant to consider 
the information provided and discuss the trial with their relatives if they wish.   
The decision to participate in clinical research is voluntary and should be based on a clear 
understanding of what is involved. 
Participants are asked to consent to being randomly allocated to fluoxetine or placebo 
capsules that are taken once daily for 180 days, in conjunction with four follow-up 
assessments over a total period of 365 days. The follow-up of participants has not been 
extended beyond the 365 day assessment at present. However it is possible that as the trial 
progresses and the results of the preliminary analyses become available, the steering 
committee may decide that it may be of scientific value to follow-up participants for five 
years. This would provide information on the possible beneficial long term treatment effects 
of fluoxetine. If this occurs we will notify the participant and ask for their consent to this 
extended follow-up.  
The site investigator or delegated member of the trial team and the participant will sign and 
date the informed consent form to confirm that consent has been obtained.  The original 
copy of the informed consent form is filed in the ISF for inspection by the trial monitor, a 
copy is given to the participant and a copy is filed in the participants medical records.  
Withdrawal of Consent  
Participants can withdraw from the trial at any time without loss of benefits to which they 
would otherwise be entitled. This process is clearly documented in the PISC form. All 
participant withdrawals need to be documented in the participant’s medical records, on the 
withdrawal of consent form and entered onto the online web based system. 
Waiver of Consent/Next of Kin/Person responsible/Legal surrogate 
In Australia and New Zealand, the rules and system differ in every state regarding the 
appointment and powers of guardians, and consent to medical treatment by persons other 
than the participant. In all the states, the intention behind the legislation is the protection of 
the rights, welfare, freedom of decision and action, and interests of the person involved.  
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The laws and definitions for the terms ‘waiver of consent’, ‘next of kin’, ‘person responsible’ 
and ‘legal surrogate’ in the context of a clinical trial may also differ between States and 
Territories in Australia and New Zealand, therefore the specific wording should be checked 
in each region and specific local ethics approval obtained. 
Data protection and retention 
All trial documentation is stored in a secure environment for a minimum of 15 years with all 
personal identifiers removed following trial closure, according to regulatory and ethical 
requirements. 
10. GOVERNANCE  
Insurance and Indemnity 
Sites participating in the trial will seek insurance or indemnity to cover their liability from 
their local institution.   
11. QUALITY ASSURANCE 
Source documents 
The purpose of source documents is to document the existence of the participant and 
substantiate the integrity of the trial data collected. The site investigator must maintain 
source documents for each participant in the trial. Source documents include original 
documents related to the trial, to medical treatment and the history of the participant. They 
can be hospital or clinic medical records, laboratory data and results of any other test or 
assessment.  
Original PISC forms and the 28 and 90 day follow up CRF will be kept at the individual 
hospital site. Original consent forms must be filed in the ISF. 180 day and 365 day original 
CRF’s will be kept at the trial coordinating centre. 
Site personnel will be trained at site initiation on completion, collection and retention of 
adequate and accurate source documents. Source documents verify the authenticity of data 
recorded on the electronic CRFs and that the trial was carried out in accordance with the 
protocol. In the event of an on-site monitoring visit or a regulatory body audit these 
documents must be produced by the site for review. 
At completion of the trial, the trial coordinating centre will confirm with the site that there 
are plans in place for the long-term storage of all the relevant data and source 
documentation (for a minimum of 15 years). 
Selection and monitoring of participating centres 
Potential centres are assessed by the trial coordinating centre to confirm they have 
adequate facilities and medical resources to conduct the trial. Prior to commencement of 
the trial at selected sites all designated research staff including the site investigator, co-site 
investigator(s) and Research Nurse(s) are trained in the methods of the trial at site initiation, 
which is held by teleconference. 
Pharmacy specific initiations will be conducted via teleconference with pharmacy staff 
participating in the trial. This will include training on the protocol and all procedures and 
requirements for management of the trial medication; supply, storage, dispensing, returns, 
and all associated record keeping. 
Prior to site initiation all the necessary ethical and regulatory approvals will be in place and 
copies of the associated documents will be held by the trial coordinating centre and filed on 
site in the investigator and pharmacy site files.  The site investigator, co-site investigator(s), 
AFFINITY Protocol Version 5, 18
th
 November 2015  Page 38 of 112 
Research Nurse(s) and pharmacist (s) will sign and provide up-to-date Curriculum Vitaes 
(CVs) (maximum of two pages) to the trial coordinating centre along with a copy of the 
signed delegation of duties log. 
Participating sites will be monitored using a risk based model, consisting of centralised 
monitoring of the eCRF by the trial coordinating centre and statistical data monitoring as 
follows: 
Centralised Monitoring of eCRF 
 Site acknowledgement that written informed consent (waiver of consent,next of 
kin, person responsible or legal surrogate if applicable)  has been obtained from 
the participant according to the protocol is required to be  documented for each 
participant on the source baseline assessment form which is then submitted on 
the eCRF. 
 Participant information submitted on the eCRF will be screened for missing and 
inconsistent data. Queries will be raised and resolved directly with the site via the 
electronic interactive query report system, email and telephone.  
 Participant follow up will be monitored continually for submission within the 
specified time parameters and contact made directly with the site if not received.  
 Monitoring / Adjudication to a standard of 100% will be centrally managed for all 
reported: Serious Adverse Events, Protocol Violations, Pregnancy Notifications and 
Withdrawal of Consent 
Statistical Data Monitoring 
 The number of events by site as follows: serious adverse events, protocol 
violations, lost to follow up, withdrawn participants, will be monitored to identify 
unusally high or low numbers of reported events at individual sites.  
 Unusually high numbers of late form submissions at individual sites. 
 Unusually high numbers of missing data at individual sites. 
Note: Unusual findings may flag the need for specific on site monitoring visits which 
will be carried out by the trial coordinating centre. 
Protocol deviations 
A protocol deviation is an unanticipated or unintentional departure from the expected 
conduct of an approved trial that is not consistent with the current protocol or consent 
document. A protocol deviation may be an omission, addition or change in any procedure 
described in the protocol  
Except for changes to eliminate an immediate hazard to participants, the approved protocol 
is followed as specified. Protocol deviations are documented on a protocol violation form 
and entered onto the online data eCRF system, on submission of the form an email is sent to 
the trial coordinating centre. The hard copy is stored in the participant’s site folder. 
Protocol amendments 
Any significant change in the trial protocol will require an amendment. Once the steering 
committee has approved a protocol amendment, it is the responsibility of the site 
investigator to submit this to each HREC for written approval. The approval letter, signed by 
the HREC chair, must refer specifically to the site investigator, the protocol number, the 
protocol title, the protocol amendment number, and the date of the protocol amendment. 
The protocol amendment may be implemented only after it has been approved by the HREC. 
A protocol change intended to eliminate an apparent immediate hazard to participants may 
be implemented immediately, but the change must then be documented in an amendment, 
reported to the HREC and the trial coordinating centre within 5 working days.  
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If the revision is an administrative change (such as the addition or removal of committee 
members), a letter explaining the change(s) along with a copy of the amended pages(s) of 
the protocol must be submitted to the HREC for their information.  No formal approval from 
the HREC is required prior to implementation of administrative changes. 
Responsibilities of the investigator at each participating site. 
 
It is the responsibility of the investigator at each participating site to:  
 obtain written approval from the relevant ethics committee and regulatory bodies 
before starting the trial; 
 ensure informed consent is obtained from the participant (or waiver of consent, next 
of kin, person responsible or legal surrogate) before any protocol specific procedures 
are carried out; 
 ensure participants are managed in accordance with ICH-GCP guidelines;  
 report any protocol violations and SAEs to their local hospital ethics committee and 
to the trial coordinating centre immediately and;   
 report any protocol amendments, safety and DMC reports to their local hospital 
Ethics/regulatory bodies. 
Auditing by regulatory bodies 
The trial may be audited by inspectors appointed by government regulatory authorities. 
CRFs, medical records, source documents and other trial files must be accessible at all trial 
sites at times of auditing during the course of the trial and after the completion of the trial.  
Termination of the trial 
Termination by the Steering Committee 
The trial management or steering committee may terminate the entire trial or terminate the 
trial at a particular centre at any time for any of the following reasons: 
 Failure to enrol participants 
 Protocol violations 
 Inaccurate or incomplete data 
 Unsafe or unethical practices 
 Questionable safety of the treatment 
 Suspected lack of efficacy of the treatment 
 Lack of treatment safety 
 Administrative decision 
Trial withdrawal by a site investigator  
If a site investigator withdraws from the trial prematurely, they are asked to: 
 Provide their local ethics committee, regulatory bodies and the trial coordinating 
centre with a written statement describing why they have withdrawn from the trial. 
(File a copy of this letter and acknowledgement received from the HREC in the ISF 
and send a copy to the trial coordinating centre via fax, email or mail). 
 Seek an alternative site investigator at the trial site to continue the management and 
follow-up of participants already randomised. 
If this is not possible, and the site must close the site investigator is asked to: 
 Inform the steering committee, the trial coordinating centre and their local ethics 
committee and regulatory bodies of the decisions and reasons, and plans for ongoing 
management and follow-up of the participants.  
 Inform the trial participants of the decision and plans for their management and 
follow-up.  
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Trial participants will be followed-up centrally by the trial coordinating centre if 
necessary. 
12. FUNDING 
The trial is funded by the National Health and Medical Research Council (NHMRC) project 
grant 1059094 for five years (2014-2018). 
The start-up phase of the trial was funded during 2013 by NHMRC program grant 1013612, 
University of Sydney bridging support grant 2012-00055, and NHMRC Program grant 
5711281.  
13. TRIAL ORGANISATION  
The AFFINITY trial is coordinated jointly by an established clinical trial team of independent 
investigators at Sir Charles Gairdner Hospital/University of Western Australia and the George 
Institute for Global Health in Sydney which has completed the NHMRC-funded VITAmins TO 
Prevent Stroke (VITATOPS) trial, led by Professor Graeme Hankey; and the Psychosocial 
Outcomes In StrokE (POISE) study, led by Associate Professor Maree Hackett. Both groups 
have well-developed systems and procedures for all aspects of the running of large-scale 
multi-centre clinical trials. Trial management is undertaken at Sir Charles Gairdner Hospital 
by a team led by Professor Graeme Hankey.  
Executive Steering Committee 
Associate Professor Maree Hackett, The George Institute for Global Health & The University 
of Sydney (co-chair) 
Professor Graeme J. Hankey, The University of Western Australia & Sir Charles Gairdner  
Hospital (co-chair) 
Professor Osvaldo Almeida, The University of Western Australia 
Professor Craig S. Anderson, The George Institute for Global Health 
Associate Professor Christopher Etherton-Beer, The University of Western Australia 
Mr Laurent Billot, The George Institute for Global Health 
Professor Martin S. Dennis, The University of Edinburgh 
Professor Leon Flicker, Royal Perth Hospital 
Associate Professor Andrew Ford, The University of Western Australia 
Associate Professor Stephen Jan, The George Institute for Global Health 
Professor Erik Lundström,  Karolinska Institutet, Stockholm. 
Professor Gillian Mead, The University of Edinburgh 
Acknowledgement is made to the late Professor Veronica Murray, Danderyd Hospital 
Stockholm for her contributions to the trial as a founding steering committee member.   
The steering committee carries the responsibility for the trial.  Tasks include: 
 Approval of the trial protocol and any amendments. 
 Prevention, recognition and resolution of problems that may interfere with the conduct 
of the trial. 
 Classification of outcome events on which no consensus is reached by the Auditing 
Committee. 
 Deciding whether or not the trial should continue, based on the recommendations of the 
DMC. 
 Writing manuscripts. 
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Principal Investigator Steering Committee 
All principal investigators at each site 
 
Data monitoring committee 
Data Monitoring Committee: 
Professor Robert Hebert, Neuroscience Research Australia 
Professor Gregory Carter, University of Newcastle & Calvary Mater Newcastle Hospital 
Professor Geoffrey Donnan, The Florey Institute of Neurosciences & Mental Health 
Unblinded Statisticians: 
Associate Professor Qilong Yi, Canadian Blood Services and University of Toronto 
Dr Qiang Li, The George Institute for Global Health, Sydney 
An independent DMC is established to oversee the safety of participants in the trial.  During 
the period of recruitment, interim analyses of baseline and follow up data is supplied, in 
strict confidence, to the chairperson of the DMC, along with any other analyses that the 
committee may request. In the light of these analyses, the DMC will advise the chairperson 
of the steering committee if, in their view, the randomised comparisons have provided both 
(i) 'proof beyond reasonable doubt' that for all, or some, the treatment is clearly indicated or 
clearly contra-indicated and (ii) evidence that might reasonably be expected to materially 
influence future patient management. Appropriate criteria of proof beyond reasonable 
doubt cannot be specified precisely, but the DMC will work on the principle that a difference 
of at least 3 standard errors in an interim analysis of a major outcome event (e.g. death from 
all causes or independent survival at the 180 day assessment) may be needed to justify 
halting, or modifying, a trial before the planned completed recruitment. This criterion has 
the practical advantage that the exact number of interim analyses would be of little 
importance, and so no fixed schedule is proposed. Following a report from the DMC, the 
steering committee will decide whether to modify entry to the trial (or seek extra data). 
Unless this happens however, the steering committee, the collaborators and central 
administrative staff will remain ignorant of the interim results. 
Tasks include: 
 Analyses of un-blinded interim data. 
 Un-blinded analysis of SAEs. 
 Formulation of recommendations to the steering committee on the continuation of the 
trial. 
 Offering unsolicited recommendations to the steering committee, for example after 
publication of results of a similar trial. 
14. AFFINITY SUBSTUDIES 
After stroke, the brain undergoes spontaneous repair and remodelling. However, 
spontaneous recovery is variable and often incomplete. A better understanding of the 
mechanisms underlying recovery after stroke promises to advance restorative therapeutics.  
Whilst the main AFFINITY trial will determine the overall efficacy of fluoxetine on functional 
recovery at 6 months after stroke (if it works), it does not address the mechanism of action 
of fluoxetine (how it works) and optimal patient selection (in whom it works).  
A recent systematic review of antidepressants in animal models of ischaemic stroke reported 
that SSRIs reduced infarct volume by 27.3% (95% CI: 20.7%-33.8%), increased neurogenesis 
by 2.2 SD (1.3–3.0), and improved neurobehavioral outcome by 51.8% (95% CI: 38.6%–
64.9%)[71]. Fluoxetine may also have neuroprotective and other neurotrophic effects 
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[13,14,18,19] However, it remains uncertain whether the observed effect of fluoxetine in 
small trials, such as the FLAME trial [9], if real, may be mediated by augmented 
neuroprotection, neurogenesis, and neuroplasticity of brain networks, or mood. 
The AFFINITY trial substudies aim to assess imaging and blood biomarkers of functional 
recovery after stroke and response to fluoxetine therapy. 
AFFINITY Imaging Biomarker study 
A recent meta-analysis of 24 functional magnetic resonance imaging (fMRI) studies of upper 
limb movement-related brain activity after stroke (n=255 patients) reported that activity in 
ipsilesional primary motor and medial-premotor cortices after stroke indicated good motor 
recovery, whereas cerebellar vermis activity signalled poor recovery as compared to healthy 
controls [72]. Further, a recent review indicated that enhanced recovery can be linked to 
increased interhemispheric connectivity and increased grey matter volume (cortical 
thickness) in sensorimotor regions [73-76]. 
While studies of imaging for prediction of functional recovery after stroke are increasing 
[77,78] few have analysed the effects of an intervention [73] particularly pharmacological 
interventions such as fluoxetine. A small clinical trial in 8 patients with stroke reported that 
fluoxetine was associated with hyperactivation in the ipsilesional primary motor cortex 
during an active motor task and significantly improved motor skills on the affected side 
compared with placebo [79,80].  
We hypothesize that response to treatment with fluoxetine (vs placebo) will be associated 
with between group differences in fMRI-based measures of task-related brain activation 
(specifically ipsilesional primary motor and medial-premotor cortices), enhanced functional 
connectivity (specifically interhemispheric connectivity) and increased brain volume (cortical 
thickness), in association with improved motor recovery and functional outcome at 6 
months after stroke. 
The primary aim of the AFFINITY MR imaging biomarker substudy, led by Professors Andrew 
Ford, Michael Bynevelt and Leanne Carey, is to determine if random allocation to fluoxetine 
is associated with  
• increased magnitude of activation in the ipsilesional primary motor and medial-
premotor cortices, as measured by task-related functional MRI (alternating finger-
tapping and rest paradigm) using the blood-oxygen-level dependent (BOLD) 
contrast fMRI technique , at 6 months after randomization, compared with 
placebo.  
Secondary aims are to determine, at 6 months post-randomisation, if allocation to fluoxetine 
vs placebo is associated with MRI imaging evidence of: 
• increased interhemispheric connectivity of sensorimotor cortices [resting state 
(RS) fMRI]  
• reduced disruption of functional connectivity of depression-related brain 
networks, including the thalamus (? mood mediation effect of fluoxetine) [RS-
fMRI] [81] 
• greater volume and thickness of grey matter (cortical thickness) in the ipsilesional 
primary motor cortex, amygdala, and hippocampus (? neurogenesis) [high 
resolution structural 3-D T1-weighted MRI] 
• greater white matter microstructural integrity and reduced loss of connectivity of 
white matter tracts [diffusion-weighted MRI (dMRI)] [82]  
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• reduced volume of the qualifying stroke lesion [T2 fluid attenuation inversion 
recovery (FLAIR); automated lesion tracing/quantification] [83];  
Changes in the above measures, between baseline and 6 months, in each treatment group 
will also be compared.   
Participants recruited to the AFFINITY trial at the SCGH, RMH, John Hunter and Austin 
hospitals will be invited to undergo the standardised brief MRI protocol (T1WI [cortical 
thickness], brief dMRI [fractional anisotropy analysis of integrity of white matter tracts], and 
RS-fMRI [resting state functional connectivity]) immediately after randomization (before the 
first dose of study drug) and a more detailed MRI protocol (additional task-related fMRI and 
more detailed dMRI of connectivity) at 6 months after randomization and therapy.  
A total of 80 participants (40 per group) will be required to reliably identify or exclude, with 
95% power and a two-tailed alpha of 0.05, a difference in magnitude of signal change in 
motor cortex activation associated with improved motor outcome, relative to usual care, 
based on effect size in our recent therapy intervention study [84]. In addition, analysis of 
data specific to modulation of cerebral activation with fluoxetine (Cohen’s D of 1.50, power 
of 95%, p of 0.05), indicates a minimum sample size of 26. We will recruit 100 participants in 
total for the AFFINITY fMRI study to allow for a dropout of up to 20% at 6 months.    
AFFINITY Blood Biomarker study  
Recovery after stroke is likely to be influenced by numerous biomarkers, but single 
biomarkers could also have important effects. Our preliminary analysis of molecular 
pathways associated with depression following mass spectrometry proteomic analysis in the 
START_PrePARE cohort study suggests the involvement of inflammatory, complement and 
coagulation systems. Further our meta-analysis of biomarkers of stroke-associated 
depressive illness revealed moderate effects for high cortisol levels and lower serum brain-
derived neurotrophic factor (BDNF) levels [85].   
Other small studies suggest that polymorphisms in three genes related to neural repair may 
contribute to variability in functional outcome after stroke; the ApoE ε4 polymorphism, the 
val66 met BDNF polymorphism, and the R0 mitochondrial DNA haplotype [86-88].  
The AFFINITY blood biomarker substudy aims to explore the hypothesis that candidate blood 
biomarkers, identified through our meta-analyses [89] and PREPARE study [90], and genetic 
polymorphisms of the ApoE ε4 and val66 met BDNF genes, the R0 mitochondrial DNA 
haplotype, and other candidate markers of the neuroinflammatory, complement and 
coagulation systems (e.g. Gadd45b, compound 21, sigma 1 receptor, neurotrophin-3 [NT-3]), 
are associated independently and significantly with functional outcome after stroke and 
modulate the effect of fluoxetine on functional recovery. We will derive gene lists associated 
with good recovery for pathway and gene ontology analyses, and to assess pathways and 
mechanisms of action associated with treatment. 
All participants enrolled in the AFFINITY trial will be invited to consent to provide 15ml of 
whole blood. 5ml will be placed in an EDTA anticoagulated tube and frozen (-80OC) for later 
DNA extraction, and 10ml will be placed in a plain serum separator tube and frozen (-80OC) 
for later separation into 2 separate aliquots (for multiple analyses) [91]. The blood will be 
stored at -80OC at each investigator site. When 50 samples have been collected, they will be 
sent as a batch on dry ice to the central laboratory at PathWest, QEII medical centre, Perth 
for final storage and analysis at the completion of the study (Adj Prof John Beilby, biochemist 
and Dr. Mark Davis, molecular geneticist). Microarray analyses will be conducted for gene-
signature analysis and investigation of mechanisms associated with functional outcome [91]. 
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15. FOCUS TRIAL (UNITED KINGDOM) EFFECTS TRIAL (SWEDEN) 
The AFFINITY trial steering committee are collaborating with colleagues in the United 
Kingdom and Sweden who are concurrently running similar trials. (Fluoxetine or Control 
under Supervision, FOCUS) at the Department of Geriatric Medicine, Edinburgh and the 
Neurosciences Trial Unit in Edinburgh, United Kingdom and (Efficacy of fluoxetine-a 
randomised controlled trial in stroke, EFFECTS) at Karolinska Institutet, Stockholm. Both 
trials have similar eligibility criteria, treatments, outcome measures and follow-up schedule.  
AFFINITY, FOCUS and EFFECTS steering committees plan to conduct a prospective meta-
analysis which will enable us to identify smaller, but clinically important effect sizes, which 
neither trial could identify individually, and also allow us to identify clinically worthwhile 
effects in pre-specified subgroups. The committees have registered the review title with the 
Cochrane Stroke Group. The advantages of carrying out closely related but independent 
trials, rather than a single international trial are: 
 Trial methods can match resources, infrastructure and regulations available in that 
country. 
 Governmental funding agencies will only be asked to fund research activity in their 
country. 
 Avoids the complexities of moving drug and placebo, and of dealing with indemnity, 
across international boundaries. 
 That each trial will test the effect of fluoxetine in their particular environment e.g. with 
the intensity of therapy available in that country, with the background use of SSRIs etc 
to ensure that the result applies to patients in that country. 
 That the health economic analyses are tailored to that country so that the implication 
for their health and social services can be deduced. 
 The AFFINITY trial is able to explore secondary outcomes which will assist in elucidating 
possible mechanisms for any effects found. 
 There is greater local ownership of the project and therefore hopefully improved 
recruitment and retention. 
Concordant trial results that are statistically significantly positive would provide really 
reliable data that would be applicable to potentially millions of future patients a year. 
16. TRIAL TIMETABLE 
Start-up phase 
A start-up phase, which aimed to randomise 200 patients in the first year to establish 
whether the protocol was feasible, was planned. This was to enable us to establish: a core 
trial management team, an IT system to manage web based randomisation, drug allocation, 
stock control, follow up, data collection and verification, and important aspects of feasibility 
including recruitment, medication adherence, questionnaire response and follow-up rates 
[all of which have been achieved].  
Specifically, the start-up phase was to  provide realistic estimates of: 
1. the range of recruitment rates per hospital and thus the likely number of sites and 
duration of the main phase. It would also help identify barriers to recruitment which may 
allow us to increase recruitment rates. 
2. the adherence rate, and reasons for non-adherence, which would influence our 
predicted effect size and power calculations. 
3. the follow-up rate. 
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Sites will be receiving a $1000 payment per participant, payable to the site when all of the 
following are complete: Randomisation, 28 and 90 day follow-up assessment and submission 
to the trial coordinating centre by fax or email the participants verified contact details 
[participant contact sheet] for central follow-up at 6 and 12 months. Invoices will be raised 
on a quarterly basis, forms are considered complete when they have been submitted and 
any data queries raised have been answered satisfactorily. 
Table 3. TIMELINES AND MILESTONES 
Date Milestone 
Feb-Jun 2011 Protocol and case report form design 
May 2011 Source drug supply and matching placebo & packaging 
Nov 2011 Apply to ethics committees  
Nov 2011 Database design commences 
Aug 2012 Start-up recruiting sites 
Jan 2013  First participant in trial 
Jul 2013 Six month assessment of first participant in trial 
Jan 2014 Twelve month assessment of first participant in trial 
Dec 2017 Completion of recruitment of 1600 participants 
Dec 2018 Completion of last twelve month assessment 
Apr 2019 Finalisation of database and data lock 
May 2019 Presentation and publication of main results 
Main phase  
The main trial will recruit a total of 1600 patients in order to have sufficient statistical power 
to detect differences in a primary outcome of mRS score for the entire group, and to detect 
differences in specific outcomes in pre-specified strata based on neurological deficits at 
baseline.  
As it may not be feasible to enrol sufficient participants to reliably detect moderate effect 
sizes in these strata on our primary outcome (mRS) we will introduce two strategies: 
1. Collect outcome measures which are likely to be more sensitive than our primary 
outcome to the possible benefits of fluoxetine in specific strata. 
2. To work collaboratively with a parallel trial (FOCUS) based in the UK and (EFFECTS) 
based in Sweden, which has a similar design to increase the overall sample size and 
the numbers of participants in each of the important strata. We will perform pre-
specified meta-analyses to maximise our chances of detecting benefits in specific 
strata. 
17. PUBLICATION OF TRIAL RESULTS 
Ownership of the data arising from this trial resides with the trial team.  The primary trial 
publication will be drafted by a writing committee whose membership has been approved by 
the steering committee.  The manuscript must be approved by the steering committee 
before submission for publication. Planned publications will be submitted with an authorship 
list that states the names of the members of the Executive Steering Committee, Principal 
Investigator Steering Committee, Un-blinded Statisticians, and Trial Co-ordinating Centre. 
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APPENDIX 1: NATIONAL INSTITUTE OF HEALTH STROKE SCORE 
National Institute of Health Stroke Score (NIHSS): Score 
1a. Level of Consciousness 
0: Alert 
1: Not alert, but arousable with minimal stimulation 
2: Not alert, requires repeated stimulation to attend 
3: Coma (makes at best only reflex movements to pain) 
 
1b. LOC questions (ask patient the month & her/his age) 
0: Answers both correctly 
1: Answers one correctly (score 1 if  patients speech affected other by than aphasia) 
2: Both incorrect 
 
1c. LOC commands (ask patient to open/close eyes & form/release a fist) 
0: Obeys both correctly 
1: Obeys one correctly 
2: Both incorrect 
 
2. Best gaze (only horizontal eye movements) 
0: Normal 
1: Partial gaze palsy (can be overcome) or single nerve palsy (III, IV or VI) 
2: Total gaze paresis or Forced deviation (cannot be overcome with rapid head turn) 
 
3. Visual field testing 
0: No visual field loss 
1: Partial hemianopia (including quadrantanopia or visual extinction (see 11)) 
2: Complete hemianopia 
3: Bilateral hemianopia (including bilateral blindness from any cause) 
 
4. Facial Paresis (ask patient to show teeth/raise eyebrows & close eyes tightly) 
0: Normal symmetrical movement 
1: Minor paralysis (flattened nasolabial fold, asymmetry on smiling) 
2: Partial paralysis (total or near total paralysis of lower face) 
3: Complete paralysis of one or both sides (absence of facial movement in the upper & lower face) 
 
5. Motor function – Arm 




) position for 5 seconds without drift) 
1: Drift 
2: Some effort against gravity 
3: No effort against gravity 
4: No movement 








6. Motor function – Leg 
0: Normal (holds leg in 30
0 
 position for 5 seconds without drift) 
1: Drift 
2: Some effort against gravity 
3: No effort against gravity 
4: No movement 








7. Limb ataxia (finger/nose, heel/shin testing) 
0: No ataxia 
1: Present in one limb 
2: Present in two limbs 
U: Untestable (joint fused or limb amputated) (do not add score) 
 
8. Sensory (use pinprick to test arms, legs, trunk & face – compare the sides) 
0: Normal 
1: Mild to moderate decrease in sensation 
2: Severe or total sensory loss (including those in coma) 
 
9 Best Language (ask patient to describe picture, name items, read sentences) 
0: No aphasia 
1: Mild to moderate aphasia 
2: Severe aphasia 
3: Mute (including those in coma) 
 
10. Dysarthria (ask patient to read several words) 
0: Normal articulation 
1: Mild to moderate slurring of words 
2: Near unintelligible or unable to speak 
U: Untestable (intubated or other physical barrier to speech) (do not add score) 
 
11. Extinction & inattention (formerly neglect) (use visual or sensory double stimulation) 
0: Normal 
1: Inattention or extinction to bilateral stimulation in one of the sensory modalities 
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APPENDIX 2: NATIONAL INSTITUTE OF HEALTH STROKE SCORE 
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APPENDIX 3: OXFORDSHIRE COMMUNITY STROKE PROJECT CLASSIFICIATION OF CLINICAL 
STROKE SYNDROMES 
 
The Oxfordshire Community Stroke Project classification of clinical stroke 
syndromes  
 
Total anterior circulation syndromes 
 hemiparesis and homonymous hemianopia contralateral to the brain lesion, and  
 either dysphasia or visuospatial perceptual disturbance  
 ± hemisensory deficit contralateral to the brain lesion.  
Partial anterior circulation syndrome 
 one or more of unilateral motor or sensory deficit, aphasia or visuospatial neglect 
(combined or not with homonymous hemianopia)
 
 
 motor or sensory deficit may be less extensive than in lacunar syndromes (for 
example, hand alone).  
Lacunar syndrome 
Any one of the following four syndromes involving at least two of the three areas 
(face, arm, leg), and involving the limb in its entirety: 
 pure motor hemiparesis, or  
 pure hemisensory deficit of one side of the body, or  
 hemisensory-motor deficit, or  
 ataxic hemiparesis (dysarthria clumsy hand syndrome or ipsilateral ataxia with 
crural hemiparesis)                                                                             
 no visual field defect  
 no new disturbance of higher cortical or brainstem function  
Posterior circulation syndromes 
Any one of: 
 cranial nerve impairment  
 unilateral or bilateral motor or sensory deficit  
 disorder of conjugate eye movement  
 cerebellar dysfunction  
 homonymous hemianopia  
 cortical blindness.  
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APPENDIX 4: PATIENT HEALTH QUESTIONNAIRE – 9 ITEM 
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APPENDIX 5: TELEPHONE INTERVIEW FOR COGNITIVE STATUS – M 
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APPENDIX 6: SF-36 (VITALITY SUBSCALE) 
 
 Q9a    The following questions are about how you feel and how things have been   
            with you in the past four weeks. As I read each statement, please give me the                                                      
            one answer that comes closest to the way you have been feeling. How much of                 
            the time during the past four weeks did you feel full of life?  
 
            1.......................................All of the time 
            2.......................................Most of the time 
            3.......................................A good bit of the time 
            4.......................................Some of the time 
            5.......................................A little of the time 
            6.......................................None of the time    
 
Q9e     And how much of the time during the past four weeks did you have a lot of 
            energy? 
 
            1.......................................All of the time 
            2.......................................Most of the time 
            3.......................................A good bit of the time 
            4.......................................Some of the time 
            5.......................................A little of the time 
one of the time
 
Q9g     How much of the time during the past four weeks did you feel worn out? 
 
            1.......................................All of the time 
            2.......................................Most of the time 
            3.......................................A good bit of the time 
            4.......................................Some of the time 
            5.......................................A little of the time 
None of the time  

Q9i      How much of the time during the past four weeks did you feel tired? 
 
            1.......................................All of the time 
            2.......................................Most of the time 
            3.......................................A good bit of the time 
            4.......................................Some of the time 
            5.......................................A little of the time 
None of the time  
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APPENDIX 7: STROKE IMPACT SCALE 
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APPENDIX 8: EQ-5D-5L  
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